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BRUSH - ARM STAR POLYMER IMAGING 
AGENTS AND USES THEREOF 
organic nanoparticles could have advantages for imaging 
strategies that require long - term tissue accumulation , such 
as tumor imaging . 
RELATED APPLICATIONS 
[ 0001 ] This application claims priority under 35 U . S . C . S 
119 ( e ) to U . S . Provisional Application , U . S . Ser . No . 62 / 528 , 
026 , filed Jun . 30 , 2017 , which is incorporated herein by 
reference . 
GOVERNMENT SUPPORT 
10002 ] This invention was made with government support 
under grant numbers R01 EB019950 and R21 EB018529 
awarded by the National Institutes of Health . The govern 
ment has certain rights in the invention . 
BACKGROUND OF THE INVENTION 
[ 0003 ] Among the many imaging modalities for medical 
diagnostics , magnetic resonance imaging ( MRI ) is one of 
the most useful due to its ability to non - invasively generate 
three - dimensional detailed anatomical images with high 
spatial resolution while not requiring an ionizing source and 
remaining insensitive to depth . 1 , 2 , 3 , 4 Current clinical MRI 
methods depict the spatial distribution and chemical envi 
ronment of water protons ( H ) within a region of interest 
( ROI ) with the use of contrast agents . These contrast agents 
are divided into two primary classes : T , contrast agents ( e . g . , 
paramagnetic metals such as gadolinium or manganese ) that 
afford positive - contrast images primarily by locally reduc 
ing the protons ' longitudinal relaxation time ( spin - lattice , 
T1 ) , and T2 contrast agents ( e . g . , superparamagnetic iron 
oxide nanoparticles ) that afford negative - contrast images by 
locally reducing the transverse relaxation time ( spin - spin , 
T2 ) of water molecules . 5 , 6 The corresponding ' H water 
relaxivities ( r , and rz , respectively ) of a contrast agent 
characterize the extent to which the agent decreases the Ti 
and T , times of water . Contrast agents with greater r , and r , 
values provide increased image contrast compared to those 
with lower values at the same concentration . ° , 7 
[ 0004 ] Most MRI contrast agents with large r? and / or r2 
values contain metals that feature a large number of unpaired 
electrons . For example , small molecule8 , 9 , 10 , 11 , 12 , 13 and 
nanoparticle - based14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 contrast agents fea 
turing Gd , Mn , Fe - oxide , and other metals have been 
reported to function as either T? or T2 contrast agents or 
both . Furthermore , metal - based contrast agents that display 
advanced functions such as multimodal imaging , 8 , 9 , 10 , 12 , 13 , 
17 , 20 , 21 enhanced target - specific accumulation , 14 , 18 , 19 or 
sensing8 , 11 , 12 , 13 , 14 have all been developed . Metal - based 
contrast agents , especially nanoparticle systems which tend 
to accumulate in biological tissues , suffer from a few key 
limitations . Most notably , they could present toxicity con - 
cerns in patients with hindered kidney function and newborn 
children ; additionally , Gd - based agents , perhaps the most 
widely used contrast agents in the clinic , have recently been 
linked to a rising prevalence of toxic Gd ions in the 
environment . 5 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 Thus , there is interest 
in developing “ metal - free ” MRI contrast agents that make 
use of organic components . Such agents could enable MRI 
in at - risk patient populations , and they could potentially 
open new avenues for functional / responsive MRI based on 
in vivo organic transformations that require longer time 
frames and contrast agents with low toxicity . For example , 
SUMMARY OF THE INVENTION 
[ 0005 ] Four main classes of metal - free MRI contrast 
agents have been most widely studied : paramagnetic nitrox 
ide - based Organic Radical Contrast Agents ( ORCAs ) , 
hyperpolarized 13C agents , 1°F MRI contrast agents , and 
chemical exchange saturation transfer ( CEST ) contrast 
agents . While 1°F MRI and CEST agents have undergone 
many advances in recent years , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 these 
approaches often suffer from low sensitivity , and in some 
cases , require a high contrast agent concentration ( 10 - 50 
mM ) , long imaging times , and / or potentially harmful high 
intensity radio - frequency fields . Hyperpolarized ' ' C agents , 
on the other hand , can theoretically afford up to 10 % sensi 
tivity improvements ; nevertheless , issues including short 
hyperpolarization lifetimes that lead to limited imaging 
times and complexity in terms of the chemistry and instru 
mentation required for generation of the hyperpolarized 
agent remain major challenges . 39 , 40 , 41 Furthermore , neither 
19F MRI , CEST , nor hyperpolarized 13C agents have 
become common in the clinic , which could prevent their 
rapid adoption . 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 In contrast , nitroxide 
ORCAs rely on standard water relaxation mechanisms to 
achieve MRI contrast , and therefore , could be immediately 
translated to clinical applications . However , several key 
challenges limit the clinical feasibility of nitroxide ORCAs . 
First , the nitroxide radical only possesses one unpaired 
electron . As a result , compared to metal - based contrast 
agents such as Gd3 + ( 7 unpaired electrons ) or Mn2 + ( 5 
unpaired electrons ) , nitroxide ORCAs inherently suffer from 
much lower ' H water relaxivity . One strategy to overcome 
this limitation is to use a poly ( nitroxide ) macromolecule 
where the relatively low per nitroxide relaxivity is multi 
plied by the number of nitroxide moieties bound to the 
macromolecule to achieve higher relaxivity . The second 
major limitation of nitroxide ORCAs is the fact that they are 
typically reduced rapidly in vivo to diamagnetic hydroxy 
lamines , thus rendering them ineffective as contrast agents 
shortly after injection . 47 , 48 , 49 , 50 Indeed , initial efforts to 
utilize nitroxides as MRI contrast agents exposed these 
shortcomings , 51 , 52 and though their rapid bioreduction has 
been cleverly exploited to enable redox - mapping in vitro 
and in vivo , 53 , 54 , 55 , 56 , 57 an in vivo - stable nitroxide ORCA 
that allows for longitudinal studies over clinically meaning 
ful timescales following systemic administration has yet to 
be developed . 
[ 0006 ] Nanoparticle - based nitroxide ORCAs with long 
term in vivo stability could be particularly useful for tumor 
imaging ; nanoparticles of suitable size ( ~ 10 - 200 nm ) are 
known to passively accumulate in tumors via the enhanced 
permeation and retention effect , especially in common 
murine ( e . g . mouse ) models , but hours to tens of hours are 
often needed to reach maximal accumulation . 58 , 59 , 60 , 61 , 62 , 63 , 
64 As stated above , there are no nitroxide - based molecules or 
materials with demonstrated capability to provide in vivo 
MRI contrast after such long times . This problem is exac 
erbated in murine models where imaging is often used for 
preclinical studies of disease development ; murine tissues 
contain higher levels of metabolic antioxidants , which lead 
to faster nitroxide reduction rates . 65 , 66 Thus , the develop 
ment of stable nitroxide - based ORCAs with high relaxivities 
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would open a new class of imaging applications whereby the 
accumulation of contrast agents in tissues could enable MRI 
without toxicity concerns . 50 , 67 , 68 Moreover , the flexibility of 
nanoparticle - based materials could facilitate future image 
guided drug delivery strategies . 
[ 0007 ] Compositions , methods , systems , and kits that 
allow for the preparation and use of a new class of Brush 
Arm Star Polymer ORCAS ( BASP - ORCAs ) are disclosed 
herein . In addition , in vitro and in vivo experiments utilizing 
BASP - ORCAs are described along with compositions , 
methods , systems , and uses thereof . BASP - ORCAs are 
designed to overcome the aforementioned challenges asso 
ciated with MRI using typical contrast agents . 
[ 0008 ] In certain embodiments , the present disclosure 
provides a brush - star arm polymer with an associated imag 
ing agent ( e . g . , a nitroxide - based contrast agent ) . Such a 
polymer may be in the form of a particle , such as a 
nanoparticle . In certain embodiments , the present disclosure 
provides a brush - arm star polymer with an imaging agent 
comprising at least 100 repeating units selected from For 
mula ( I ) and Formula ( II ) : 
Formula ( I ) 
[ 0010 ] X is an imaging agent as described herein ; 
[ 0011 ] P is alkylene , heteroalkylene , or polymer , 
[ 0012 ] L is a bond , 0 , S , S - S - , C , C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , C . - C12 
heteroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
heteroalkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 heteroalkylene ) , ( Co 
C12 alkylene ) heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , or ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 heteroalkylene ) , 
wherein each alkylene , alkenylene , alkynylene , heteroalky 
lene , arylene , heteroarylene , or heterocyclylene is optionally 
substituted with 1 - 24 independently selected R ' , and com 
binations thereof ; 
[ 0013 ] each R ' is independently alkyl , alkenyl , alkynyl , 
heteroalkyl , halo , cyano , oxo , nitro , ORA , — N ( R4 ) , 
- NR4C ( O ) R4 , — NR4C ( O ) OR4 , — NR4C ( O ) N ( R4 ) 2 , 
- C ( O N ( R4 ) , C ( O ) R4 , C ( O ) ORA , OC ( O ) R4 , 
- OC ( O ) OR “ , - OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) „ R4 ; [ 0014 ] each R4 is independently hydrogen , C . - C . alkyl , 
C1 - C6 heteroalkyl , or C1 - C6 haloalkyl ; 
[ 0015 ] each of a and b are independently an integer 
between 1 and 10000 , inclusive ; 
[ 0016 ] each of “ 1 ” , “ 2 ” , “ 3 ” , “ 4 ” , “ 5 ” , and “ 6 ” is inde 
pendently a terminal group selected from the group consist 
ing of hydrogen , halogen , optionally substituted alkyl , 
optionally substituted alkenyl , optionally substituted alky 
nyl , optionally substituted carbocyclyl , optionally substi 
tuted heterocyclyl , optionally substituted aryl , optionally 
substituted heteroaryl , optionally substituted acyl , optionally 
substituted hydroxyl , optionally substituted amino , and 
optionally substituted thiol ; or represents a bond to a another 
repeating unit of Formula ( I ) or Formula ( II ) ; 
[ 0017 ] y is an integer between 1 and 100 , inclusive ; and 
[ 0018 ] m is 1 or 2 . 
[ 0019 ] In certain embodiments , the imaging agent is a 
chelated metal , inorganic compound , organometallic com 
pound , organic compound , or salt thereof . In certain embodi 
ments , the imaging agent is an organic compound . In certain 
embodiments , the imaging agent is an organic radical . In 
certain embodiments , the imaging agent is a nitroxide 
containing imaging agent . In certain embodiments , the 
imaging agent is 
a 
and 
Formula ( II ) 
mm 
and salts thereof , wherein : 
[ 0009 ] each of A , A ' , and B is independently C1 - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , or C - C12 
heteroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , alky 
nylene , heteroalkylene , heteroalkenylene , or heteroalky 
nylene is optionally substituted with 1 - 24 independently 
selected R ' ; 
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In certain embodiments , the imaging agent is useful for 
performing magnetic resonance imaging . 
[ 0020 ] In certain embodiments , the imaging agent is a salt 
of an organic compound . In certain embodiments , the imag 
ing agent is 
CO 
In certain embodiments , the imaging agent is useful for 
performing near - infrared fluorescence imaging . [ 0021 ] In certain embodiments , the present disclosure 
provides methods to produce a brush - arm star polymer 
comprising reacting one or more macromonomers associ 
ated with an imaging agent with a metathesis catalyst to 
form a living polymer ; and mixing a crosslinker with the 
living polymer . In certain embodiments , at least two differ 
ent macromonomers each containing a different imaging 
agents are reacted together to form the brush - arm star 
polymer . 
[ 0022 ] In certain embodiments , the macromonomer is of 
Formula ( III ) : 
or a salt thereof , wherein : 
[ 0023 ] each of A , A ' , and B is independently C2 - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , or C7 - C12 
heteroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , alky 
nylene , heteroalkylene , heteroalkenylene , or heteroalky 
nylene is optionally substituted with 1 - 24 independently 
selected R ' ; 
[ 0024 ] X is an imaging agent described herein ; 
[ 0025 ] P is alkylene , heteroalkylene , or polymer ; 
[ 0026 ] L is a bond , 0 , S , S S , C . - C , 2 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , C7 - C12 
heteroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
heteroalkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 heteroalkylene ) , ( Co 
C12 alkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , or ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 heteroalkylene ) , 
wherein each alkylene , alkenylene , alkynylene , heteroalky 
lene , arylene , heteroarylene , or heterocyclylene is optionally 
substituted with 1 - 24 independently selected R ' , and com 
binations thereof ; 
[ 0027 ] each R is independently alkyl , alkenyl , alkynyl , 
heteroalkyl , halo , cyano , oxo , nitro , ORA , — N ( R4 ) 2 , 
- NR4C ( O ) R4 , NR4C ( O ) OR4 , NR4C ( O ) N ( R4 ) , 
C ( O ) N ( R4 ) 2 , C ( O ) R4 , - C ( O ) OR4 , OC ( O ) R4 , 
OC ( O ) OR “ , OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) mR4 ; 
[ 0028 ] each R4 is independently hydrogen , C . - C . alkyl , 
C1 - C6 heteroalkyl , or C - C6 haloalkyl ; 
[ 0029 ] y is an integer between 1 and 100 , inclusive ; and 
[ 0030 ) m is 1 or 2 . 
[ 0031 ] In certain embodiments , the macromonomer is of 
the formula : 
Formula ( III ) 
L - A - X 
- B 
- OH . 
- NH 
Nuo 
N 
NO . 
O 
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[ 0032 ] In certain embodiments , the macromonomer is of 
the formula : 
functional groups are generally defined as described therein . 
Additionally , general principles of organic chemistry , as 
- OH 
?? 
N 
O 
[ 0033 ] In certain embodiments , the present disclosure 
describes compositions comprising a polymer described 
herein ( i . e . , BASP - ORCAs ) . In certain embodiments , the 
composition further comprises a pharmaceutically accept 
able excipient . 
10034 ] In certain embodiments , the present disclosure 
describes kits comprising a polymer described herein ( i . e . , 
BASP - ORCAs ) , or a composition comprising a polymer 
( i . e . , BASP - ORCAs ) , and instructions for use . [ 0035 ] In certain embodiments , the present disclosure 
provides methods of imaging a subject , the method com 
prising the steps of : administering to a subject a polymer 
described herein ( i . e . , BASP - ORCAS ) , or a composition 
comprising a polymer described herein ( i . e . , BASP - OR 
CAs ) ; and acquiring an image of at least a portion of the 
subject . In certain embodiments , the imaging modality is 
magnetic resonance imaging . In certain embodiments , the 
imaging modality is near - infrared fluorescence imaging . 
[ 0036 ] In certain embodiments , the present disclosure provides compounds , polymers , particles , nanoparticles , 
compositions , and kits described herein for use in a method 
of the present disclosure . 
[ 0037 ] The details of certain embodiments of the invention 
are set forth in the Detailed Description of Certain Embodi 
ments , as described below . Other features , objects , and 
advantages of the invention will be apparent from the 
Definitions , Examples , Figures , and Claims . 
well as specific functional moieties and reactivity , are 
described in Organic Chemistry , Thomas Sorrell , University 
Science Books , Sausalito , 1999 ; Smith and March , March ' s 
Advanced Organic Chemistry , 5th Edition , John Wiley & 
Sons , Inc . , New York , 2001 ; Larock , Comprehensive 
Organic Transformations , VCH Publishers , Inc . , New York , 
1989 ; and Carruthers , Some Modern Methods of Organic 
Synthesis , 3rd Edition , Cambridge University Press , Cam 
bridge , 1987 . 
[ 0039 ] Compounds described herein can comprise one or 
more asymmetric centers , and thus can exist in various 
stereoisomeric forms , e . g . , enantiomers and / or diastereom 
ers . For example , the compounds described herein can be in 
the form of an individual enantiomer , diastereomer or geo 
metric isomer , or can be in the form of a mixture of 
stereoisomers , including racemic mixtures and mixtures 
enriched in one or more stereoisomer . Isomers can be 
isolated from mixtures by methods known to those skilled in 
the art , including chiral high pressure liquid chromatography 
( HPLC ) and the formation and crystallization of chiral salts ; 
or preferred isomers can be prepared by asymmetric syn 
theses . See , for example , Jacques et al . , Enantiomers , Race 
mates and Resolutions ( Wiley Interscience , New York , 
1981 ) ; Wilen et al . , Tetrahedron 33 : 2725 ( 1977 ) ; Eliel , E . L . 
Stereochemistry of Carbon Compounds ( McGraw - Hill , NY , 
1962 ) ; and Wilen , S . H . , Tables of Resolving Agents and 
Optical Resolutions p . 268 ( E . L . Eliel , Ed . , Univ . of Notre 
Dame Press , Notre Dame , Ind . 1972 ) . The invention addi 
tionally encompasses compounds as individual isomers sub 
stantially free of other isomers , and alternatively , as mix 
tures of various isomers . 
[ 0040 ] In a formula , ww is a single bond where the 
stereochemistry of the moieties immediately attached 
Definitions 
[ 0038 ] Definitions of specific functional groups and 
chemical terms are described in more detail below . The 
chemical elements are identified in accordance with the 
Periodic Table of the Elements , CAS version , Handbook of 
Chemistry and Physics , 75th Ed . , inside cover , and specific 
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thereto is not specified , - - - is absent or a single bond , and 
- - - or - - - is a single or double bond . 
[ 0041 ] Unless otherwise stated , structures depicted herein 
are also meant to include compounds that differ only in the 
presence of one or more isotopically enriched atoms . For 
example , compounds having the present structures except 
for the replacement of hydrogen by deuterium or tritium , 
replacement of ' ' F with " F , or the replacement of a carbon 
by a 13C - or 14C - enriched carbon are within the scope of the 
disclosure . Such compounds are useful , for example , as 
analytical tools or probes in biological assays . 
[ 0042 ] When a range of values is listed , it is intended to 
encompass each value and subrange within the range . For 
example “ C1 - 6 alkyl ” is intended to encompass , C1 , C2 , C3 , 
C4 , C5 , C6 , C1 - 6 , C1 - 5 , C - 4 , C1 - 3 , C1 - 2 , C2 - 6 , C2 - 5 , C2 - 4 , C2 - 3 , 
C3 - 6 , C3 - 5 , C3 - 4 , C4 - 6 , C4 - 5 , and C5 - 6 alkyl . [ 0043 ] The term “ aliphatic ” refers to alkyl , alkenyl , alky 
nyl , and carbocyclic groups . Likewise , the term “ heteroali 
phatic ” refers to heteroalkyl , heteroalkenyl , heteroalkynyl , 
and heterocyclic groups . 
[ 0044 ] The term “ alkyl ” refers to a radical of a straight 
chain or branched saturated hydrocarbon group having from 
1 to 10 carbon atoms ( “ C1 - 10 alkyl ” ) . In some embodiments , 
an alkyl group has 1 to 9 carbon atoms ( “ C1 . 9 alkyl ” ) . In 
some embodiments , an alkyl group has 1 to 8 carbon atoms 
( “ C1 - 8 alkyl ” ) . In some embodiments , an alkyl group has 1 
to 7 carbon atoms ( “ C , . alkyl ” ) . In some embodiments , an 
alkyl group has 1 to 6 carbon atoms ( " C1 - 6 alkyl ” ) . In some 
embodiments , an alkyl group has 1 to 5 carbon atoms ( “ C1 - 5 
alkyl ” ) . In some embodiments , an alkyl group has 1 to 4 
carbon atoms ( " C1 - 4 alkyl ” ) . In some embodiments , an alkyl 
group has 1 to 3 carbon atoms ( “ C1 - 3 alkyl ” ) . In some 
embodiments , an alkyl group has 1 to 2 carbon atoms ( “ C1 - 2 
alkyl ” ) . In some embodiments , an alkyl group has 1 carbon 
atom ( “ C , alkyl ” ) . In some embodiments , an alkyl group has 
2 to 6 carbon atoms ( “ C2 - 6 alkyl ” ) . Examples of C1 -6 alkyl 
groups include methyl ( C1 ) , ethyl ( C2 ) , propyl ( C3 ) ( e . g . , 
n - propyl , isopropyl ) , butyl ( C4 ) ( e . g . , n - butyl , tert - butyl , 
sec - butyl , iso - butyl ) , pentyl ( C ) ( e . g . , n - pentyl , 3 - pentanyl , 
amyl , neopentyl , 3 - methyl - 2 - butanyl , tertiary amyl ) , and 
hexyl ( C6 ) ( e . g . , n - hexyl ) . Additional examples of alkyl 
groups include n - heptyl ( C7 ) , n - octyl ( C3 ) , and the like . 
Unless otherwise specified , each instance of an alkyl group 
is independently unsubstituted ( an " unsubstituted alkyl ” ) or 
substituted ( a “ substituted alkyl ” ) with one or more sub 
stituents ( e . g . , halogen , such as F ) . In certain embodiments , 
the alkyl group is an unsubstituted C1 - 10 alkyl ( such as 
unsubstituted C1 - 6 alkyl , e . g . , CHz ( Me ), unsubstituted 
ethyl ( Et ) , unsubstituted propyl ( Pr , e . g . , unsubstituted 
n - propyl ( n - Pr ) , unsubstituted isopropyl ( i - Pr ) ) , unsubsti 
tuted butyl ( Bu , e . g . , unsubstituted n - butyl ( n - Bu ) , unsub 
stituted tert - butyl ( tert - Bu or t - Bu ) , unsubstituted sec - butyl 
( sec - Bu or s - Bu ) , unsubstituted isobutyl ( i - Bu ) ) . In certain 
embodiments , the alkyl group is a substituted C1 - 10 alkyl 
( such as substituted C1 - 6 alkyl , e . g . , CH F , CHF2 , 
- CFz or benzyl ( Bn ) ) . 
[ 0045 ] The term “ haloalkyl ” is a substituted alkyl group , 
wherein one or more of the hydrogen atoms are indepen 
dently replaced by a halogen , e . g . , fluoro , bromo , chloro , or 
iodo . “ Perhaloalkyl ” is a subset of haloalkyl , and refers to an 
alkyl group wherein all of the hydrogen atoms are indepen - 
dently replaced by a halogen , e . g . , fluoro , bromo , chloro , or 
iodo . In some embodiments , the haloalkyl moiety has 1 to 8 
carbon atoms ( " C1 -8 haloalkyl ” ) . In some embodiments , the 
haloalkyl moiety has 1 to 6 carbon atoms ( “ C1 - 6 haloalkyl ” ) . 
In some embodiments , the haloalkyl moiety has 1 to 4 
carbon atoms ( “ C1 -4 haloalkyl ” ) . In some embodiments , the 
haloalkyl moiety has 1 to 3 carbon atoms ( “ C ; . haloalkyl ” ) . 
In some embodiments , the haloalkyl moiety has 1 to 2 
carbon atoms ( “ C1 - 2 haloalkyl ” ) . In some embodiments , all 
of the haloalkyl hydrogen atoms are replaced with fluoro to 
provide a perfluoroalkyl group . In some embodiments , all of 
the haloalkyl hydrogen atoms are replaced with chloro to 
provide a “ perchloroalkyl ” group . Examples of haloalkyl 
groups include — CF3 , CF CF3 , CF CF CF3 , - CC13 , 
CFC12 , CF2Cl , and the like . [ 0046 ] The term " heteroalkyl ” refers to an alkyl group , 
which further includes at least one heteroatom ( e . g . , 1 , 2 , 3 , 
or 4 heteroatoms ) selected from oxygen , nitrogen , or sulfur 
within ( i . e . , inserted between adjacent carbon atoms of ) 
and / or placed at one or more terminal position ( s ) of the 
parent chain . In certain embodiments , a heteroalkyl group 
refers to a saturated group having from 1 to 10 carbon atoms 
and 1 or more heteroatoms within the parent chain ( “ het 
eroC1 - 10 alkyl ” ) . In some embodiments , a heteroalkyl group 
is a saturated group having 1 to 9 carbon atoms and 1 or 
more heteroatoms within the parent chain ( “ heteroC1 - 9 
alkyl ” ) . In some embodiments , a heteroalkyl group is a 
saturated group having 1 to 8 carbon atoms and 1 or more 
heteroatoms within the parent chain ( “ heteroC , . , alkyl ” ) . In 
some embodiments , a heteroalkyl group is a saturated group 
having 1 to 7 carbon atoms and 1 or more heteroatoms 
within the parent chain ( “ heteroC1 - 7 alkyl ” ) . In some 
embodiments , a heteroalkyl group is a saturated group 
having 1 to 6 carbon atoms and 1 or more heteroatoms 
within the parent chain ( “ heteroC1 -6 alkyl ” ) . In some 
embodiments , a heteroalkyl group is a saturated group 
having 1 to 5 carbon atoms and 1 or 2 heteroatoms within the 
parent chain ( “ heteroC1 . 5 alkyl " ) . In some embodiments , a 
heteroalkyl group is a saturated group having 1 to 4 carbon 
atoms and 1 or 2 heteroatoms within the parent chain 
( " heteroC , . 4 alkyl ” ) . In some embodiments , a heteroalkyl 
group is a saturated group having 1 to 3 carbon atoms and 
1 heteroatom within the parent chain ( “ heteroC1 - 3 alkyl ” ) . In 
some embodiments , a heteroalkyl group is a saturated group 
having 1 to 2 carbon atoms and 1 heteroatom within the 
parent chain ( " heteroC , . , alkyl ” ) . In some embodiments , a 
heteroalkyl group is a saturated group having 1 carbon atom 
and 1 heteroatom ( “ heteroC , alkyl ” ) . In some embodiments , 
a heteroalkyl group is a saturated group having 2 to 6 carbon 
atoms and 1 or 2 heteroatoms within the parent chain 
( " heteroC , alkyl " ) . Unless otherwise specified , each 
instance of a heteroalkyl group is independently unsubsti 
tuted ( an " unsubstituted heteroalkyl " ) or substituted ( a “ sub 
stituted heteroalkyl ” ) with one or more substituents . In 
certain embodiments , the heteroalkyl group is an unsubsti 
tuted heteroC1 - 10 alkyl . In certain embodiments , the het 
eroalkyl group is a substituted heteroC1 - 10 alkyl . 
[ 0047 ] The term “ alkenyl ” refers to a radical of a straight 
chain or branched hydrocarbon group having from 2 to 10 
carbon atoms and one or more carbon - carbon double bonds 
( e . g . , 1 , 2 , 3 , or 4 double bonds ) . In some embodiments , an 
alkenyl group has 2 to 9 carbon atoms ( “ C2 - 9 alkenyl ” ) . In 
some embodiments , an alkenyl group has 2 to 8 carbon 
atoms ( “ C2 - 8 alkenyl ” ) . In some embodiments , an alkenyl 
group has 2 to 7 carbon atoms ( “ C2 - 7 alkenyl ” ) . In some 
embodiments , an alkenyl group has 2 to 6 carbon atoms 
( “ C2 . 6 alkenyl ” ) . In some embodiments , an alkenyl group 
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has 2 to 5 carbon atoms ( “ C2 - 5 alkenyl ” ) . In some embodi 
ments , an alkenyl group has 2 to 4 carbon atoms ( “ C2 - 4 
alkenyl ” ) . In some embodiments , an alkenyl group has 2 to 
3 carbon atoms ( “ C , z alkenyl ” ) . In some embodiments , an 
alkenyl group has 2 carbon atoms ( “ C2 alkenyl ” ) . The one or 
more carbon - carbon double bonds can be internal ( such as in 
2 - butenyl ) or terminal ( such as in 1 - butenyl ) . Examples of 
C2 - 4 alkenyl groups include ethenyl ( C2 ) , 1 - propenyl ( C3 ) , 
2 - propenyl ( C3 ) , 1 - butenyl ( C4 ) , 2 - butenyl ( C4 ) , butadienyl 
( C4 ) , and the like . Examples of C2 - 6 alkenyl groups include 
the aforementioned C2 - 4 alkenyl groups as well as pentenyl 
( C3 ) , pentadienyl ( C5 ) , hexenyl ( C . ) , and the like . Additional 
examples of alkenyl include heptenyl ( C7 ) , octenyl ( C3 ) , 
octatrienyl ( C3 ) , and the like . Unless otherwise specified , 
each instance of an alkenyl group is independently unsub 
stituted ( an “ unsubstituted alkenyl ” ) or substituted ( a “ sub 
stituted alkenyl ” ) with one or more substituents . In certain 
embodiments , the alkenyl group is an unsubstituted C2 _ 10 
alkenyl . In certain embodiments , the alkenyl group is a 
substituted C2 . 10 alkenyl . In an alkenyl group , a C = C 
double bond for which the stereochemistry is not specified 
( e . g . , - CH = CHCH3 , 
, or 
may be in the ( E ) - or ( Z ) - configuration . [ 0048 ] The term " heteroalkenyl ” refers to an alkenyl 
group , which further includes at least one heteroatom ( e . g . , 
1 , 2 , 3 , or 4 heteroatoms ) selected from oxygen , nitrogen , or 
sulfur within ( i . e . , inserted between adjacent carbon atoms 
of ) and / or placed at one or more terminal position ( s ) of the 
parent chain . In certain embodiments , a heteroalkenyl group 
refers to a group having from 2 to 10 carbon atoms , at least 
one double bond , and 1 or more heteroatoms within the 
parent chain ( “ heteroC2 - 10 alkenyl ” ) . In some embodiments , 
a heteroalkenyl group has 2 to 9 carbon atoms at least one 
double bond , and 1 or more heteroatoms within the parent 
chain ( “ heteroC2 - 9 alkenyl ” ) . In some embodiments , a het 
eroalkenyl group has 2 to 8 carbon atoms , at least one double 
bond , and 1 or more heteroatoms within the parent chain 
( “ heteroC2 - 8 alkenyl ” ) . In some embodiments , a heteroalk 
enyl group has 2 to 7 carbon atoms , at least one double bond , 
and 1 or more heteroatoms within the parent chain ( “ het 
eroC2 - 7 alkenyl ” ) . In some embodiments , a heteroalkenyl 
group has 2 to 6 carbon atoms , at least one double bond , and 
1 or more heteroatoms within the parent chain ( “ heteroC2 -6 
alkenyl ” ) . In some embodiments , a heteroalkenyl group has 
2 to 5 carbon atoms , at least one double bond , and 1 or 2 
heteroatoms within the parent chain ( “ heteroC , s alkenyl ” ) . 
In some embodiments , a heteroalkenyl group has 2 to 4 
carbon atoms , at least one double bond , and 1 or 2 heteroa 
toms within the parent chain ( “ heteroC2 - 4 alkenyl ” ) . In some 
embodiments , a heteroalkenyl group has 2 to 3 carbon 
atoms , at least one double bond , and 1 heteroatom within the 
parent chain ( “ heteroC2 -3 alkenyl ” ) . In some embodiments , 
a heteroalkenyl group has 2 to 6 carbon atoms , at least one 
double bond , and 1 or 2 heteroatoms within the parent chain 
( " heteroC , alkenyl ” ) . Unless otherwise specified , each 
instance of a heteroalkenyl group is independently unsub 
stituted ( an “ unsubstituted heteroalkenyl ” ) or substituted ( a 
“ substituted heteroalkenyl ” ) with one or more substituents . 
In certain embodiments , the heteroalkenyl group is an 
unsubstituted heteroC2 - 10 alkenyl . In certain embodiments , 
the heteroalkenyl group is a substituted heteroC2 - 10 alkenyl . 
[ 0049 ] The term “ alkynyl ” refers to a radical of a straight 
chain or branched hydrocarbon group having from 2 to 10 
carbon atoms and one or more carbon - carbon triple bonds 
( e . g . , 1 , 2 , 3 , or 4 triple bonds ) ( “ C2 - 10 alkynyl ” ) . In some 
embodiments , an alkynyl group has 2 to 9 carbon atoms 
( “ C2 - 9 alkynyl ” ) . In some embodiments , an alkynyl group 
has 2 to 8 carbon atoms ( “ C2 - 8 alkynyl ” ) . In some embodi 
ments , an alkynyl group has 2 to 7 carbon atoms ( “ C2 - 7 
alkynyl ” ) . In some embodiments , an alkynyl group has 2 to 
6 carbon atoms ( “ C2 - 6 alkynyl ” ) . In some embodiments , an 
alkynyl group has 2 to 5 carbon atoms ( “ C2 - 5 alkynyl ” ) . In 
some embodiments , an alkynyl group has 2 to 4 carbon 
atoms ( “ C2 - 4 alkynyl ” ) . In some embodiments , an alkynyl 
group has 2 to 3 carbon atoms ( “ C2 - 3 alkynyl ” ) . In some 
embodiments , an alkynyl group has 2 carbon atoms ( “ C2 
alkynyl ” ) . The one or more carbon - carbon triple bonds can 
be internal ( such as in 2 - butynyl ) or terminal ( such as in 
1 - butynyl ) . Examples of C2 - 4 alkynyl groups include , with 
out limitation , ethynyl ( C2 ) , 1 - propynyl ( C3 ) , 2 - propynyl ( C3 ) , 1 - butynyl ( C4 ) , 2 - butynyl ( C4 ) , and the like . Examples 
of C2 - 6 alkenyl groups include the aforementioned C2 - 4 
alkynyl groups as well as pentynyl ( C5 ) , hexynyl ( Co ) , and 
the like . Additional examples of alkynyl include heptynyl 
( C7 ) , octynyl ( C3 ) , and the like . Unless otherwise specified , 
each instance of an alkynyl group is independently unsub 
stituted ( an “ unsubstituted alkynyl ” ) or substituted ( a “ sub 
stituted alkynyl ” ) with one or more substituents . In certain 
embodiments , the alkynyl group is an unsubstituted C2 - 10 
alkynyl . In certain embodiments , the alkynyl group is a 
substituted C2 - 10 alkynyl . 
[ 0050 ] The term " heteroalkynyl ” refers to an alkynyl 
group , which further includes at least one heteroatom ( e . g . , 
1 , 2 , 3 , or 4 heteroatoms ) selected from oxygen , nitrogen , or 
sulfur within ( i . e . , inserted between adjacent carbon atoms 
of ) and / or placed at one or more terminal position ( s ) of the 
parent chain . In certain embodiments , a heteroalkynyl group 
refers to a group having from 2 to 10 carbon atoms , at least 
one triple bond , and 1 or more heteroatoms within the parent 
chain ( “ heteroC210 alkynyl " ) . In some embodiments , a 
heteroalkynyl group has 2 to 9 carbon atoms , at least one 
triple bond , and 1 or more heteroatoms within the parent 
chain ( " heteroC29 alkynyl ” ) . In some embodiments , a het 
eroalkynyl group has 2 to 8 carbon atoms , at least one triple 
bond , and 1 or more heteroatoms within the parent chain 
( “ heteroC , . , alkynyl ” ) . In some embodiments , a heteroalky 
nyl group has 2 to 7 carbon atoms , at least one triple bond , 
and 1 or more heteroatoms within the parent chain ( “ het 
eroC2 . 7 alkynyl ” ' ) . In some embodiments , a heteroalkynyl 
group has 2 to 6 carbon atoms , at least one triple bond , and 
1 or more heteroatoms within the parent chain ( “ heteroC , 
alkynyl ” ) . In some embodiments , a heteroalkynyl group has 
2 to 5 carbon atoms , at least one triple bond , and 1 or 2 
heteroatoms within the parent chain ( “ heteroC2 - 5 alkynyl ” ) . 
In some embodiments , a heteroalkynyl group has 2 to 4 
carbon atoms , at least one triple bond , and 1 or 2 heteroa 
toms within the parent chain ( " heteroC24 alkynyl ” ) . In some 
embodiments , a heteroalkynyl group has 2 to 3 carbon 
atoms , at least one triple bond , and 1 heteroatom within the 
parent chain ( “ heteroC2 - 3 alkynyl ” ) . In some embodiments , 
a heteroalkynyl group has 2 to 6 carbon atoms , at least one 
triple bond , and 1 or 2 heteroatoms within the parent chain 
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( " heteroC2 - 6 alkynyl ” ) . Unless otherwise specified , each 
instance of a heteroalkynyl group is independently unsub 
stituted ( an “ unsubstituted heteroalkynyl ” ) or substituted ( a 
“ substituted heteroalkynyl ” ) with one or more substituents . 
In certain embodiments , the heteroalkynyl group is an 
unsubstituted heteroC , 10 alkynyl . In certain embodiments , 
the heteroalkynyl group is a substituted heteroC2 - 10 alkynyl . 
[ 0051 ] The term “ carbocyclyl ” or “ carbocyclic ” refers to a 
radical of a non - aromatic cyclic hydrocarbon group having 
from 3 to 14 ring carbon atoms ( “ C3 - 14 carbocyclyl ” ) and 
zero heteroatoms in the non - aromatic ring system . In some 
embodiments , a carbocyclyl group has 3 to 10 ring carbon 
atoms ( “ Cz . 10 carbocyclyl ” ) . In some embodiments , a car 
bocyclyl group has 3 to 8 ring carbon atoms ( “ C2 - 8 carbo 
cyclyl " ) . In some embodiments , a carbocyclyl group has 3 to 
7 ring carbon atoms ( “ C2 _ , carbocyclyl ” ) . In some embodi 
ments , a carbocyclyl group has 3 to 6 ring carbon atoms 
( “ C3 - 6 carbocyclyl ” ) . In some embodiments , a carbocyclyl 
group has 4 to 6 ring carbon atoms ( “ C4 - 6 carbocyclyl ” ) . In 
some embodiments , a carbocyclyl group has 5 to 6 ring 
carbon atoms ( “ C5 - 6 carbocyclyl ” ) . In some embodiments , a 
carbocyclyl group has 5 to 10 ring carbon atoms ( “ C5 - 10 
carbocyclyl ” ) . Exemplary C3 - 6 carbocyclyl groups include , 
without limitation , cyclopropyl ( C3 ) , cyclopropenyl ( C3 ) , 
cyclobutyl ( C4 ) , cyclobutenyl ( C4 ) , cyclopentyl ( C3 ) , cyclo 
pentenyl ( C3 ) , cyclohexyl ( C6 ) , cyclohexenyl ( C6 ) , cyclo 
hexadienyl ( C6 ) , and the like . Exemplary C3 - 8 carbocyclyl 
groups include , without limitation , the aforementioned C3 - 6 
carbocyclyl groups as well as cycloheptyl ( C7 ) , cyclohep 
tenyl ( C7 ) , cycloheptadienyl ( C7 ) , cycloheptatrienyl ( C7 ) , 
cyclooctyl ( C2 ) , cyclooctenyl ( C3 ) , bicyclo [ 2 . 2 . 1 ] heptanyl 
( C7 ) , bicyclo [ 2 . 2 . 2 ] octanyl ( Co ) , and the like . Exemplary 
C3 - 10 carbocyclyl groups include , without limitation , the 
aforementioned C3 - 8 carbocyclyl groups as well as 
cyclononyl ( C ) , cyclononenyl ( C7 ) , cyclodecyl ( C10 ) , 
cyclodecenyl ( C10 ) , octahydro - 1H - indenyl ( C2 ) , decahy 
dronaphthalenyl ( C10 ) , spiro [ 4 . 5 ] decanyl ( C10 ) , and the like . 
As the foregoing examples illustrate , in certain embodi 
ments , the carbocyclyl group is either monocyclic ( “ mono 
cyclic carbocyclyl ” ) or polycyclic ( e . g . , containing a fused , 
bridged or spiro ring system such as a bicyclic system ( “ bicyclic carbocyclyl ” ) or tricyclic system ( “ tricyclic car 
bocyclyl ” ' ) ) and can be saturated or can contain one or more 
carbon - carbon double or triple bonds . “ Carbocyclyl ” also 
includes ring systems wherein the carbocyclyl ring , as 
defined above , is fused with one or more aryl or heteroaryl 
groups wherein the point of attachment is on the carbocyclyl 
ring , and in such instances , the number of carbons continue 
to designate the number of carbons in the carbocyclic ring 
system . Unless otherwise specified , each instance of a 
carbocyclyl group is independently unsubstituted ( an 
" unsubstituted carbocyclyl ” ) or substituted ( a “ substituted 
carbocyclyl ” ) with one or more substituents . In certain 
embodiments , the carbocyclyl group is an unsubstituted 
C3 - 14 carbocyclyl . In certain embodiments , the carbocyclyl 
group is a substituted C3 - 14 carbocyclyl . 
[ 0052 ] In some embodiments , " carbocyclyl ” is a monocy 
clic , saturated carbocyclyl group having from 3 to 14 ring 
carbon atoms ( “ C3 - 14 cycloalkyl ” ) . In some embodiments , a 
cycloalkyl group has 3 to 10 ring carbon atoms ( “ C3 - 10 
cycloalkyl ” ) . In some embodiments , a cycloalkyl group has 
3 to 8 ring carbon atoms ( “ C3 - 8 cycloalkyl ” ) . In some 
embodiments , a cycloalkyl group has 3 to 6 ring carbon 
atoms ( “ C3 - 6 cycloalkyl ” ) . In some embodiments , a 
cycloalkyl group has 4 to 6 ring carbon atoms ( “ C4 - 6 
cycloalkyl ” ) . In some embodiments , a cycloalkyl group has 
5 to 6 ring carbon atoms ( “ C5 . 6 cycloalkyl " ) . In some 
embodiments , a cycloalkyl group has 5 to 10 ring carbon 
atoms ( “ C5 - 10 cycloalkyl ” ) . Examples of C5 - 6 cycloalkyl 
groups include cyclopentyl ( C3 ) and cyclohexyl ( C3 ) . 
Examples of C3 - 6 cycloalkyl groups include the aforemen 
tioned C5 - 6 cycloalkyl groups as well as cyclopropyl ( C3 ) 
and cyclobutyl ( C4 ) . Examples of C3 - 8 cycloalkyl groups 
include the aforementioned C3 - 6 cycloalkyl groups as well as 
cycloheptyl ( C7 ) and cyclooctyl ( C ) . Unless otherwise 
specified , each instance of a cycloalkyl group is indepen 
dently unsubstituted ( an “ unsubstituted cycloalkyl ” ) or sub 
stituted ( a “ substituted cycloalkyl ” ) with one or more sub 
stituents . In certain embodiments , the cycloalkyl group is an 
unsubstituted C2 - 14 cycloalkyl . In certain embodiments , the 
cycloalkyl group is a substituted C3 - 14 cycloalkyl . In certain 
embodiments , the carbocyclyl includes 0 , 1 , or 2 CEC 
double bonds in the carbocyclic ring system , as valency 
permits . 
[ 0053 ] The term " heterocyclyl ” or " heterocyclic ” refers to 
a radical of a 3 - to 14 - membered non - aromatic ring system 
having ring carbon atoms and 1 to 4 ring heteroatoms , 
wherein each heteroatom is independently selected from 
nitrogen , oxygen , and sulfur ( 143 - 14 membered heterocy 
clyl ” ) . In heterocyclyl groups that contain one or more 
nitrogen atoms , the point of attachment can be a carbon or 
nitrogen atom , as valency permits . A heterocyclyl group can 
either be monocyclic ( “ monocyclic heterocyclyl ” ) or poly 
cyclic ( e . g . , a fused , bridged or spiro ring system such as a 
bicyclic system ( " bicyclic heterocyclyl ” ) or tricyclic system 
( “ étricyclic heterocyclyl " ) ) , and can be saturated or can 
contain one or more carbon - carbon double or triple bonds . 
Heterocyclyl polycyclic ring systems can include one or 
more heteroatoms in one or both rings . “ Heterocyclyl ” also 
includes ring systems wherein the heterocyclyl ring , as 
defined above , is fused with one or more carbocyclyl groups 
wherein the point of attachment is either on the carbocyclyl 
or heterocyclyl ring , or ring systems wherein the heterocy 
clyl ring , as defined above , is fused with one or more aryl or 
heteroaryl groups , wherein the point of attachment is on the 
heterocyclyl ring , and in such instances , the number of ring 
members continue to designate the number of ring members 
in the heterocyclyl ring system . Unless otherwise specified , 
each instance of heterocyclyl is independently unsubstituted 
( an “ unsubstituted heterocyclyl ” ' ) or substituted ( a “ substi 
tuted heterocyclyl " ) with one or more substituents . In certain 
embodiments , the heterocyclyl group is an unsubstituted 
3 - 14 membered heterocyclyl . In certain embodiments , the 
heterocyclyl group is a substituted 3 - 14 membered hetero 
cyclyl . In certain embodiments , the heterocyclyl is substi 
tuted or unsubstituted , 3 - to 7 - membered , monocyclic het 
erocyclyl , wherein 1 , 2 , or 3 atoms in the heterocyclic ring 
system are independently oxygen , nitrogen , or sulfur , as 
valency permits . 
[ 0054 ] In some embodiments , a heterocyclyl group is a 
5 - 10 membered non - aromatic ring system having ring car 
b on atoms and 1 - 4 ring heteroatoms , wherein each heteroa 
tom is independently selected from nitrogen , oxygen , and 
sulfur ( “ 5 - 10 membered heterocyclyl ” ) . In some embodi 
ments , a heterocyclyl group is a 5 - 8 membered non - aromatic 
ring system having ring carbon atoms and 1 - 4 ring heteroa 
toms , wherein each heteroatom is independently selected 
from nitrogen , oxygen , and sulfur ( “ 5 - 8 membered hetero 
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cyclyl ” ) . In some embodiments , a heterocyclyl group is a 
5 - 6 membered non - aromatic ring system having ring carbon 
atoms and 1 - 4 ring heteroatoms , wherein each heteroatom is 
independently selected from nitrogen , oxygen , and sulfur 
( “ 5 - 6 membered heterocyclyl ” ) . In some embodiments , the 
5 - 6 membered heterocyclyl has 1 - 3 ring heteroatoms 
selected from nitrogen , oxygen , and sulfur . In some embodi 
ments , the 5 - 6 membered heterocyclyl has 1 - 2 ring heteroa 
toms selected from nitrogen , oxygen , and sulfur . In some 
embodiments , the 5 - 6 membered heterocyclyl has 1 ring 
heteroatom selected from nitrogen , oxygen , and sulfur . 
[ 0055 ] Exemplary 3 - membered heterocyclyl groups con 
taining 1 heteroatom include , without limitation , azirdinyl , 
oxiranyl , and thiiranyl . Exemplary 4 - membered heterocy 
clyl groups containing 1 heteroatom include , without limi 
tation , azetidinyl , oxetanyl , and thietanyl . Exemplary 
5 - membered heterocyclyl groups containing 1 heteroatom 
include , without limitation , tetrahydrofuranyl , dihydrofura 
nyl , tetrahydrothiophenyl , dihydrothiophenyl , pyrrolidinyl , 
dihydropyrrolyl , and pyrrolyl - 2 , 5 - dione . Exemplary 5 - mem 
bered heterocyclyl groups containing 2 heteroatoms include , 
without limitation , dioxolanyl , oxathiolanyl and dithiolanyl . 
Exemplary 5 - membered heterocyclyl groups containing 3 
heteroatoms include , without limitation , triazolinyl , oxadi - 
azolinyl , and thiadiazolinyl . Exemplary 6 - membered hetero 
cyclyl groups containing 1 heteroatom include , without 
limitation , piperidinyl , tetrahydropyranyl , dihydropyridinyl , 
and thianyl . Exemplary 6 - membered heterocyclyl groups 
containing 2 heteroatoms include , without limitation , piper 
azinyl , morpholinyl , dithianyl , and dioxanyl . Exemplary 
6 - membered heterocyclyl groups containing 3 heteroatoms 
include , without limitation , triazinyl . Exemplary 7 - mem 
bered heterocyclyl groups containing 1 heteroatom include , 
without limitation , azepanyl , oxepanyl and thiepanyl . Exem 
plary 8 - membered heterocyclyl groups containing 1 heteroa 
tom include , without limitation , azocanyl , oxecanyl and 
thiocanyl . Exemplary bicyclic heterocyclyl groups include , 
without limitation , indolinyl , isoindolinyl , dihydrobenzo 
furanyl , dihydrobenzothienyl , tetrahydrobenzothienyl , tetra 
hydrobenzofuranyl , tetrahydroindolyl , tetrahydroquinolinyl , 
tetrahydroisoquinolinyl , decahydroquinolinyl , decahy 
droisoquinolinyl , octahydrochromenyl , octahydroiso 
chromenyl , decahydronaphthyridinyl , decahydro - 1 , 8 - naph 
thyridinyl , octahydropyrrolo [ 3 , 2 - b ] pyrrole , indolinyl , 
phthalimidyl , naphthalimidyl , chromanyl , chromenyl , 
1H - benzo [ e ] [ 1 , 4 ] diazepinyl , 1 , 4 , 5 , 7 - tetrahydropyrano [ 3 , 4 
b ] pyrrolyl , 5 , 6 - dihydro - 4H - furo [ 3 , 2 - b ] pyrrolyl , 6 , 7 - di 
hydro - 5H - furo [ 3 , 2 - b ] pyranyl , 5 , 7 - dihydro - 4H - thieno [ 2 , 3 - c ] 
pyranyl , 2 , 3 - dihydro - 1H - pyrrolo [ 2 , 3 - b ] pyridinyl , 2 , 3 
dihydrofuro [ 2 , 3 - b ] pyridinyl , 4 , 5 , 6 , 7 - tetrahydro - 1H - pyrrolo [ 2 , 3 - b ] pyridinyl , 4 , 5 , 6 , 7 - tetrahydrofuro [ 3 , 2 - c ] pyridinyl , 
4 , 5 , 6 , 7 - tetrahydrothieno [ 3 , 2 - b ] pyridinyl , 1 , 2 , 3 , 4 - tetra 
hydro - 1 , 6 - naphthyridinyl , and the like . 
[ 0056 ] The term “ aryl ” refers to a radical of a monocyclic 
or polycyclic ( e . g . , bicyclic or tricyclic ) 4n + 2 aromatic ring 
system ( e . g . , having 6 , 10 , or 14 xt electrons shared in a 
cyclic array ) having 6 - 14 ring carbon atoms and zero 
heteroatoms provided in the aromatic ring system ( " C6 - 14 
aryl ” ) . In some embodiments , an aryl group has 6 ring 
carbon atoms ( “ Co aryl ” ; e . g . , phenyl ) . In some embodi 
ments , an aryl group has 10 ring carbon atoms ( “ C10 aryl ” ; 
e . g . , naphthyl such as 1 - naphthyl and 2 - naphthyl ) . In some 
embodiments , an aryl group has 14 ring carbon atoms ( “ C14 
aryl ” ; e . g . , anthracyl ) . “ Aryl ” also includes ring systems 
wherein the aryl ring , as defined above , is fused with one or 
more carbocyclyl or heterocyclyl groups wherein the radical 
or point of attachment is on the aryl ring , and in such 
instances , the number of carbon atoms continue to designate 
the number of carbon atoms in the aryl ring system . Unless 
otherwise specified , each instance of an aryl group is inde 
pendently unsubstituted ( an “ unsubstituted aryl ” ) or substi 
tuted ( a “ substituted aryl ” ) with one or more substituents . In 
certain embodiments , the aryl group is an unsubstituted 
C6 - 14 aryl . In certain embodiments , the aryl group is a 
substituted C6 - 14 aryl . 
[ 0057 ] The term “ heteroary? ” refers to a radical of a 5 - 14 
membered monocyclic or polycyclic ( e . g . , bicyclic , tricy 
clic ) 4n + 2 aromatic ring system ( e . g . , having 6 , 10 , or 14 ut 
electrons shared in a cyclic array ) having ring carbon atoms 
and 1 - 4 ring heteroatoms provided in the aromatic ring 
system , wherein each heteroatom is independently selected 
from nitrogen , oxygen , and sulfur ( “ 5 - 14 membered het 
eroaryl ” ) . In heteroaryl groups that contain one or more 
nitrogen atoms , the point of attachment can be a carbon or 
nitrogen atom , as valency permits . Heteroaryl polycyclic 
ring systems can include one or more heteroatoms in one or 
both rings . “ Heteroaryl ” includes ring systems wherein the 
heteroaryl ring , as defined above , is fused with one or more 
carbocyclyl or heterocyclyl groups wherein the point of 
attachment is on the heteroaryl ring , and in such instances , 
the number of ring members continue to designate the 
number of ring members in the heteroaryl ring system . 
“ Heteroaryl ” also includes ring systems wherein the het 
eroaryl ring , as defined above , is fused with one or more aryl 
groups wherein the point of attachment is either on the aryl 
or heteroaryl ring , and in such instances , the number of ring 
members designates the number of ring members in the 
fused polycyclic ( aryl / heteroaryl ) ring system . Polycyclic 
heteroaryl groups wherein one ring does not contain a 
heteroatom ( e . g . , indolyl , quinolinyl , carbazolyl , and the 
like ) the point of attachment can be on either ring , i . e . , either 
the ring bearing a heteroatom ( e . g . , 2 - indolyl ) or the ring that 
does not contain a heteroatom ( e . g . , 5 - indolyl ) . In certain 
embodiments , the heteroaryl is substituted or unsubstituted , 
5 - or 6 - membered , monocyclic heteroaryl , wherein 1 , 2 , 3 , 
or 4 atoms in the heteroaryl ring system are independently 
oxygen , nitrogen , or sulfur . In certain embodiments , the 
heteroaryl is substituted or unsubstituted , 9 - or 10 - mem 
bered , bicyclic heteroaryl , wherein 1 , 2 , 3 , or 4 atoms in the 
heteroaryl ring system are independently oxygen , nitrogen , 
or sulfur . 
[ 0058 ] . In some embodiments , a heteroaryl group is a 5 - 10 
membered aromatic ring system having ring carbon atoms 
and 1 - 4 ring heteroatoms provided in the aromatic ring 
system , wherein each heteroatom is independently selected 
from nitrogen , oxygen , and sulfur ( “ 5 - 10 membered het 
eroaryl ” ) . In some embodiments , a heteroaryl group is a 5 - 8 
membered aromatic ring system having ring carbon atoms 
and 1 - 4 ring heteroatoms provided in the aromatic ring 
system , wherein each heteroatom is independently selected 
from nitrogen , oxygen , and sulfur ( “ 5 - 8 membered het 
eroaryl ” ) . In some embodiments , a heteroaryl group is a 5 - 6 
membered aromatic ring system having ring carbon atoms 
and 1 - 4 ring heteroatoms provided in the aromatic ring 
system , wherein each heteroatom is independently selected 
from nitrogen , oxygen , and sulfur ( “ 5 - 6 membered het 
eroaryl ” ) . In some embodiments , the 5 - 6 membered het 
eroaryl has 1 - 3 ring heteroatoms selected from nitrogen , 
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oxygen , and sulfur . In some embodiments , the 5 - 6 mem 
bered heteroaryl has 1 - 2 ring heteroatoms selected from 
nitrogen , oxygen , and sulfur . In some embodiments , the 5 - 6 
membered heteroaryl has 1 ring heteroatom selected from 
nitrogen , oxygen , and sulfur . Unless otherwise specified , 
each instance of a heteroaryl group is independently unsub 
stituted ( an " unsubstituted heteroaryl ” ) or substituted ( a 
“ substituted heteroaryl ” ) with one or more substituents . In 
certain embodiments , the heteroaryl group is an unsubsti 
tuted 5 - 14 membered heteroaryl . In certain embodiments , 
the heteroaryl group is a substituted 5 - 14 membered het 
eroaryl . 
[ 0059 ] Exemplary 5 - membered heteroaryl groups contain 
ing 1 heteroatom include , without limitation , pyrrolyl , fura 
nyl , and thiophenyl . Exemplary 5 - membered heteroaryl 
groups containing 2 heteroatoms include , without limitation , imidazolyl , pyrazolyl , oxazolyl , isoxazolyl , thiazolyl , and 
isothiazolyl . Exemplary 5 - membered heteroaryl groups con 
taining 3 heteroatoms include , without limitation , triazolyl , 
oxadiazolyl , and thiadiazolyl . Exemplary 5 - membered het 
eroaryl groups containing 4 heteroatoms include , without 
limitation , tetrazolyl . Exemplary 6 - membered heteroaryl 
groups containing 1 heteroatom include , without limitation , 
pyridinyl . Exemplary 6 - membered heteroaryl groups con 
taining 2 heteroatoms include , without limitation , pyridazi 
nyl , pyrimidinyl , and pyrazinyl . Exemplary 6 - membered 
heteroaryl groups containing 3 or 4 heteroatoms include , 
without limitation , triazinyl and tetrazinyl , respectively . 
Exemplary 7 - membered heteroaryl groups containing 1 het 
eroatom include , without limitation , azepinyl , oxepinyl , and 
thiepinyl . Exemplary 5 , 6 - bicyclic heteroaryl groups include , 
without limitation , indolyl , isoindolyl , indazolyl , benzotri 
azolyl , benzothiophenyl , isobenzothiophenyl , benzofuranyl , 
benzoisofuranyl , benzimidazolyl , benzoxazolyl , benzisox 
azolyl , benzoxadiazolyl , benzthiazolyl , benzisothiazolyl , 
benzthiadiazolyl , indolizinyl , and purinyl . Exemplary 6 , 6 
bicyclic heteroaryl groups include , without limitation , naph 
thyridinyl , pteridinyl , quinolinyl , isoquinolinyl , cinnolinyl , 
quinoxalinyl , phthalazinyl , and quinazolinyl . Exemplary tri 
cyclic heteroaryl groups include , without limitation , phenan 
thridinyl , dibenzofuranyl , carbazolyl , acridinyl , phenothi 
azinyl , phenoxazinyl and phenazinyl . 
[ 0060 ] “ Heteroaralkyl ” is a subset of “ alkyl ” and refers to 
an alkyl group substituted by a heteroaryl group , wherein the 
point of attachment is on the alkyl moiety . 
[ 0061 ] The term “ unsaturated bond ” refers to a double or 
triple bond . 
[ 0062 ] The term “ unsaturated ” or “ partially unsaturated ” 
refers to a moiety that includes at least one double or triple 
bond . 
[ 0063 ] The term " saturated ” refers to a moiety that does 
not contain a double or triple bond , i . e . , the moiety only 
contains single bonds . 
[ 0064 ] Affixing the suffix " - ene ” to a group indicates the 
group is a divalent moiety , e . g . , alkylene is the divalent 
moiety of alkyl , alkenylene is the divalent moiety of alkenyl , 
alkynylene is the divalent moiety of alkynyl , heteroalkylene 
is the divalent moiety of heteroalkyl , heteroalkenylene is the 
divalent moiety of heteroalkenyl , heteroalkynylene is the 
divalent moiety of heteroalkynyl , carbocyclylene is the 
divalent moiety of carbocyclyl , heterocyclylene is the diva 
lent moiety of heterocyclyl , arylene is the divalent moiety of 
aryl , and heteroarylene is the divalent moiety of heteroaryl . 
[ 0065 ] A group is optionally substituted unless expressly 
provided otherwise . The term “ optionally substituted ” refers 
to being substituted or unsubstituted . In certain embodi 
ments , alkyl , alkenyl , alkynyl , heteroalkyl , heteroalkenyl , 
heteroalkynyl , carbocyclyl , heterocyclyl , aryl , and het 
eroaryl groups are optionally substituted . " Optionally sub 
stituted ” refers to a group which may be substituted or 
unsubstituted ( e . g . , " substituted ” or “ unsubstituted ” alkyl , 
" substituted " or " unsubstituted ” alkenyl , " substituted " or 
" unsubstituted ” alkynyl , “ substituted ” or “ unsubstituted ” 
heteroalkyl , “ substituted ” or “ unsubstituted ” heteroalkenyl , 
“ substituted ” or “ unsubstituted ” heteroalkynyl , " substi 
tuted ” or “ unsubstituted ” carbocyclyl , “ substituted ” or 
" unsubstituted ” heterocyclyl , " substituted " or " unsubsti 
tuted ” aryl or “ substituted ” or “ unsubstituted ” heteroaryl 
group ) . In general , the term “ substituted ” means that at least 
one hydrogen present on a group is replaced with a permis 
sible substituent , e . g . , a substituent which upon substitution 
results in a stable compound , e . g . , a compound which does 
not spontaneously undergo transformation such as by rear 
rangement , cyclization , elimination , or other reaction . 
Unless otherwise indicated , a “ substituted ” group has a 
substituent at one or more substitutable positions of the 
group , and when more than one position in any given 
structure is substituted , the substituent is either the same or 
different at each position . The term “ substituted ” is contem 
plated to include substitution with all permissible substitu 
ents of organic compounds , and includes any of the sub 
stituents described herein that results in the formation of a 
stable compound . The present invention contemplates any 
and all such combinations in order to arrive at a stable 
compound . For purposes of this invention , heteroatoms such 
as nitrogen may have hydrogen substituents and / or any 
suitable substituent as described herein which satisfy the 
valencies of the heteroatoms and results in the formation of 
a stable moiety . The invention is not intended to be limited 
in any manner by the exemplary substituents described 
herein . 
[ 0066 ] Exemplary carbon atom substituents include , but 
are not limited to , halogen , CN , - NO2 , N3 , — SO H , 
- SOH , OH , ORaa , ON ( Rbb ) 2 , - N ( Rbb ) 2 , 
- N ( Rbb ) x + X - , - N ( ORC ) Rbb , SH , SRaa , SSRC , 
C ( O ) Rad , CO , H , CHO , CORSC ) , CO , Ra ,
OCEO ) Raa , OCO , Raa , - CO )N ( Rbb ) , - oc ( O ) N ( Rb ) 2 , NRbbCEO ) Raa , NRbbCO Raa , 
- NRbbC ( = O ) N ( Rbb ) , C ( = NRbb ) Raa , Ce = NRbb ) 
ORT , OCENRbb ) Raa , - OCENRbb ) ORaa , 
- CENRbb ) N ( Rbb ) , OCENRbb ) N ( Rbb ) , NRbD 
ENRbb ) N ( Rbb ) 2 , CEO ) NROLSO Raa , — NRbbSO , Raa , 
SON ( Rbb ) 2 , SO Raa , SOZORaa , OSO Raa , 
S ( = O ) Raa , - OS ( O ) Raa , Si ( Raa ) z , OSi ( Raa ) z , 
CES ) N ( Rbb ) 2 , CEO ) SRaa , CES ) SRaa , SC ( S ) SRaa , — SC ( = O ) SRaa , - OCO ) SRa , SCO ) 
ORaa , SCO ) Raa , P ( = O ) , Raa , OPO ) , Raa , 
- P ( O ) ( Raa ) 2 , OP = O ) ( Raa ) 2 , COP ( O ) ( ORC ) 2 , 
P = O ) , N ( Rbb ) 2 , OP = O ) , N ( Rbb ) 2 , P = O ) ( NR65 ) 2 , OPO ) ( NRbb ) 2 , NRbbP = O ) ( ORC ) 2 , NRbbp 
FO ) ( NRbb ) 2 , — P ( RC ) 2 , P ( RC ) , OP ( RC ) 2 , OP ( R ) 3 , - B ( Raa ) 2 , B ( ORC ) 2 , BRA ( OR ) , C1 - 10 alkyl , 
C1 - 10 perhaloalkyl , C2 - 10 alkenyl , C2 - 10 alkynyl , heteroC1 - 10 
alkyl , heteroC2 - 10 alkenyl , heteroC2 - 10 alkynyl , C3 - 10 carbo 
cyclyl , 3 - 14 membered heterocyclyl , C6 - 14 aryl , and 5 - 14 
membered heteroaryl , wherein each alkyl , alkenyl , alkynyl , 
heteroalkyl , heteroalkenyl , heteroalkynyl , carbocyclyl , het 
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erocyclyl , aryl , and heteroaryl is independently substituted 
with 0 , 1 , 2 , 3 , 4 , or 5 Rdd groups ; 
[ 0067 ] or two geminal hydrogens on a carbon atom are 
replaced with the group = 0 , = S , = NN ( Rbb ) 2 , = NNRbbC 
GORA , = NNRbbC ( O ) OR , = NNRÉS ( = O ) Raa , 
= NRbb , or = NOR ; 
[ 0068 ] each instance of Rad is , independently , selected 
from C1 - 10 alkyl , C1 - 10 perhaloalkyl , C2 - 10 alkenyl , C2 - 10 
alkynyl , heteroC1 -10 alkyl , heteroC2 - 10alkenyl , heteroC2 
1oalkynyl , C3 - 10 carbocyclyl , 3 - 14 membered heterocyclyl , 
C6 - 14 aryl , and 5 - 14 membered heteroaryl , or two Raa groups 
are joined to form a 3 - 14 membered heterocyclyl or 5 - 14 
membered heteroaryl ring , wherein each alkyl , alkenyl , 
alkynyl , heteroalkyl , heteroalkenyl , heteroalkynyl , carbocy 
clyl , heterocyclyl , aryl , and heteroaryl is independently 
substituted with 0 , 1 , 2 , 3 , 4 , or 5 Rdd groups ; 
[ 0069 ] each instance of Rbb is , independently , selected 
from hydrogen , OH , ORaa , — N ( RC ) 2 , CN , 
- C ( O ) Raa , CEO ) N ( RCC ) , CO , Raa , SO , Raa , 
- C NRCORaa , _ CENRC ) N ( RC ) 2 , SO N ( RC ) 2 , 
- SO , R “ , SO , OR , SORaa , C S ) N ( RCC ) , 
- CO )SRC , CES ) SRC , - PO ) Raa , — P ( O ) ( R44 ) 2 , — P ( 0 ) 2N ( Rº ) 2 , — P ( = O ) ( NRC ) 2 , C1 - 10 alkyl , 
C1 - 10 perhaloalkyl , C2 - 10 alkenyl , C2 - 10 alkynyl , heteroC ) . 
ioalkyl , heteroC2 - 1oalkenyl , heteroC2 - 10 alkynyl , C3 - 10 car 
bocyclyl , 3 - 14 membered heterocyclyl , C6 - 14 aryl , and 5 - 14 
membered heteroaryl , or two Rb groups are joined to form 
a 3 - 14 membered heterocyclyl or 5 - 14 membered heteroaryl 
ring , wherein each alkyl , alkenyl , alkynyl , heteroalkyl , het 
eroalkenyl , heteroalkynyl , carbocyclyl , heterocyclyl , aryl , 
and heteroaryl is independently substituted with 0 , 1 , 2 , 3 , 4 , 
or 5 Rdd groups ; 
[ 0070 ] each instance of RºC is , independently , selected 
from hydrogen , C - 10 alkyl , C - 10 perhaloalkyl , C2 - 10 alk 
enyl , C2 - 10 alkynyl , heteroC1 - 10 alkyl , heteroC2 - 10 alkenyl , 
heteroC2 - 10 alkynyl , C3 - 10 carbocyclyl , 3 - 14 membered het 
erocyclyl , C6 - 14 aryl , and 5 - 14 membered heteroaryl , or two 
RC groups are joined to form a 3 - 14 membered heterocyclyl 
or 5 - 14 membered heteroaryl ring , wherein each alkyl , 
alkenyl , alkynyl , heteroalkyl , heteroalkenyl , heteroalkynyl , 
carbocyclyl , heterocyclyl , aryl , and heteroaryl is indepen 
dently substituted with 0 , 1 , 2 , 3 , 4 , or 5 Rdd groups ; 
[ 0071 ] each instance of Rdd is , independently , selected 
from halogen , CN , — NO2 , N3 , — SO , H , SO2H , 
OH , OR , ON ( RM2 , N ( RH ) 2 , N ( RH ) 3 + X " , 
- N ( OR ) RF , SH , Sree , SSRee , CEO ) Ree , 
- CO , H , CO , Ree , OC ( O ) Ree , OCO , Ree , 
CO )N ( RH ) 2 , OCO )N ( RH ) 2 - NRC = ) Ree , 
- NRCO Ree , NRC = O ) N ( R ) 2 , C = NRB ORee , 
- OCNRT Ree , OCENRBORE , CENRÍN ( RH ) 2 OC = NRØN ( RH ) 2 NR CNRØN ( RO ) 2 , 
- NRASO Ree , SO N ( R ) , SO Ree , SOZORE , 
- OSO Ree , - S ( O ) Ree , Si ( R ) 3 , OSi ( Ree ) 3 , 
- CES )N ( R ) , CEO ) SRee , C = S ) SRee , SC ( S ) SRee , P ( 0 ) Ree , P ( = O ) ( Re ) 2 , OP = O ) ( Re ) 2 , OP ( = O ) ( OR ) 2 , C1 - 6 alkyl , C1 . 6 perhaloalkyl , 
C2 - 6 alkenyl , C2 - 6 alkynyl , heteroC1 - galkyl , heteroC2 - galk 
enyl , heteroC2 - galkynyl , C3 - 10 carbocyclyl , 3 - 10 membered 
heterocyclyl , C6 - 10 aryl , 5 - 10 membered heteroaryl , wherein 
each alkyl , alkenyl , alkynyl , heteroalkyl , heteroalkenyl , het 
eroalkynyl , carbocyclyl , heterocyclyl , aryl , and heteroaryl is 
independently substituted with 0 , 1 , 2 , 3 , 4 , or 5 R groups , 
or two geminal Rdd substituents can be joined to form — O 
or = S ; 
[ 0072 ] each instance of Ree is , independently , selected 
from C1 - 6 alkyl , C1 - 6 perhaloalkyl , C2 - 6 alkenyl , C2 - 6 alky 
nyl , heteroC1 - 6 alkyl , heteroC2 - galkenyl , heteroC2 - 6 alkynyl , 
C3 - 10 carbocyclyl , C6 - 10 aryl , 3 - 10 membered heterocyclyl , 
and 3 - 10 membered heteroaryl , wherein each alkyl , alkenyl , 
alkynyl , heteroalkyl , heteroalkenyl , heteroalkynyl , carbocy 
clyl , heterocyclyl , aryl , and heteroaryl is independently 
substituted with 0 , 1 , 2 , 3 , 4 , or 5 R88 groups ; [ 0073 ] each instance of Rf is , independently , selected from 
hydrogen , C1 - 6 alkyl , C1 - 6 perhaloalkyl , C2 - 6 alkenyl , C2 - 6 
alkynyl , heteroC1 - talkyl , heteroC2 - galkenyl , heteroC2 - galky 
nyl , C3 - 10 carbocyclyl , 3 - 10 membered heterocyclyl , C6 - 10 
aryl and 5 - 10 membered heteroaryl , or two RB groups are joined to form a 3 - 10 membered heterocyclyl or 5 - 10 
membered heteroaryl ring , wherein each alkyl , alkenyl , 
alkynyl , heteroalkyl , heteroalkenyl , heteroalkynyl , carbocy 
clyl , heterocyclyl , aryl , and heteroaryl is independently 
substituted with 0 , 1 , 2 , 3 , 4 , or 5 R88 groups ; and [ 0074 ] each instance of R88 is , independently , halogen , 
CN , - NO2 , N3 , — SO H , SO3H , OH , OC1 - 6 
alkyl , - ON ( C1 - 6 alkyl ) 2 , — N ( C1 - 6 alkyl ) 2 , - N ( C1 -6 alkyl ) 
3 + X “ , – NH ( C1 - 6 alkyl ) 2 + X , NH ( C1 - 6 alkyl ) * X , 
- NH3 + X , - N ( OC1 -6 alkyl ) ( C1 - 6 alkyl ) , - N ( OH ) ( C1 - 6 
alkyl ) , - NH ( OH ) , SH , SC1 - 6 alkyl , SS ( C1 - 6 alkyl ) , 
CEO ) ( C1 - 6 alkyl ) , CO2H , CO2 ( C1 - 6 alkyl ) , OC 
FO ) ( C1 - 6 alkyl ) , - OCO2 ( C1 -6 alkyl ) , — CEO ) NH2 ,
CEO ) N ( C1 -6 alkyl ) 2 , OC ( = O ) NH ( C1 - 6 alkyl ) , 
- NHC ( = O ) ( C1 -6 alkyl ) , - N ( C1 - 6 alkyl ) C ( = O ) ( C1 -6 
alkyl ) , NHCO ( C1 - 6 alkyl ) , NHCEO ) N ( C - 6 alkyl ) 2 , 
NHC ( CO ) NH ( C1 - 6 alkyl ) , NHC ( O ) NH , 
C NH ) O ( C1 - 6 alkyl ) , - OCE = NH ) ( C1 - 6 alkyl ) , OC ( NH ) OC1 - 6 alkyl , C NH ) N ( C1 - 6 alkyl ) 2 , CC = NH ) 
NH ( C1 - 6 alkyl ) , C ( - NHNH , LOCK _ NH ) N ( C1 - 6 
alkyl ) , OC ( NH ) NH ( C1 - 6 alkyl ) , OC ( NH ) NH , NHC ( NHN ( C1 - 6 alkyl ) , NHC ( — NH ) NH – NHSO , ( C1 - 6 
alkyl ) , SO , N ( C1 - 6 alkyl ) 2 , SO2NH ( C1 - alkyl ) , 
SO2NH2 , S02C1 - 6 alkyl , SO20C1 - 6 alkyl , 
- OSO2C1 - 6 alkyl , SOC1 -6 alkyl , Si ( C1 - 6 alkyl ) 3 , OSIC . . alkyl ) z - CES )N ( C1 - 6 alkyl ) 2 , CES ) NH ( C1 - 6 
alkyl ) , CES ) NH2 , C O ) S ( C1 - 6 alkyl ) , C ( S ) SC1 - 6 
alkyl , SCES )SC1 - 6 alkyl , — P ( 0 ) 2 ( C1 - 6 alkyl ) , 
- P ( = O ) ( C1 - 6 alkyl ) 2 , OP = O ) ( C1 - 6 alkyl ) 2 , OP ( = O ) ( OC1 - 6 alkyl ) 2 , C1 - 6 alkyl , C1 - 6 perhaloalkyl , C2 - 6 alkenyl , 
C2 - 6 alkynyl , heteroC1 - talkyl , heteroC2 - talkenyl , heteroC2 
6alkynyl , C3 - 10 carbocyclyl , C6 - 10 aryl , 3 - 10 membered het 
erocyclyl , 5 - 10 membered heteroaryl ; or two geminal Reg 
substituents can be joined to form = O or = S ; wherein X 
is a counterion . 
[ 0075 ] In certain embodiments , the carbon atom substitu 
ents are independently halogen , substituted or unsubstituted 
C1 - 6 alkyl , ORaa , SRaa , - N ( Rbb ) 2 , CN , SCN , 
- NO , , - C ( O ) Raa , CO Raa , CEO ) N ( Rbb ) 2 , 
- OC ( O ) Raa , OCO , Raa , OC ( = O ) N ( Rbb ) , 
NRbbCO ) Raa , NRbbCo , Raq , or - NRbbC = ON ( Rbb ) 2 . In certain embodiments , the carbon atom substituents 
are independently halogen , substituted or unsubstituted C1 - 6 
alkyl , OR , SRa , — N ( Rb + ) 2 , CN , SCN , or 
— NO2 . [ 0076 ] The term " halo ” or “ halogen ” refers to fluorine 
( fluoro , F ) , chlorine ( chloro , Cl ) , bromine ( bromo , 
- Br ) , or iodine ( iodo , — I ) . 
[ 0077 ] The term “ hydroxyl ” or “ hydroxy ” refers to the 
group - OH . The term “ substituted hydroxyl ” or “ substi 
tuted hydroxyl , ” by extension , refers to a hydroxyl group 
US 2019 / 0038782 A1 Feb . 7 , 2019 
wherein the oxygen atom directly attached to the parent 
molecule is substituted with a group other than hydrogen , 
and includes groups selected from ORA , ON ( Rbb ) 2 , 
- OC ( = O ) SRaa , - OC ( O ) Raa , OCO , Raa , OC 
FO ) N ( Rbb ) , OCENRbb ) Raa , OC = NR5b ) ORaa , 
- OCENRbb ) N ( Rbb ) , - OS ( O ) Raa , OSO , Raa , 
- OSi ( Raa ) 3 , OP ( RC ) 2 , OP ( RC ) , OP = O ) , Raa , 
- OP ( = O ) ( R49 ) 2 , OP = O ) ( ORC ) , OP = O ) , N ( Rbb ) 
2 , and OPO ) ( NRbb ) 2 , wherein Raa , Rbb , and RCC are as 
defined herein . [ 0078 ] The term “ thiol ” or “ thio ” refers to the group SH . 
The term “ substituted thiol ” or “ substituted thio , ” by exten 
sion , refers to a thiol group wherein the sulfur atom directly 
attached to the parent molecule is substituted with a group 
other than hydrogen , and includes groups selected from 
— SRaa , S = SRC , SCISSRaa , — SCOSRaa , 
- SCO ) ORaa , and SC ( O ) Raa , wherein Raa and Rce 
are as defined herein . 
[ 0079 ] The term “ amino ” refers to the group - NH2 . The 
term “ substituted amino , ” by extension , refers to a mono 
substituted amino , a disubstituted amino , or a trisubstituted 
amino . In certain embodiments , the “ substituted amino ” is a 
monosubstituted amino or a disubstituted amino group . 
[ 0080 ] The term “ monosubstituted amino ” refers to an 
amino group wherein the nitrogen atom directly attached to 
the parent molecule is substituted with one hydrogen and 
one group other than hydrogen , and includes groups selected 
from _ NH ( R ^  ^  ) , NHCUZO ) Rºd , NHCO , Rºd , NHC 
GO ) N ( Rbb ) , — NHCENRbb ) N ( Rbb ) , — NHSO , Raa , 
- NHP ( O ) ( ORC ) , and NHP ( O ) ( NRb62 , wherein 
Raa , Rbb and Rce are as defined herein , and wherein Rbb of 
the group — NH ( Rbb ) is not hydrogen . 
[ 0081 ] The term “ disubstituted amino ” refers to an amino 
group wherein the nitrogen atom directly attached to the 
parent molecule is substituted with two groups other than 
hydrogen , and includes groups selected from — N ( R ” ) 2 , 
- NRb6 CEO ) Raa , NRbbCo , Raa , NRbbCEO ) N ( Rbb ) 2 , NRbbC = NRbb ) N ( Rbb ) 2 NRbbso , Raa , 
- NRb6P ( = O ) ( ORC ) , and NRbbP ( = O ) ( NRbb ) 2 , 
wherein Raa , Rbb , and RCC are as defined herein , with the 
proviso that the nitrogen atom directly attached to the parent 
molecule is not substituted with hydrogen . 
[ 0082 ] The term “ trisubstituted amino ” refers to an amino 
group wherein the nitrogen atom directly attached to the 
parent molecule is substituted with three groups , and 
includes groups selected from - N ( Rºb ) 3 and — N ( Rbb ) 3 + 
X “ , wherein Rb6 and X - are as defined herein . [ 0083 ] The term “ sulfonyl ” refers to a group selected from 
- SO N ( R ) 2 , SO , Raa , and — SO ORA , wherein Raa 
and Rbb are as defined herein . [ 0084 ] The term " sulfinyl ” refers to the group - S ( O ) 
Raa , wherein Raa is as defined herein . 
[ 0085 ] The term " carbonyl ” refers a group wherein the 
carbon directly attached to the parent molecule is sp ? 
hybridized , and is substituted with an oxygen , nitrogen or 
sulfur atom , e . g . , a group selected from ketones ( - C ( = O ) 
Raa ) , carboxylic acids ( CO2H ) , aldehydes ( CHO ) , 
esters ( - CO Raa , CEO ) SRa , C = S ) SRaa ) , amides 
CEO ) N ( Rbb ) 2 , CEO ) NRbbSO Raa , CAS )N ( Rbb ) , ) , and imines ( C = NRbb ) Raa , Ce = NRbb ) ORaa ) , 
- C = NR ) N ( Rbb ) 2 ) , wherein Raa and Rbb are as defined 
herein . 
[ 0086 ] The term “ silyl ” refers to the group — Si ( Raa ) 3 , 
wherein Raa is as defined herein . 
[ 0087 ] The term “ boronyl ” refers to boranes , boronic 
acids , boronic esters , borinic acids , and borinic esters , e . g . , 
boronyl groups of the formula — B ( Ra ) , B ( ORC ) 2 , and 
- BR ( ORC ) , wherein Rad and RCC are as defined herein . [ 0088 ] The term “ phosphino ” refers to the group — P ( RC ) 
7 , wherein RCC is as defined herein . An exemplary phosphino 
group is triphenylphosphine . 
[ 0089 ] The term “ phosphono ” refers to the group 
_ O ( P = O ) ( ORC ) Raa , wherein Raa and RCC are as defined 
herein . 
[ 0090 ] The term " phosphoramido ” refers to the group 
O ( P = O ) ( NRbb ) , wherein each Rbb is as defined herein . 
[ 0091 ] The term “ oxo ” refers to the group = 0 , and the 
term “ thiooxo ” refers to the group = S . 
[ 0092 ] Nitrogen atoms can be substituted or unsubstituted 
as valency permits , and include primary , secondary , tertiary , 
and quaternary nitrogen atoms . Exemplary nitrogen atom 
substituents include , but are not limited to , hydrogen , — OH , 
_ OR , — N ( RC ) 2 , - CN , CEO ) Raa , - C ( O ) N ( RCC ) 
2 , CO , Raa , — SO Raa , Ce = NRbb ) Raa , - CENRC ) 
ORA , - C NRC ) N ( RCC ) 2 , SO , N ( RC ) 2 , — SO RC , 
- SO , OR “ , – SOR , CES )N ( RCC ) 2 , - C ( O ) SRCE , 
CES ) SRC , P ( = O ) , Raa , — P ( O ) ( R44 ) 2 , — P ( O ) 2N ( RC ) 2 , P = O ) ( NRC ) 2 , C1 - 10 alkyl , C - 10 perhaloalkyl , 
C2 -10 alkenyl , C2 - 10 alkynyl , heteroC1 -10alkyl , heteroC2 
1oalkenyl , heteroC2 - 10alkynyl , C3 - 10 carbocyclyl , 3 - 14 mem 
bered heterocyclyl , C6 - 14 aryl , and 5 - 14 membered het 
eroaryl , or two RCC groups attached to an N atom are joined 
to form a 3 - 14 membered heterocyclyl or 5 - 14 membered 
heteroaryl ring , wherein each alkyl , alkenyl , alkynyl , het 
eroalkyl , heteroalkenyl , heteroalkynyl , carbocyclyl , hetero 
cyclyl , aryl , and heteroaryl is independently substituted with 
0 , 1 , 2 , 3 , 4 , or 5 Rad groups , and wherein Raa , R " , RCC and 
Rdd are as defined above . 
10093 ] . In certain embodiments , the substituent present on 
the nitrogen atom is an nitrogen protecting group ( also 
referred to herein as an “ amino protecting group ” ) . Nitrogen 
protecting groups include , but are not limited to , OH , 
- OR , — N ( RC ) , C ( O ) Raa , C ( O ) N ( RC ) , 
- CO , Raa , — SO , Raa , Ce = NRC ) Raa , — C = NRCC ) 
ORaa , C = NRC ) N ( RC ) , SO , N ( RC ) , SO , RC , 
SOZOR " , — SOR , CES ) N ( RC ) 2 , CEO ) SR°C , 
CCS ) SRC , C1 - 10 alkyl ( e . g . , aralkyl , heteroaralkyl ) , 
C2 -10 alkenyl , C2 - 10 alkynyl , heteroC1 - 10 alkyl , heteroC2 - 10 
alkenyl , heteroC2 - 10 alkynyl , C3 - 10 carbocyclyl , 3 - 14 mem 
bered heterocyclyl , C6 - 14 aryl , and 5 - 14 membered het 
eroaryl groups , wherein each alkyl , alkenyl , alkynyl , het 
eroalkyl , heteroalkenyl , heteroalkynyl , carbocyclyl , 
heterocyclyl , aralkyl , aryl , and heteroaryl is independently 
substituted with 0 , 1 , 2 , 3 , 4 , or 5 Rda groups , and wherein 
Raa , Rbb , Rce and Rdd are as defined herein . Nitrogen 
protecting groups are well known in the art and include those 
described in detail in Protecting Groups in Organic Synthe 
sis , T . W . Greene and P . G . M . Wuts , 3rd edition , John Wiley 
& Sons , 1999 , incorporated herein by reference . 
[ 0094 ] For example , nitrogen protecting groups such as 
amide groups ( e . g . , CCOR ) include , but are not 
limited to , formamide , acetamide , chloroacetamide , trichlo 
roacetamide , trifluoroacetamide , phenylacetamide , 3 - phe 
nylpropanamide , picolinamide , 3 - pyridylcarboxamide , 
N - benzoylphenylalanyl derivative , benzamide , p - phenyl 
benzamide , O - nitophenylacetamide , O - nitrophenoxyacet 
amide , acetoacetamide , ( N ' - dithiobenzyloxyacylamino ) ac 
etamide , 3 - ( p - hydroxyphenyl ) propanamide , 3 - ( 0 
US 2019 / 0038782 A1 Feb . 7 , 2019 
12 
nitrophenyl ) propanamide , 2 - methyl - 2 - ( o - nitrophenoxy ) 
propanamide , 2 - methyl - 2 - o - phenyl azophenoxy ) 
propanamide , 4 - chlorobutanamide , 3 - methyl - 3 
nitrobutanamide , o - nitrocinnamide , N - acetylmethionine 
derivative , O - nitrobenzamide and o - ( benzoyloxymethyl ) 
benzamide . 
[ 0095 ] Nitrogen protecting groups such as carbamate 
groups ( e . g . , — C O OR ) include , but are not limited to , 
methyl carbamate , ethyl carbamante , 9 - fluorenylmethyl car 
bamate ( Fmoc ) , 9 - ( 2 - sulfo ) fluorenylmethyl carbamate , 9 - ( 2 , 
7 - dibromo ) fluoroenylmethyl carbamate , 2 , 7 - di - t - butyl - 19 
( 10 , 10 - dioxo - 10 , 10 , 10 , 10 - tetrahydrothioxanthyl ) ] methyl 
carbamate ( DBD - Tmoc ) , 4 - methoxyphenacyl carbamate 
( Phenoc ) , 2 , 2 , 2 - trichloroethyl carbamate ( Troc ) , 2 - trimeth 
ylsilylethyl carbamate ( Teoc ) , 2 - phenylethyl carbamate 
( hz ) , 1 - ( 1 - adamantyl ) - 1 - methylethyl carbamate ( Adpoc ) , 
1 , 1 - dimethyl - 2 - haloethyl carbamate , 1 , 1 - dimethyl - 2 , 2 - di 
bromoethyl carbamate ( DB - t - BOC ) , 1 , 1 - dimethyl - 2 , 2 , 2 
trichloroethyl carbamate ( TCBOC ) , 1 - methyl - 1 - ( 4 - bipheny 
lyl ) ethyl carbamate ( Bpoc ) , 1 - ( 3 , 5 - di - t - butylphenyl ) - 1 
methylethyl carbamate ( t - Bumeoc ) , 2 - ( 2 - and 4 ' - pyridyl ) 
ethyl carbamate ( Pyoc ) , 2 - ( N , N - dicyclohexylcarboxamido ) 
ethyl carbamate , t - butylcarbamate ( BOC or Boc ) , 
1 - adamantyl carbamate ( Adoc ) , vinyl carbamate ( Voc ) , allyl 
carbamate ( Alloc ) , 1 - isopropylallyl carbamate ( Ipaoc ) , cin 
namyl carbamate ( Coc ) , 4 - nitrocinnamyl carbamate ( Noc ) , 
8 - quinolyl carbamate , N - hydroxypiperidinyl carbamate , 
alkyldithio carbamate , benzyl carbamate ( Cbz ) , p - methoxy 
benzyl carbamate ( Moz ) , p - nitobenzyl carbamate , p - bro 
mobenzyl carbamate , p - chlorobenzyl carbamate , 2 , 4 - dichlo 
robenzyl carbamate , 4 - methylsulfinylbenzyl carbamate 
( Msz ) , 9 - anthrylmethyl carbamate , diphenylmethyl carbam 
ate , 2 - methylthioethyl carbamate , 2 - methylsulfonylethyl 
carbamate , 2 - ( p - toluenesulfonyl ) ethyl carbamate , [ 2 - ( 1 , 3 
dithianyl ) ] methyl carbamate ( Dmoc ) , 4 - methylthiophenyl 
carbamate ( Mtpc ) , 2 , 4 - dimethylthiophenyl carbamate ( Bmpc ) , 2 - phosphonioethyl carbamate ( Peoc ) , 2 - triphenyl 
phosphonioisopropyl carbamate ( Ppoc ) , 1 , 1 - dimethyl - 2 
cyanoethyl carbamate , m - chloro - p - acyloxybenzyl carbam 
ate , p - ( dihydroxyboryl ) benzyl c arbamate , 
5 - benzisoxazolylmethyl carbamate , 2 - ( trifluoromethyl ) - 6 
chromonylmethyl carbamate ( Tcroc ) , m - nitrophenyl car 
bamate , 3 , 5 - dimethoxybenzyl carbamate , o - nitrobenzyl car 
bamate , 3 , 4 - dimethoxy - 6 - nitrobenzyl carbamate , phenyl?o 
nitrophenyl ) methyl carbamate , t - amyl carbamate , S - benzyl 
thiocarbamate , p - cyanobenzyl carbamate , cyclobutyl car 
bamate , cyclohexyl carbamate , cyclopentyl carbamate , 
cyclopropylmethyl carbamate , p - decyloxybenzyl carbam 
ate , 2 , 2 - dimethoxyacylvinyl carbamate , 0 - ( N , N - dimethyl 
carboxamido ) benzyl carbamate , 1 , 1 - dimethyl - 3 - ( N , N - dim 
ethylcarboxamido ) propyl carbamate , 1 , 1 - dimethylpropynyl 
carbamate , di ( 2 - pyridyl ) methyl carbamate , 2 - furanylmethyl 
carbamate , 2 - iodoethyl carbamate , isoborynl carbamate , 
isobutyl carbamate , isonicotinyl carbamate , p - ( p ' - methoxy 
phenylazo ) benzyl carbamate , 1 - methylcyclobutyl carbam 
ate , 1 - methylcyclohexyl carbamate , 1 - methyl - 1 - cyclopropy 
Imethyl carbamate , 1 - methyl - 1 - ( 3 , 5 - dimethoxyphenyl ) ethyl 
carbamate , l - methyl - 1 - ( p - phenylazophenyl ) ethyl carbam 
ate , 1 - methyl - 1 - phenylethyl carbamate , 1 - methyl - 1 - ( 4 
pyridyl ) ethyl carbamate , phenyl carbamate , p - ( phenylazo ) 
benzyl carbamate , 2 , 4 , 6 - tri - t - butylphenyl carbamate , 
4 - ( trimethylammonium ) benzyl carbamate , and 2 , 4 , 6 - trim 
ethylbenzyl carbamate . 
[ 0096 ] Nitrogen protecting groups such as sulfonamide 
groups ( e . g . , - S ( O ) 2R44 ) include , but are not limited to , 
p - toluenesulfonamide ( Ts ) , benzenesulfonamide , 2 , 3 , 6 , 
trimethyl - 4 - methoxybenzenesulfonamide ( Mt ) , 2 , 4 , 6 
trimethoxybenzenesulfonamide ( Mtb ) , 2 , 6 - dimethyl - 4 
methoxybenzenesulfonamide ( Pme ) , 2 , 3 , 5 , 6 - tetramethyl - 4 
methoxybenzenesulfonamide ( Mte ) , 4 - methoxybenzenesulfonamide ( Mbs ) , 2 , 4 , 6 - trimethylben 
zenesulfonamide ( Mts ) , 2 , 6 - dimethoxy - 4 - methylbenzene 
sulfonamide ( iMds ) , 2 , 2 , 5 , 7 , 8 - pentamethylchroman - 6 - sul 
fonamide ( Pmc ) , methanesulfonamide ( Ms ) , O - trimethyl 
silylethanesulfonamide ( SES ) , 9 - anthracenesulfonamide , 
4 - ( 4 , 8 ' - dimethoxynaphthylmethyl ) benzenesulfonamide ( DNMBS ) , benzylsulfonamide , trifluoromethylsulfonamide , 
and phenacylsulfonamide . 
[ 0097 ] Other nitrogen protecting groups include , but are 
not limited to , phenothiazinyl - ( 10 ) - acyl derivative , N ' - p 
toluenesulfonylaminoacyl derivative , N ' - phenylaminothioa 
cyl derivative , N - benzoylphenylalanyl derivative , N - acetyl 
methionine derivative , 4 , 5 - diphenyl - 3 - oxazolin - 2 - one , 
N - phthalimide , N - dithiasuccinimide ( Dts ) , N - 2 , 3 - diphenyl 
maleimide , N - 2 , 5 - dimethylpyrrole , N - 1 , 1 , 4 , 4 - tetramethyld 
isilylazacyclopentane adduct ( STABASE ) , 5 - substituted 
1 , 3 - dimethyl - 1 , 3 , 5 - triazacyclohexan - 2 - one , 5 - substituted 
1 , 3 - dibenzyl - 1 , 3 , 5 - triazacyclohexan - 2 - one , 1 - substituted 
3 , 5 - dinitro - 4 - pyridone , N - methylamine , N - allylamine , 
N - [ 2 - ( trimethyl silyl ) ethoxy ] methylamine ( SEM ) , N - 3 - ac 
etoxypropylamine , N - ( 1 - isopropyl - 4 - nitro - 2 - oxo - 3 - py 
roolin - 3 - yl ) amine , quaternary ammonium salts , N - ben 
zylamine , N - di ( 4 - methoxyphenyl ) methyl amine , N - 5 dibenzosuberylamine , N - triphenylmethylamine ( Tr ) , N - [ ( 4 
methoxyphenyl ) diphenylmethyl ] amine ( MMTr ) , N - 9 
phenylfluorenylamine ( PhF ) , N - 2 , 7 - dichloro - 9 
fluorenylmethyleneamine , N - ferrocenylmethylamino ( Fcm ) , 
N - 2 - picolylamino N ' - oxide , N - 1 , 1 - dimethylthiomethyl 
eneamine , N - benzylideneamine , N - p - methoxybenzylide 
neamine , N - diphenylmethyleneamine , N - [ ( 2 - pyridyl ) mesi 
tyl ] methyleneamine , N - ( N , N - dimethylaminomethylene ) 
amine , N , N ' - isopropylidenediamine , N - p 
nitrobenzylideneamine , N - salicylideneamine , N - 5 
chlorosalicylideneamine , N - ( 5 - chloro - 2 - hydroxyphenyl ) 
phenylmethyleneamine , N - cyclohexylideneamine , N - ( 5 , 5 
dimethyl - 3 - oxo - 1 - cyclohexenyl ) amine , N - borane 
derivative , N - diphenylborinic acid derivative , N - [ phenyl ( pentaacylchromium - or tungsten ) acyl ] amine , N - copper 
chelate , N - zinc chelate , N - nitroamine , N - nitrosoamine , 
amine N - oxide , diphenylphosphinamide ( Dpp ) , dimethylth 
iophosphinamide ( Mpt ) , diphenylthiophosphinamide ( Ppt ) , 
dialkyl phosphoramidates , dibenzyl phosphoramidate , 
diphenyl phosphoramidate , benzenesulfenamide , O - ni 
trobenzenesulfenamide ( Nps ) , 2 , 4 - dinitrobenzenesulfena 
mide , pentachlorobenzenesulfenamide , 2 - nitro - 4 - methoxy 
benzenesulfenamide , triphenylmethylsulfenamide , and 3 - nitropyridinesulfenamide ( Npys ) . 
[ 0098 ] In certain embodiments , the substituent present on 
an oxygen atom is an oxygen protecting group ( also referred 
to herein as an “ hydroxyl protecting group ” ) . Oxygen pro 
tecting groups include , but are not limited to , - Raa , 
- N ( Rbb ) , C ( O ) SRaa , - C ( O ) Raa , - CO Raa , 
- C = O ) N ( Rbb ) 2 , CENRbb ) Raa , - C NRbb ) ORaa , 
- CE = NRbb ) N ( Rbb ) 2 , - S ( = O ) Raa , SO Raa , Si ( Raa ) 
3 , — P ( RCC ) 2 , — P ( R ) 3 , — P ( O ) Raa , PC = O ) ( Raa ) 2 , 
P ( = O ) ( ORC ) 2 , P = O ) N ( Rbb ) 2 , and - P = O ) ( NR65 ) 2 , wherein Raa , Rbb , and RCC are as defined herein . Oxygen 
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protecting groups are well known in the art and include those 
described in detail in Protecting Groups in Organic Synthe 
sis , T . W . Greene and P . G . M . Wuts , 3rd edition , John Wiley 
& Sons , 1999 , incorporated herein by reference . 
[ 0099 ] Exemplary oxygen protecting groups include , but 
are not limited to , methyl , methoxylmethyl ( MOM ) , meth 
ylthiomethyl ( MTM ) , t - butylthiomethyl , ( phenyldimethylsi 
lyl ) methoxymethyl ( SMOM ) , benzyloxymethyl ( BOM ) , 
p - methoxybenzyloxymethyl ( PMBM ) , ( 4 - methoxyphe 
noxy ) methyl ( p - AOM ) , guaiacolmethyl ( GUM ) , t - butoxym 
ethyl , 4 - pentenyloxymethyl ( POM ) , siloxymethyl , 
2 - methoxyethoxymethyl ( MEM ) , 2 , 2 , 2 - trichloroethoxym 
ethyl , bis ( 2 - chloroethoxy ) methyl , 2 - ( trimethyl Silyl ) 
ethoxymethyl ( SEMOR ) , tetrahydropyranyl ( THP ) , 3 - bro 
motetrahydropyranyl , tetrahydrothiopyranyl , 
1 - methoxycyclohexyl , 4 - methoxytetrahydropyranyl ( MTHP ) , 4 - methoxytetrahydrothiopyranyl , 4 - methoxytetra 
hydrothiopyranyl S , S - dioxide , 1 - [ ( 2 - chloro - 4 - methyl ) phe 
nyl ] - 4 - methoxypiperidin - 4 - yl ( CTMP ) , 1 , 4 - dioxan - 2 - yl , tet 
rahydrofuranyl , tetrahydrothiofuranyl , 2 , 3 , 3a , 4 , 5 , 6 , 7 , 7a 
octahydro - 7 , 8 , 8 - trimethyl - 4 , 7 - methanobenzofuran - 2 - yl , 
1 - ethoxyethyl , 1 - ( 2 - chloroethoxy ) ethyl , 1 - methyl - 1 
methoxyethyl , 1 - methyl - 1 - benzyloxyethyl , 1 - methyl - 1 - ben 
zyloxy - 2 - fluoroethyl , 2 , 2 , 2 - trichloroethyl , 2 - trimethyl silyl 
ethyl , 2 - ( phenylselenyl ) ethyl , t - butyl , allyl , p - chlorophenyl , 
p - methoxyphenyl , 2 , 4 - dinitrophenyl , benzyl ( Bn ) , 
p - methoxybenzyl , 3 , 4 - dimethoxybenzyl , O - nitrobenzyl , 
p - nitrobenzyl , p - halobenzyl , 2 , 6 - dichlorobenzyl , p - cya 
nobenzyl , p - phenylbenzyl , 2 - picolyl , 4 - picolyl , 3 - methyl - 2 
picolyl N - oxido , diphenylmethyl , p , p ' - dinitrobenzhydryl , 
5 - dibenzosuberyl , triphenylmethyl , a - naphthyldiphenylm 
ethyl , p - methoxyphenyldiphenylmethyl , di ( p - methoxyphe 
nyl ) phenylmethyl , tri ( p - methoxyphenyl ) methyl , 4 - ( 4 ' - bro 
mophenacyloxyphenyl ) diphenylmethyl , 4 , 49 , 4 " - tris ( 4 , 5 
dichlorophthalimidophenyl ) methyl , 4 , 4 ' , 4 " - tris ( levulinoyloxyphenyl ) methyl , 4 , 41 , 4 " - tris 
( benzoyloxyphenyl ) methyl , 3 - ( imidazol - 1 - yl ) bis ( 4 ' , 4 " - 
dimethoxyphenyl ) methyl , 1 , 1 - bis ( 4 - methoxyphenyl ) - 1 ' 
pyrenylmethyl , 9 - anthryl , 9 - ( 9 - phenyl ) xanthenyl , 9 - 19 
phenyl - 10 - oxo ) anthryl , 1 , 3 - benzodithiolan - 2 - yl , 
benzisothiazolyl S , S - dioxido , trimethylsilyl ( TMS ) , trieth 
ylsilyl ( TES ) , triisopropylsilyl ( TIPS ) , dimethylisopropylsi 
lyl ( IPDMS ) , diethylisopropylsilyl ( DEIPS ) , dimethylthex 
ylsilyl , t - butyldimethylsilyl ( TBDMS ) , t - butyldiphenylsilyl 
( TBDPS ) , tribenzylsilyl , tri - p - xylylsilyl , triphenylsilyl , 
diphenylmethylsilyl ( DPMS ) , t - butylmethoxyphenylsilyl 
( TBMPS ) , formate , benzoylformate , acetate , chloroacetate , 
dichloroacetate , trichloroacetate , trifluoroacetate , methoxy 
acetate , triphenylmethoxyacetate , phenoxyacetate , p - chloro 
phenoxyacetate , 3 - phenylpropionate , 4 - oxopentanoate ( le 
vulinate ) , 4 , 4 - ( ethylenedithio ) pentanoate ( levulinoyldithioacetal ) , pivaloate , adamantoate , crotonate , 
4 - methoxycrotonate , benzoate , p - phenylbenzoate , 2 , 4 , 6 
trimethylbenzoate ( mesitoate ) , methyl carbonate , 9 - fluore 
nylmethyl carbonate ( Fmoc ) , ethyl carbonate , 2 , 2 , 2 - trichlo 
roethyl carbonate ( Troc ) , 2 - trimethylsilyl ) ethyl carbonate 
( TMSEC ) , 2 - ( phenylsulfonyl ) ethyl carbonate ( Psec ) , 2 - ( tri 
phenylphosphonio ) ethyl carbonate ( Peoc ) , isobutyl carbon 
ate , vinyl carbonate , allyl carbonate , t - butyl carbonate ( BOC 
or Boc ) , p - nitrophenyl carbonate , benzyl carbonate , 
p - methoxybenzyl carbonate , 3 , 4 - dimethoxybenzyl carbon 
ate , O - nitrobenzyl carbonate , p - nitrobenzyl carbonate , 
S - benzyl thiocarbonate , 4 - ethoxy - 1 - napththyl carbonate , 
methyl dithiocarbonate , 2 - iodobenzoate , 4 - azidobutyrate , 
4 - nitro - 4 - methylpentanoate , 0 - ( dibromomethyl ) benzoate , 
2 - formylbenzenesulfonate , 2 - ( methylthiomethoxy ) ethyl , 
4 - ( methylthiomethoxy ) butyrate , 2 - methylthiomethoxym 
ethyl ) benzoate , 2 , 6 - dichloro - 4 - methylphenoxyacetate , 2 , 6 
dichloro - 4 - ( 1 , 1 , 3 , 3 - tetramethylbutyl ) phenoxyacetate , 2 , 4 bis ( 1 , 1 - dimethylpropyl ) phenoxyacetate , 
chlorodiphenylacetate , isobutyrate , monosuccinoate , ( E ) - 2 
methyl - 2 - butenoate , 0 - ( methoxyacyl ) benzoate , a - naph 
thoate , nitrate , alkyl N , N , N ' , N ' - tetramethylphosphorodiami 
date , alkyl N - phenylcarbamate , borate , dimethylphosphinothioyl , alkyl 2 , 4 - dinitrophenylsulfenate , 
sulfate , methanesulfonate ( mesylate ) , benzylsulfonate , and 
tosylate ( Ts ) . 
[ 0100 ] In certain embodiments , the substituent present on 
a sulfur atom is a sulfur protecting group ( also referred to as 
a “ thiol protecting group ” ) . Sulfur protecting groups include , 
but are not limited to , Raa , - N ( Rbb ) 2 , - C ( O ) SRaa , 
- C ( O ) Raa , - CO , Raa , - C O ) N ( Rbb ) 2 , C NRbb ) 
Raa , C = NRbb ) ORaa , - C = NRbb ) N ( Rbb ) 2 , - S ( = O ) 
Raa , SO Raa , Si ( Raa ) , P ( RO )2 = P ( R ) 3 , 
— P ( = O ) , Raa , — P ( O ) ( Raa ) 2 , P ( = O ) ( ORC ) 2 , 
- P40 ) , N ( Rbb ) , and — P ( O ) ( NRbb ) 2 , wherein Raa , 
Rbb , and Rce are as defined herein . Sulfur protecting groups 
are well known in the art and include those described in 
detail in Protecting Groups in Organic Synthesis , T . W . 
Greene and P . G . M . Wuts , 3rd edition , John Wiley & Sons , 
1999 , incorporated herein by reference . 
[ 0101 ] The term " heteroatom ” refers to an atom that is not 
hydrogen or carbon . In certain embodiments , the heteroatom 
is a nitrogen , oxygen , or sulfur . In certain embodiments , the 
heteroatom is a nitrogen or oxygen . In certain embodiments , 
the heteroatom is nitrogen . In certain embodiments , the 
heteroatom is oxygen . In certain embodiments , the heteroa 
tom is sulfur . 
10102 ] . A “ counterion ” or “ anionic counterion ” is a nega 
tively charged group associated with a positively charged 
group in order to maintain electronic neutrality . An anionic 
counterion may be monovalent ( i . e . , including one formal 
negative charge ) . An anionic counterion may also be mul 
tivalent ( i . e . , including more than one formal negative 
charge ) , such as divalent or trivalent . Exemplary counterions 
include halide ions ( e . g . , F - , Cl - , Br , 14 ) , NO3 - , C104 , 
OH® , H2PO4 , HCO3 , HSO4 , sulfonate ions ( e . g . , meth 
ansulfonate , trifluoromethanesulfonate , p - toluenesulfonate , 
benzenesulfonate , 10 - camphor sulfonate , naphthalene - 2 
sulfonate , naphthalene - 1 - sulfonic acid - 5 - sulfonate , ethan - 1 
sulfonic acid - 2 - sulfonate , and the like ) , carboxylate ions 
( e . g . , acetate , propanoate , benzoate , glycerate , lactate , tar 
trate , glycolate , gluconate , and the like ) , BF4 , PF4 , PF6 , 
AsF6 , SbF6 , B [ 3 , 5 - ( CF3 ) 2C6H3 ) 4 ] " , B ( C6F3 ) 4 , BPh4 ; 
Al ( OC ( CF3 ) 3 ) 4 , and carborane anions ( e . g . , CB1H12 or ( HCB1 , Me Br . ) ) . Exemplary counterions which may be 
multivalent include CO2 -, HPO 2 - , PO43 - , B40 2 - , 30 . 2 - , 
S2032 - , carboxylate anions ( e . g . , tartrate , citrate , fumarate , 
maleate , malate , malonate , gluconate , succinate , glutarate , 
adipate , pimelate , suberate , azelate , sebacate , salicylate , 
phthalates , aspartate , glutamate , and the like ) , and carbo 
ranes . 
10103 ] The term " solvate ” refers to forms of the com 
pound , or a salt thereof , that are associated with a solvent , 
usually by a solvolysis reaction . This physical association 
may include hydrogen bonding . Conventional solvents 
include water , methanol , ethanol , acetic acid , DMSO , THF , 
diethyl ether , and the like . The compounds described herein 
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may be prepared , e . g . , in crystalline form , and may be 
solvated . Suitable solvates include pharmaceutically accept - 
able solvates and further include both stoichiometric sol 
vates and non - stoichiometric solvates . In certain instances , 
the solvate will be capable of isolation , for example , when 
one or more solvent molecules are incorporated in the 
crystal lattice of a crystalline solid . “ Solvate ” encompasses 
both solution - phase and isolatable solvates . Representative 
solvates include hydrates , ethanolates , and methanolates 
[ 0104 ] The term “ tautomers ” or “ tautomeric ” refers to two 
or more interconvertible compounds resulting from at least 
one formal migration of a hydrogen atom and at least one 
change in valency ( e . g . , a single bond to a double bond , a 
triple bond to a single bond , or vice versa ) . The exact ratio 
of the tautomers depends on several factors , including 
temperature , solvent , and pH . Tautomerizations ( i . e . , the 
reaction providing a tautomeric pair ) may catalyzed by acid 
or base . Exemplary tautomerizations include keto - to - enol , 
amide - to - imide , lactam - to - lactim , enamine - to - imine , and 
enamine - to - ( a different enamine ) tautomerizations . 
[ 0105 ] It is also to be understood that compounds that 
have the same molecular formula but differ in the nature or 
sequence of bonding of their atoms or the arrangement of 
their atoms in space are termed “ isomers ” . Isomers that 
differ in the arrangement of their atoms in space are termed 
“ stereoisomers ” . 
10106 ] Stereoisomers that are not mirror images of one 
another are termed “ diastereomers ” and those that are non 
superimposable mirror images of each other are termed 
" enantiomers ” . When a compound has an asymmetric cen 
ter , for example , it is bonded to four different groups , a pair 
of enantiomers is possible . An enantiomer can be charac 
terized by the absolute configuration of its asymmetric 
center and is described by the R - and S - sequencing rules of 
Cahn and Prelog , or by the manner in which the molecule 
rotates the plane of polarized light and designated as dex 
trorotatory or levorotatory ( i . e . , as ( + ) or ( - ) - isomers respec 
tively ) . A chiral compound can exist as either individual 
enantiomer or as a mixture thereof . A mixture containing 
equal proportions of the enantiomers is called a “ racemic 
mixture ” . 
[ 0107 ] The term “ polymer ” refers to a molecule including 
two or more ( e . g . , 3 or more , 4 or more , 5 or more , 10 or 
more ) repeating units which are covalently bound together . 
In certain embodiments , a polymer comprises 3 or more , 5 
or more , 10 or more , 50 or more , 100 or more , 500 or more , 
1000 or more , 2000 or more , 3000 or more , 4000 or more , 
5000 or more , 6000 or more , 7000 or more , 8000 or more , 
9000 or more , or 10000 or more repeating units . In certain 
embodiments , a polymer comprises more than 5000 repeat 
ing units . The repeating units of a polymer are referred to as 
" monomers . " A " homopolymer ” is a polymer that consists 
of a single repeating monomer . A “ copolymer ” is a polymer 
that comprises two or more different monomer subunits . 
Copolymers include , but are not limited to , random , block , 
alternating , segmented , linear , branched , grafted , and 
tapered copolymers . A " graft polymer ” is a segmented 
copolymer with a linear backbone of one composite and 
randomly distributed branches of another composite . The 
major difference between graft polymers and bottlebrush 
polymers ( or brush - arm polymers ) is the grafting density . 
The targeted graft density for bottlebrush polymers is that in 
at least one segment of the copolymer is one graft from each 
backbone monomer unit . A " star polymer ” is a polymer that 
consists of several polymers chains connected at a core 
atom , core molecule , or core polymer . Polymers may be 
natural ( e . g . , naturally occurring polypeptides ) , or synthetic 
( e . g . , non - naturally occurring ) . A polymer may have an 
overall molecular weight of 50 Da or greater , 100 Da or 
greater , 500 Da or greater , 1000 Da or greater , 2000 Da or 
greater , 5000 Da or greater , 10000 Da or greater , 20000 Da 
or greater , or 50000 Da or greater . Exemplary polymers 
include , without limitation , poly ( ethylene glycol ) 200 
( PEG200 ) , PEG400 , PEG600 , PEG800 , PEG1000 . 
PEG1500 , PEG2000 , PEG3000 , PEG4000 , and PEG6000 . [ 0108 ] The terms “ living polymer ” and “ living polymer 
ization ” refer a polymerization where the ability of a grow 
ing polymer chain to terminate has been removed . Chain 
termination and chain transfer reactions are absent , and the 
rate of the chain initiation is also much larger than the rate 
of chain propagation . The result is that the polymer chains 
grow at a constant rate than see in traditional chain polym 
erization and their lengths remain very similar . 
[ 0109 ] The terms “ number average molecular weight , " 
“ number average molar mass , ” and “ M , " are measurements 
of the molecular mass of a polymer . The number average 
molecular mass is the ordinary arithmetic mean or average 
of the molecular masses of the individual polymers . It is 
determined by measuring the molecular mass of n polymer 
molecules , summing the masses , and dividing by n . For 
example , a polymer having 100 repeating units of a mono 
mer with a molecular weight of 100 g / mol would have a 
number average molecular weight ( Mn ) of 10 , 000 g / mol 
[ M , = ( 100 ) * ( 100 g / mol ) / ( 1 ) = 10 , 000 g / mol ) ] . The number 
average molecular mass of a polymer can be determined by 
gel permeation chromatography , viscometry via the Mark 
Houwink equation , colligative methods such as vapor pres 
sure osmometry , end - group determination , or ' H NMR . 
0110 ] The term “ monomer ” refers to a molecule that may 
bind covalently to other molecules to form a polymer . The 
process by which the monomers are combined to form a 
polymer is called polymerization . A macromolecule with 
one end - group that enables it to act as a monomer is called 
a macromonomer . Molecules made of a small number of 
monomer units are called oligomers . 
[ 0111 ] The term " solvent ” refers to a substance that dis 
solves one or more solutes , resulting in a solution . A solvent 
may serve as a medium for any reaction or transformation 
described herein . The solvent may dissolve one or more 
reactants or reagents in a reaction mixture . The solvent may 
facilitate the mixing of one or more reagents or reactants in 
a reaction mixture . The solvent may also serve to increase or 
decrease the rate of a reaction relative to the reaction in a 
different solvent . Solvents can be polar or non - polar , protic 
or aprotic . Common organic solvents useful in the methods 
described herein include , but are not limited to , acetone , 
acetonitrile , benzene , benzonitrile , 1 - butanol , 2 - butanone , 
butyl acetate , tert - butyl methyl ether , carbon disulfide car 
bon tetrachloride , chlorobenzene , 1 - chlorobutane , chloro 
form , cyclohexane , cyclopentane , 1 , 2 - dichlorobenzene , 1 , 2 
dichloroethane , dichloromethane ( DCM ) , N , N dimethylacetamide N , N - dimethylformamide ( DMF ) , 1 , 3 
dimethyl - 3 , 4 , 5 , 6 - tetrahydro - 2 - pyrimidinone ( DMPU ) , 1 , 4 
dioxane , 1 , 3 - dioxane , diethylether , 2 - ethoxyethyl ether , 
ethyl acetate , ethyl alcohol , ethylene glycol , dimethyl ether , 
heptane , n - hexane , hexanes , hexamethylphosphoramide ( HMPA ) , 2 - methoxyethanol , 2 - methoxyethyl acetate , 
methyl alcohol , 2 - methylbutane , 4 - methyl - 2 - pentanone , 
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2 - methyl - 1 - propanol , 2 - methyl - 2 - propanol , 1 - methyl - 2 - pyr 
rolidinone , dimethylsulfoxide ( DMSO ) , nitromethane , 1 - oc 
tanol , pentane , 3 - pentanone , 1 - propanol , 2 - propanol , pyri 
dine , tetrachloroethylene , tetrahyrdofuran ( THF ) , 
2 - methyltetrahydrofuran , toluene , trichlorobenzene , 1 , 1 , 2 
trichlorotrifluoroethane , 2 , 2 , 4 - trimethylpentane , trimethyl 
amine , triethylamine , N , N - diisopropylethylamine , diisopro 
pylamine , water , o - xylene , p - xylene . 
[ 0112 ] A “ subject " to which administration is contem 
plated includes , but is not limited to , humans ( i . e . , a male or 
female of any age group , e . g . , a pediatric subject ( e . g . , 
infant , child , adolescent ) or adult subject ( e . g . , young adult , 
middle - aged adult , or senior adult ) ) and / or other non - human 
animals , for example , mammals ( e . g . , primates ( e . g . , cyno 
molgus monkeys , rhesus monkeys ) ; commercially relevant 
mammals such as cattle , pigs , horses , sheep , goats , cats , 
and / or dogs ) ; and birds ( e . g . , commercially relevant birds 
such as chickens , ducks , geese , and / or turkeys ) . In certain 
embodiments , the animal is a mammal . In certain embodi 
ments , the animal is a mouse . In certain embodiments , the 
animal is a human . The animal may be a male or female at 
any stage of development . The animal may be a transgenic 
animal or genetically engineered animal . In certain embodi 
ments , the subject is a non - human animal . 
[ 0113 ] The term “ administer , " " administering , " or 
" administration ” refers to implanting , absorbing , ingesting , 
injecting , inhaling , or otherwise introducing a compound or 
cell described herein or generated as described herein , or a 
composition thereof , in or on a subject . 
[ 0114 ] As used herein , the term " salt ” refers to any and all 
salts , and encompasses pharmaceutically acceptable salts . 
[ 0115 ] As used herein , the term “ pharmaceutically accept - 
able salt ” refers to those salts which are , within the scope of 
sound medical judgment , suitable for use in contact with the 
tissues of humans and lower animals without undue toxicity , 
irritation , allergic response and the like , and are commen 
surate with a reasonable benefit / risk ratio . Pharmaceutically 
acceptable salts are well known in the art . For example , 
Berge et al . , describe pharmaceutically acceptable salts in 
detail in J . Pharmaceutical Sciences , 1977 , 66 , 1 - 19 , incor 
porated herein by reference . Pharmaceutically acceptable 
salts of the compounds of this invention include those 
derived from suitable inorganic and organic acids and bases . 
Examples of pharmaceutically acceptable , nontoxic acid 
addition salts are salts of an amino group formed with 
inorganic acids such as hydrochloric acid , hydrobromic acid , 
phosphoric acid , sulfuric acid , and perchloric acid or with 
organic acids such as acetic acid , oxalic acid , maleic acid , 
tartaric acid , citric acid , succinic acid , or malonic acid or by 
using other methods known in the art such as ion exchange . 
Other pharmaceutically acceptable salts include adipate , 
alginate , ascorbate , aspartate , benzenesulfonate , benzoate , 
bisulfate , borate , butyrate , camphorate , camphorsulfonate , 
citrate , cyclopentanepropionate , digluconate , dodecylsul 
fate , ethanesulfonate , formate , fumarate , glucoheptonate , 
glycerophosphate , gluconate , hemisulfate , heptanoate , 
hexanoate , hydroiodide , 2 - hydroxy - ethanesulfonate , lacto 
bionate , lactate , laurate , lauryl sulfate , malate , maleate , 
malonate , methanesulfonate , 2 - naphthalenesulfonate , nico 
tinate , nitrate , oleate , oxalate , palmitate , pamoate , pectinate , 
persulfate , 3 - phenylpropionate , phosphate , picrate , pivalate , 
propionate , stearate , succinate , sulfate , tartrate , thiocyanate , 
p - toluenesulfonate , undecanoate , valerate salts , and the like . 
Salts derived from appropriate bases include alkali metal , 
alkaline earth metal , ammonium and N + ( C1 -4 alkyl ) 4 salts . 
Representative alkali or alkaline earth metal salts include 
sodium , lithium , potassium , calcium , magnesium , and the 
like . Further pharmaceutically acceptable salts include , 
when appropriate , nontoxic ammonium , quaternary ammo 
nium , and amine cations formed using counterions such as 
halide , hydroxide , carboxylate , sulfate , phosphate , nitrate , 
lower alkyl sulfonate , and aryl sulfonate . 
[ 0116 ] An " effective amount " of a compound described 
herein refers to an amount sufficient to elicit the desired 
biological response , i . e . , treating the condition . As will be 
appreciated by those of ordinary skill in this art , the effective 
amount of a compound described herein may vary depend 
ing on such factors as the desired biological endpoint , the 
pharmacokinetics of the compound , the condition being 
treated , the mode of administration , and the age and health 
of the subject . An effective amount encompasses therapeutic 
and prophylactic treatment . 
[ 0117 ] A “ therapeutically effective amount ” of a com 
pound described herein is an amount sufficient to provide a 
therapeutic benefit in the treatment of a condition or to delay 
or minimize one or more symptoms associated with the 
condition . A therapeutically effective amount of a compound 
means an amount of therapeutic agent , alone or in combi 
nation with other therapies , which provides a therapeutic 
benefit in the treatment of the condition . The term “ thera 
peutically effective amount " can encompass an amount that 
improves overall therapy , reduces or avoids symptoms or 
causes of the condition , and / or enhances the therapeutic 
efficacy of another therapeutic agent . 
[ 0118 ] The term " small molecule ” refers to molecules , 
whether naturally - occurring or artificially created ( e . g . , via 
chemical synthesis ) that have a relatively low molecular 
weight . Typically , a small molecule is an organic compound 
( i . e . , it contains carbon ) . The small molecule may contain 
multiple carbon - carbon bonds , stereocenters , and other 
functional groups ( e . g . , amines , hydroxyl , carbonyls , and 
heterocyclic rings , etc . ) . In certain embodiments , the 
molecular weight of a small molecule is not more than about 
1 , 000 g / mol , not more than about 900 g / mol , not more than 
about 800 g / mol , not more than about 700 g / mol , not more 
than about 600 g / mol , not more than about 500 g / mol , not 
more than about 400 g / mol , not more than about 300 g / mol , 
not more than about 200 g / mol , or not more than about 100 
g / mol . In certain embodiments , the molecular weight of a 
small molecule is at least about 100 g / mol , at least about 200 
g / mol , at least about 300 g / mol , at least about 400 g / mol , at 
least about 500 g / mol , at least about 600 g / mol , at least about 
700 g / mol , at least about 800 g / mol , or at least about 900 
g / mol , or at least about 1 , 000 g / mol . Combinations of the 
above ranges ( e . g . , at least about 200 g / mol and not more 
than about 500 g / mol ) are also possible . In certain embodi 
ments , the small molecule is a therapeutically active agent 
such as a drug ( e . g . , a molecule approved by the U . S . Food 
and Drug Administration as provided in the Code of Federal 
Regulations ( C . F . R . ) ) . The small molecule may also be 
complexed with one or more metal atoms and / or metal ions . 
In this instance , the small molecule is also referred to as a 
" small organometallic molecule . ” Preferred small molecules 
are biologically active in that they produce a biological 
effect in animals , preferably mammals , more preferably 
humans . Small molecules include , but are not limited to , 
radionuclides and imaging agents . 
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[ 0119 ] The terms “ imaging agent ” and “ contrast agent ” 
refer to a substance used to enhance the contrast of structures 
or fluids within the body in medical imaging . It is commonly 
used to enhance the visibility of blood vessels and the 
gastrointestinal tract in medical imaging . 
[ 0120 ] The term “ crosslinker ” refers to a compound that 
allows for two or more molecules or polymers to be joined 
by covalent bonds . In certain embodiments , the crosslinker 
results in a covalent attachment between two polymers . [ 0121 ] The term “ ring - opening metathesis polymerization 
( ROMP ) ” refers to a type of olefin metathesis chain - growth 
polymerization that is driven by the relief of ring strain in 
cyclic olefins ( e . g . norbornene or cyclopentene ) . The cata 
lysts used in the ROMP reaction include RuC1z / alcohol 
mixture , bis ( cyclopentadienyl ) dimethylzirconium ( IV ) , 
dichloro [ 1 , 3 - bis ( 2 , 6 - isopropylphenyl ) - 2 - imidazolidi 
nylidene ] ( benzylidene ) ( tricyclohexylphosphine ) ruthenium 
( II ) , dichloro [ 1 , 3 - Bis ( 2 - methylphenyl ) - 2 - imidazolidi 
nylidene ] ( benzylidene ) ( tricyclohexylphosphine ) ruthenium 
( II ) , dichloro [ 1 , 3 - bis ( 2 , 4 , 6 - trimethylphenyl ) - 2 imidazolidinylidene ] [ 3 - ( 2 - pyridinyl ) propylidene ] ruthenium 
( II ) , dichloro ( 3 - methyl - 2 - butenylidene ) bis ( tricyclopentylphosphine ) ruthenium ( II ) , dichloro [ 1 , 3 - bis ( 2 
methylphenyl ) - 2 - imidazolidinylidene ] ( 2 - isopropoxyphe 
nylmethylene ) ruthenium ( II ) ( Grubbs C571 ) , dichloro ( ben 
zylidene ) bis ( tricyclohexylphosphine ) ruthenium ( II ) ( Grubbs 
I ) , dichloro [ 1 , 3 - bis ( 2 , 4 , 6 - trimethylphenyl ) - 2 - imidazolidi 
nylidene ] ( benzylidene ) ( tricyclohexylphosphine ) ruthenium 
( II ) ( Grubbs II ) , and dichloro [ 1 , 3 - bis ( 2 , 4 , 6 - trimethylphe 
nyl ) - 2 - imidazolidinylidene ] ( benzylidene ) bis ( 3 
bromopyridine ) ruthenium ( II ) ( Grubbs III ) . 
[ 0122 ] The terms “ electron paramagnetic resonance ( EPR ) 
spectroscopy ” or “ electron spin resonance ( ESR ) spectros 
copy ” refer to a method for studying materials with unpaired 
electrons . EPR relies on the excitation of electron spins and 
is particularly useful for studying metal complexes or 
organic radicals ( e . g . , nitroxide radicals ) . 
[ 0123 ] The term “ imaging ” refers to a technique and 
process of creating visual representations of the interior of a 
body or portion thereof ( e . g . , brain , heart , lung , liver , kidney , 
spleen , muscle , tissue , and tumor ) for clinical analysis and 
medical intervention , as well as visualization of the function 
of organs and / or tissues . Medical imaging seeks to reveal 
internal structures hidden by the skin and bones , as well as 
to diagnose and sometimes treat disease . Medical imaging 
also establishes a database of normal anatomy and physiol 
ogy to make it possible to identify abnormalities . Examples 
of imaging modalities include , but are not limited to , radi 
ography , magnetic resonance imaging ( MRI ) , nuclear medi 
cine , ultrasound , elastography , tactile imaging , photoacous 
tic imaging , tomography , echocardiography , near - infrared 
fluorescence ( NIRF ) imaging , and magnetic particle imag 
MM are combined in the ratio j : 0 . 01j . This combination of 
MMs is exposed to 1 . 0 equivalents of Grubbs III initiator to 
produce a living bottlebrush with an average degree of 
polymerization ( DP ) = j + 0 . 011 = m . N equivalents of Acetal 
XL is then added ( in aliquots of 5 eq . Acetal - XL every 5 
minutes ) to provide the final BASP - ORCA . The properties 
of the BASP - ORCAs are defined by their m and N values ( see Table 1 ) . 
[ 0126 ] FIGS . 2A - 2C show the transmission electron 
microscopy image of BASP - ORCA1 ( DEM = 37 + 7 ) after 
being negatively stained with uranyl acetate ( FIG . 2A ) , 
electron paramagnetic resonance ( EPR ) spectra for BASP 
ORCA1 and chex - MM ( FIG . 2B ) , and T? and Tz - weighted 
MRI phantoms for BASP - ORCA1 , chex - MM , PBS buffer , 
chex - bottlebrush , and a PEG - BASP lacking chex ( FIG . 2C ) . 
In FIG . 2C the concentration of chex - containing samples 
( BASP - ORCA1 , chex - MM , and chex - bottlebrush ) ranges 
from 1 mM to 4 mM chex . The concentration of PEG - BASP 
lacking chex ranges from 6 mg / mL to 21 mg / mL , which is 
equivalent to the mass per volume concentration range of 
BASP - ORCA1 . 
[ 0127 ] FIGS . 3A - 3C are EPR spectra for BASP - ORCA1 
at 1 minute , 40 minutes , and 180 minutes following expo 
sure to 20 equivalents of sodium ascorbate ( Asc ) per nitrox 
ide moeity ( FIG . 3A ) , ascorbate reduction kinetics for 
BASP - ORCA1 , chex - bottlebrush , and chex - MM ( FIG . 3B ) , 
and Cy5 . 5 emission at 700 nm in response to Asc and 
glutathione ( GSH ) ( FIG . 3C ) . 
[ 0128 ] FIGS . 4A - 4B show in vivo NIRF images of NCR 
nude mouse before and 20 hours after injection of BASP 
ORCA1 ( FIG . 4A ) and ex vivo NIRF images of selected 
organs ( FIG . 4B ) . Units of radiant efficiency : 
p / sec / cm ? / sr 
UW / cm2 
[ 0129 ] FIGS . 5A - 5D show in vivo MRI imaging with 
BASP - ORCA . FIG . 5A shows Tz - weighted MR images of 
tumor bearing NCR nude mouse before ( top row ) and 20 
hours after ( bottom row ) injection of 0 . 16 mmol chex / kg 
( “ low dose ” ) of BASP - ORCA1 . Each series of images 
corresponds to progressive slices in the z - axis through the 
tumor of the same mouse . 
[ 0130 ] FIG . 5B shows Tz - weighted MR images of tumor 
bearing NCR nude mouse before ( top row ) and 20 hours 
after ( bottom row ) injection of 0 . 23 mmol chex / kg ( “ high 
dose ” ) of BASP - ORCA1 . Each series of images corresponds 
to progressive slices in the z - axis through the tumor of the 
same mouse . FIG . 5C shows Tz - weighted coronal MR 
images before ( top ) and 20 hours after ( bottom ) injection of 
0 . 23 mmol chex / kg ( “ high dose ” ) of BASP - ORCA1 . FIG . 
5D shows the percent MRI contrast change at various times 
following BASP - ORCA1 injection compared to pre - injec 
tion . 
[ 0131 ] FIGS . 6A - 6B show EPR spectra obtained for 
homogenized tissue samples collected for the same mice 
imaged in FIGS . 5A - 5D 22 hours following BASP - ORCA1 
injection ( FIG . 6A ) and fluorescence radiant efficiencies of 
the homogenized tissue samples ( FIG . 6B ) . Right - hand bars : 
Muscle - normalized concentration of chex per milligram of 
protein as obtained from EPR integration of tissue homo 
ing . 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0124 ] The accompanying drawings , which constitute a 
part of this specification , illustrate several exemplary 
embodiments of the invention and together with the descrip 
tion , serve to explain certain principles of the invention . The 
embodiments disclosed in the drawings are exemplary and 
do not limit the scope of this disclosure . 
0125 ) FIGS . 1A - 1B show chemical structures of BASP 
components ( FIG . 1A ) and the general brush - first ROMP 
procedure ( FIG . 1B ) . Branched MMs chex - MM and Cy - 
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Formula ( I ) 
mm 
and 
PA 
Formula ( II ) 
genates . Left - hand bars : Muscle - normalized concentration 
of Cy5 . 5 in tissue homogenates as obtained from NIRF 
imaging . 
[ 0132 ] FIGS . 7A - 7B show GPC traces . FIG . 7A shows 
GPC traces of BASP - ORCAs with different brush length ( m ) and cross - linker equivalents ( N ) . * indicates negligible 
residual MM ; * * denotes uncoupled bottlebrush . In all cases , 
the MM - to - bottlebrush conversions were almost quantita 
tive , while the bottlebrush - to - BASP conversions were 
> 85 % . FIG . 7B shows GPC traces of chex - bottlebrush and 
PEG - BASP used for phantom MRI comparison with BASP 
ORCA1 . 
[ 0133 ] FIG . 8 shows the EPR spectra of BASP - ORCAs of 
varying composition . 
[ 0134 ] FIGS . 9A - 9D show computational analysis of EPR 
spectra obtained during reduction kinetics experiments . t1 = 1 
minutes , t16 = 40 minutes , t29 = 180 minutes following addi 
tion of Asc solution . 
10135 ] FIG . 10 shows the excitation and emission spectra 
of BASP - ORCA1 . 
[ 0136 ] FIG . 11 shows the cell viability assay for BASP 
ORCA1 in the toxin - sensitive HUVEC and cancerous HeLa 
cell lines as measured by CellTiter Glo . No toxicity was 
observed until high concentrations were reached ( up to 0 . 3 
mg / mL and 5 mg / mL for HUVEC and HeLa , respectively ) . 
[ 0137 ] FIG . 12 shows in vivo gross toxicity of BASP 
ORCA1 following intravenous injections in BALB / c mice . 
[ 0138 ] FIGS . 13A - 13C show pharmacokinetics ( PK ) 
( FIG . 13A ) , biodistribution ( BD ) ( FIG . 13B ) , and excre 
ments collected 24 hours after administration of BASP 
ORCA1 in BALB / c mice as imaged by NIRF a = 640 / 
700 nm ) ( FIG . 13C ) . PK data were fit into a two - component 
model using standard procedures ( R2 = 0 . 95 ) . 101 , 102 
[ 0139 ] FIG . 14 shows ex vivo BD as assessed by NIRF 
imaging exem = 640 / 700 nm ) of subcutaneous tumor - bear 
ing NCR - NU mice following injection of BASP - ORCA1 . 
DETAILED DESCRIPTION OF CERTAIN 
EMBODIMENTS 
[ 0140 ] The present disclosure provides methods , com 
pounds , particles , nanoparticles , compositions , systems , and 
kits focused on the synthesis and uses of brush - arm star 
polymers containing at least one imaging agent . In certain 
embodiments , the polymers are brush - arm star polymer 
organic radical contrast agents ( BASP - ORCAS ) . In certain 
embodiments , the brush - arm star polymer organic radical 
contrast agents are comprised of brush - arm polymers cova 
lently linked to a polymer core via crosslinkers . In certain 
embodiments , BASP - ORCAs contain a high concentration 
of reduction - resistant nitroxide groups bound between a 
poly ( ethylene glycol ) ( PEG ) shell and a polyacetal core . 
[ 0141 ] These polymers are shown to be effective for 
medical imaging ( e . g . , brain , heart , lung , liver , kidney , 
spleen , muscle , tissue , and tumor ) . In certain embodiments , 
the imaging modality is magnetic resonance imaging . In 
certain embodiments , the imaging modality is near - infrared 
fluorescence imaging . 
or a salt thereof , wherein : [ 0143 ] each of A , A ' , and B is independently C7 - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , or C - C12 
heteroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , alky 
nylene , heteroalkylene , heteroalkenylene , or heteroalky 
nylene is optionally substituted with 1 - 24 independently 
selected R ' ; ( 0144 ] X is an imaging agent ; [ 0145 ] P is alkylene , heteroalkylene , or polymer ; 
[ 0146 ] L is a bond , O - , - S — , - S — 5 — , C , - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , C7 - C12 
heteroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
heteroalkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 heteroalkylene ) , ( Co 
C12 alkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , or ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 heteroalkylene ) , 
wherein each alkylene , alkenylene , alkynylene , heteroalky 
lene , arylene , heteroarylene , or heterocyclylene is optionally 
substituted with 1 - 24 independently selected R ' , and com 
binations thereof ; [ 0147 ] each R is independently alkyl , alkenyl , alkynyl , 
heteroalkyl , halo , cyano , oxo , nitro , OR4 , — N ( R4 ) 2 , 
- NR4C ( O ) R4 , NR4C ( O ) OR4 , NR4C ( O ) N ( R4 ) , 
C ( O ) N ( R4 ) 2 , - C ( O ) R4 , - C ( O ) ORA , OC ( O ) R4 , 
OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) „ R4 ; [ 0148 ] each R4 is independently hydrogen , C . - C . alkyl , 
C - C6 heteroalkyl , or C1 - C6 haloalkyl ; each of a and b are 
independently an integer between 1 and 10000 , inclusive ; 
Brush - Arm Star Polymers 
[ 0142 ] One aspect of the present disclosure relates to 
brush - arm star polymers comprising at least 100 repeating 
units selected from Formula ( I ) and Formula ( II ) : 
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poly ( ethylene glycol ) with a molecular weight about 3500 
g / mol . In certain embodiments , P is poly ( ethylene glycol ) 
with a molecular weight about 4000 g / mol . In certain 
embodiments , Pis poly ( ethylene glycol ) with a molecular 
weight about 4500 g / mol . In certain embodiments , P is 
poly ( ethylene glycol ) with a molecular weight about 5000 
g / mol . In certain embodiments , P is poly ( ethylene glycol ) 
with a molecular weight about 5500 g / mol . In certain 
embodiments , P is poly ( ethylene glycol ) with a molecular 
weight about 6000 g / mol . 
[ 0154 ] In certain embodiments , B is C7 - C12 alkylene , 
optionally substituted with 1 - 24 independently selected R ' ; 
R1 is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR4 , - N ( R4 ) 2 , - NR4C ( O ) R4 , - NR4C ( O ) OR “ , 
- NR4C ( O ) N ( R4 ) , C ( O ) N ( R4 ) , - C ( O ) R4 , - C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) R4 ; each R4 is independently hydrogen , C , - C6 
alkyl , C . - C . heteroalkyl , or C , - C6 haloalkyl ; and m is 1 or 
2 . 
[ 0155 ] In certain embodiments , A is C1 - C12 alkylene , 
optionally substituted with 1 - 24 independently selected R ' ; 
Rl is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR4 , - N ( R4 ) 2 , NR4C ( O ) R4 , - NR4C ( O ) OR4 , 
- NR4C ( O ) N ( R4 ) , C ( O ) N ( R4 ) , - C ( O ) R4 , - C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR4 , - OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) mR4 ; each R4 is independently hydrogen , C . - C . 
alkyl , C1 - C6 heteroalkyl , or C - Chaloalkyl ; and m is 1 or 
[ 0149 ] each of “ 1 ” , “ 2 ” , “ 3 ” , “ 4 ” , “ 5 ” , and “ 6 ” is inde 
pendently a terminal group selected from the group consist 
ing of hydrogen , halogen , optionally substituted alkyl , 
optionally substituted alkenyl , optionally substituted alky 
nyl , optionally substituted carbocyclyl , optionally substi 
tuted heterocyclyl , optionally substituted aryl , optionally 
substituted heteroaryl , optionally substituted acyl , optionally 
substituted hydroxyl , optionally substituted amino , and 
optionally substituted thio ; or represents a bond to a struc 
ture of Formula ( I ) or Formula ( II ) ; [ 0150 ] y is an integer between 1 and 100 , inclusive ; and 
[ 0151 ] m is 1 or 2 . [ 0152 ] In certain embodiments , Pis a polyether , polyester , 
polyacrylamide , polycarbonate , polysiloxane , polyfluoro 
carbon , polysulfone , or polystyrene . In certain embodi 
ments , P is a polyether selected from the group consisting of 
polyethylene glycol ( PEG ) , polyoxymethylene ( POM ) , 
polypropylene glycol ( PPG ) , polytetramethylene glycol 
( PTMG ) , poly ( ethyl ethylene ) phosphate ( PEEP ) , and poly 
( oxazoline ) . In certain embodiments , P is a polyester 
selected from the group consisting of polyglycolic acid 
( PGA ) , polylactic acid ( PLA ) , poly ( lactic - co - glycolic acid ) 
( PLGA ) , polycaprolactone ( PCL ) , polyhydroxyalkanoate 
( PHA ) , polyhydroxybutryate ( PHB ) , polyethylene adipate 
( PEA ) , polybutylene succinate ( PBS ) , or poly ( 3 - hydroxy 
butyrate - co - 3 - hydroxyvalerate ) ( PHBV ) . In certain embodi 
ments , P is a poly ( N - alkylacrylamide ) . In certain embodi 
ments , P is a polycarbonate selected from the group 
consisting of poly ( Bisphenol A carbonate ) , poly [ Bisphenol 
A carbonate - co - 4 , 4 ' - ( 3 , 3 , 5 - trimethylcyclohexylidene ) diphe 
nol carbonate ) , or poly ( propylene carbonate ) . In certain 
embodiments , P is a polysiloxane . In certain embodiments , 
Pis polydimethylsiloxane ( PDMS ) . In certain embodiments , 
Pis a polyfluorocarbon selected from the group consisting of 
poly ( chlorotrifluoroethylene ) , poly ( ethylene - co - tetrafluoro 
ethylene ) , poly ( tetrafluoroethylene ) , poly ( tetrafluoroethyl 
ene - co - perfluoro ( propylvinyl ether ) ) , poly ( vinylidene fluo 
ride ) , and poly ( vinylidene fluoride - co 
hexafluoropropylene ) . In certain embodiments , P is a 
polysulfone selected from the group consisting of poly [ 1 
[ 4 - ( 3 - carboxy - 4 - hydroxyphenylazo ) benzenesulfonamido ] 
1 , 2 - ethanediyl , sodium salt ] , poly ( 1 - hexadecene - sulfone ) , 
poly ( oxy - 1 , 4 - phenylenesulfonyl - 1 , 4 - phenylene ) , poly ( oxy 
1 , 4 - phenylenesulfonyl - 1 , 4 - phenylene ) , and polyphenylsul 
fone . 
[ 0153 ] In certain embodiments , Pis poly ( ethylene glycol ) 
with a molecular weight ranging from about 200 g / mol to 
about 6000 g / mol . In certain embodiments , P is poly ( ethyl 
ene glycol ) with a molecular weight about 200 g / mol . In 
certain embodiments , P is poly ( ethylene glycol ) with a 
molecular weight about 200 g / mol . In certain embodiments , 
Pis poly ( ethylene glycol ) with a molecular weight about 500 
g / mol . In certain embodiments , P is poly ( ethylene glycol ) 
with a molecular weight about 1000 g / mol . In certain 
embodiments , P is poly ( ethylene glycol ) with a molecular 
weight about 1500 g / mol . In certain embodiments , P is 
poly ( ethylene glycol ) with a molecular weight about 2000 
g / mol . In certain embodiments , P is poly ( ethylene glycol ) 
with a molecular weight about 2500 g / mol . In certain 
embodiments , P is poly ( ethylene glycol ) with a molecular 
weight about 3000 g / mol . In certain embodiments , P is 
[ 0156 ] In certain embodiments , Al is C , - C12 alkylene , 
optionally substituted with 1 - 24 independently selected R ' ; 
R ! is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR “ , - N ( R4 ) 2 , NR4C ( O ) R4 , - NR4C ( O ) OR4 , 
- NR4C ( O ) N ( R4 ) , C ( O ) N ( R4 ) 2 , - C ( O ) R4 , C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) ORA , OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) „ R4 ; each R4 is independently hydrogen , C . - C . 
alkyl , C , - Co heteroalkyl , or C , - C6 haloalkyl ; and m is 1 or 
[ 0157 ] In certain embodiments , L is selected from a group 
consisting of 
m 
and c 
HN . 
minn 
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- continued 18F - fluoromisonidazole ( FMISO ) , chelated gallium , che 
lated technetium - 99m , and chelated thallium . 
[ 0162 ] In certain embodiments , the imaging agent is radio 
graphic imaging agent . In certain embodiments , the radio 
graphic imaging agent is selected from the group consisting 
of chelated barium , gastrografin , metrizoic acid , iotalamic 
acid , ioxaglate , iopamidol , iohexol , ioxilan , iopromide , 
iodixanol , and ioversol . [ 0163 ] . In certain embodiments , the imaging agent X is a 
radical - containing compound . In certain embodiments , the 
imaging agent is a nitroxide radical - containing compound . 
In certain embodiments , the imaging agent X is of the 
formula : wherein : q , p , and o are independently an integer between 0 
and 20 , inclusive . 
[ 0158 ] In certain embodiments , L is independently 
selected from O 
and 
[ 0164 ] In certain embodiments , the imaging agent X is an 
organic compound . In certain embodiments , the imaging 
agent is a salt of an organic compound . In certain embodi 
ments , the imaging agent X is of the formula : 
nem 
HN . 
W 
[ 0165 ] In certain embodiments , the repeating unit of For 
mula ( I ) is of formula : 
Formula ( I ) 
[ 0159 ] In certain embodiments , X is a chelated metal , inorganic compound , organometallic compound , organic 
compound , or salt thereof . In certain embodiments , the 
imaging agent contains a metal selected from the group 
consisting of scandium , titanium , vanadium , chromium , 
manganese , iron , cobalt , nickel , copper , zinc , yttrium , zir 
conium , niobium , molybdenum , technetium , ruthenium , 
rhodium , palladium , silver , cadmium , hafnium , tantalum , 
tungsten , rhenium , osmium , iridium , platinum , gold , mer 
cury , rutherfordium , dubnium , seaborgium , bohrium , has 
sium , meitnerium , gadolinium , gallium , thallium , and 
barium . In certain embodiments , X is and inorganic com 
pound . In certain embodiments , X is an organic compound . 
In certain embodiments , X is metal - free . 
[ 0160 ] In certain embodiments , the imaging agent is an 
magnetic resonance imaging ( MRI ) agent . In certain 
embodiments , the MRI agent is a chelated gadolinium . In 
certain embodiments , the MRI agent is a nitroxide radical 
containing compound . 
[ 0161 ] In certain embodiments , the imaging agent is a 
nuclear medicine imaging agent . In certain embodiments , 
the nuclear medicine imaging agent is selected from the 
group consisting of 64Cu diacetyl - bis ( N4 - methylthiosemi 
carbazone ) ( 64Cu - ASTM ) , 18F - fluorodeoxyglucose ( FDG ) , 
18F - fluoride , 3 ' - deoxy - 3 ' - [ 18F ] fluorothymi dine ( FLT ) , and 
or a salt thereof , wherein : [ 0166 ] each of A , A ' , and B is independently C , - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , or C , - C12 
heteroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , alky 
nylene , heteroalkylene , heteroalkenylene , or heteroalky 
nylene is optionally substituted with 1 - 24 independently 
selected R ' ; 
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( 0167 ] X is an imaging agent ; [ 0168 ] P is alkylene , heteroalkylene , or polymer ; 
[ 0169 ] L is a bond , 0 , S , S S - , C - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , C7 - C12 
heteroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
heteroalkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 heteroalkylene ) , ( Co 
C12 alkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , or ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 heteroalkylene ) , 
wherein each alkylene , alkenylene , alkynylene , heteroalky 
lene , arylene , heteroarylene , or heterocyclylene is optionally 
substituted with 1 - 24 independently selected R ' , and com 
binations thereof ; [ 0170 ] each R ' is independently alkyl , alkenyl , alkynyl , 
heteroalkyl , halo , cyano , oxo , nitro , OR4 , - N ( R4 ) 2 , 
- NR4C ( O ) R4 , — NR4C ( O ) OR4 , NR4C ( O ) N ( R4 ) ,
C ( O ) N ( R4 ) 2 , - C ( O ) R4 , - C ( O ) OR4 , OC ( O ) R4 , 
OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) , R4 ; [ 0171 ] each R4 is independently hydrogen , CZ - C6 alkyl , 
CZ - C6 heteroalkyl , or C , - C6 haloalkyl ; 
[ 0172 ] y is an integer between 1 and 100 , inclusive ; and 
0173 ] m is 1 or 2 . 
[ 0174 ] In certain embodiments , the repeating unit is of 
formula : 
nnn OH . 
NH 
No 
N 
- O 
nh 
20 
In certain embodiments , the repeating unit is of the formula : 
OH 
NH 
Nuo 
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[ 0175 ] In certain embodiments , the repeating unit of For 
mula ( II ) is of formula : 
Formula ( II ) 
N _ L _ N 
or a salt thereof , wherein : [ 0176 ] L is a bond , O - , - S , s S — , C1 - C12 
alkylene , C2 - C12 alkenylene , C2 - C12 alkynylene , C - C12 
heteroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
heteroalkylene ) - arylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) heteroarylene - ( Co - C12 alkylene ) , ( Co - C12 het 
eroalkylene ) - heteroarylene - ( Co - C12 heteroalkylene ) , ( Co 
C12 alkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( C - C12 
heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , or ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 heteroalkylene ) , 
wherein each alkylene , alkenylene , alkynylene , heteroalky 
lene , arylene , heteroarylene , or heterocyclylene is optionally 
substituted with 1 - 24 independently selected R ' , and com 
binations thereof ; [ 0177 ] each Rl is independently alkyl , alkenyl , alkynyl , 
heteroalkyl , halo , cyano , oxo , nitro , OR4 , - N ( R4 ) 2 , 
- NR4C ( O ) R4 , NR4C ( O ) OR4 , NR4C ( O ) N ( R4 ) , 
- C ( O ) N ( R4 ) 2 , - C ( O ) R4 , - C ( O ) OR4 , OC ( O ) R4 , 
OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) MR4 ; [ 0178 ] each R4 is independently hydrogen , C7 - C . alkyl , 
C - C , heteroalkyl , or C , - Co haloalkyl ; and 
10179 ] m is 1 or 2 . 
[ 0180 ] In certain embodiments , the repeating unit is of 
formula : 
[ 0181 ] In certain embodiments , the ratio of repeating unit 
of Formula ( I ) and repeating unit of Formula ( II ) is between 
about 1 : 20 to about 20 : 1 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 1 : 20 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 1 : 19 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula 
( I ) and repeating unit of Formula ( II ) is about 1 : 18 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 1 : 17 , 
respectively . In certain embodiments , the ratio of repeating 
unit of Formula ( I ) and repeating unit of Formula ( II ) is 
about 1 : 16 , respectively . In certain embodiments , the ratio of 
repeating unit of Formula ( I ) and repeating unit of Formula 
( II ) is about 1 : 15 , respectively . In certain embodiments , the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is about 1 : 14 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 1 : 13 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 1 : 12 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula ( I ) and repeating unit of Formula ( II ) is about 1 : 11 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 1 : 10 , 
respectively . In certain embodiments , the ratio of repeating 
unit of Formula ( I ) and repeating unit of Formula ( II ) is 
about 1 : 9 , respectively . In certain embodiments , the ratio of 
repeating unit of Formula ( I ) and repeating unit of Formula 
( II ) is about 1 : 8 , respectively . In certain embodiments , the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is about 1 : 7 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 1 : 6 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 1 : 5 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula 
( I ) and repeating unit of Formula ( II ) is about 1 : 4 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 1 : 3 , 
respectively . In certain embodiments , the ratio of repeating 
mm 
nh 
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unit of Formula ( I ) and repeating unit of Formula ( II ) is 
about 1 : 2 , respectively . In certain embodiments , the ratio of 
repeating unit of Formula ( I ) and repeating unit of Formula 
( II ) is about 1 : 1 , respectively . In certain embodiments , the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is about 2 : 1 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 3 : 1 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 4 : 1 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula 
( I ) and repeating unit of Formula ( II ) is about 5 : 1 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 6 : 1 , 
respectively . In certain embodiments , the ratio of repeating 
unit of Formula ( I ) and repeating unit of Formula ( II ) is 
about 7 : 1 , respectively . In certain embodiments , the ratio of 
repeating unit of Formula ( I ) and repeating unit of Formula 
( II ) is about 8 : 1 , respectively . In certain embodiments , the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is about 9 : 1 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 10 : 1 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 11 : 1 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula 
( I ) and repeating unit of Formula ( II ) is about 12 : 1 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 13 : 1 , 
respectively . In certain embodiments , the ratio of repeating 
unit of Formula ( I ) and repeating unit of Formula ( II ) is 
about 14 : 1 , respectively . In certain embodiments , the ratio of 
repeating unit of Formula ( I ) and repeating unit of Formula 
( II ) is about 15 : 1 , respectively . In certain embodiments , the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is about 16 : 1 , respectively . In certain embodi 
ments , the ratio of repeating unit of Formula ( I ) and repeat 
ing unit of Formula ( II ) is about 17 : 1 , respectively . In certain 
embodiments , the ratio of repeating unit of Formula ( I ) and 
repeating unit of Formula ( II ) is about 18 : 1 , respectively . In 
certain embodiments , the ratio of repeating unit of Formula ( I ) and repeating unit of Formula ( II ) is about 19 : 1 , respec 
tively . In certain embodiments , the ratio of repeating unit of 
Formula ( I ) and repeating unit of Formula ( II ) is about 20 : 1 , 
respectively . 
[ 0182 ] In certain embodiments , the polymer forms a par 
ticle or nanoparticle of a diameter between about 10 nm and 
about 1000 nm . In certain embodiments , the polymer forms 
a particle of a diameter between about 10 nm and about 100 
nm . In certain embodiments , the polymer forms a particle of 
a diameter between about 100 nm and about 200 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 200 nm and about 300 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 300 nm and about 400 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 400 nm and about 500 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 500 nm and about 600 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 600 nm and about 700 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 700 nm and about 800 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 800 nm and about 900 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 900 nm and about 1000 nm . In 
certain embodiments , the polymer forms a particle of a 
diameter between about 28 nm and about 49 nm . In certain 
embodiments , the polymer forms a particle of a diameter 
between about 25 nm and about 40 nm . 
Methods for Preparing Brush - Arm Star Polymers 
[ 0183 ] In another aspect of the present disclosure , a 
method of producing a brush - arm star polymer comprising 
an imaging agent is described herein , the method comprises 
the steps of : reacting one or more macromonomers contain ing an imaging agent with a metathesis catalyst to form a 
living polymer ; and mixing a crosslinker with the living 
polymer . In certain embodiments , at least two different 
macromonomers each containing a different imaging agent 
are reacted . 
[ 0184 ] In certain embodiments , the brush - arm star poly 
mer is prepared by reacting macromonomer 
( chex - MM ) 
165 
- NH 
NUO 
- 0 
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macromonomer 
OH 
- NH 
( Cy - MM ) 
a and ring - opening metathesis catalyst in a solvent to form 
a living polymer in the first step . In the second step the living 
polymer is then mixed with crosslinker 
bon tetrachloride , chlorobenzene , 1 - chlorobutane , chloro form , cyclohexane , cyclopentane , 1 , 2 - dichlorobenzene , 1 , 2 
dichloroethane , dichloromethane ( DCM ) , N , N 
( Acetal - XL ) 
to form the brush - arm star polymer . In certain embodiments 
the ring - opening methathesis catalyst is Grubbs 3rd genera 
tion bispyridyl catalyst ( Grubbs III ) . 
[ 0185 ] In certain embodiments , the reaction time of the 
first step is between about 10 minutes and about 60 minutes . 
In certain embodiments , the reaction time of the first step is 
about 30 minutes . In certain embodiments , the reaction time 
of the second step is between about 1 hour and about 24 
hours . In certain embodiments , the reaction time of the 
second step is about 6 hours . 
10186 ] . In certain embodiments , the solvent used to prepare 
the brush - arm star polymer can be polar or non - polar , protic 
or aprotic . Common organic solvents useful in the methods 
described herein include , but are not limited to , acetone , 
acetonitrile , benzene , benzonitrile , 1 - butanol , 2 - butanone , 
butyl acetate , tert - butyl methyl ether , carbon disulfide car 
dimethylacetamide N , N - dimethylformamide ( DMF ) , 1 , 3 
dimethyl - 3 , 4 , 5 , 6 - tetrahydro - 2 - pyrimidinone ( DMPU ) , 1 , 4 
dioxane , 1 , 3 - dioxane , diethylether , 2 - ethoxyethyl ether , 
ethyl acetate , ethyl alcohol , ethylene glycol , dimethyl ether , 
heptane , n - hexane , hexanes , hexamethylphosphoramide ( HMPA ) , 2 - methoxyethanol , 2 - methoxyethyl acetate , 
methyl alcohol , 2 - methylbutane , 4 - methyl - 2 - pentanone , 
2 - methyl - 1 - propanol , 2 - methyl - 2 - propanol , 1 - methyl - 2 - pyr 
rolidinone , dimethylsulfoxide ( DMSO ) , nitromethane , 1 - oc 
tanol , pentane , 3 - pentanone , 1 - propanol , 2 - propanol , pyri 
dine , tetrachloroethylene , tetrahyrdofuran ( THF ) , 
2 - methyltetrahydrofuran , toluene , trichlorobenzene , 1 , 1 , 2 
trichlorotrifluoroethane , 2 , 2 , 4 - trimethylpentane , trimethyl 
amine , triethylamine , N , N - diisopropylethylamine , diisopro 
pylamine , water , 0 - xylene , p - xylene . In certain 
embodiments , the solvent used to prepare the brush - arm star 
polymer is tetrahyrdofuran ( THF ) . 
US 2019 / 0038782 A1 Feb . 7 , 2019 
24 
[ 0187 ] In certain embodiments , the molar ratio of chex 
MM and Cy - MM is between about 1 : 1 and about 1000 : 1 . In 
certain embodiments , the molar ratio of chex - MM and 
Cy - MM is about 100 : 1 . 
[ 0188 ] In certain embodiments , the molar ratio of ( chex 
MM + Cy - MM ) and ring - opening metathesis catalyst is 
between about 1 : 1 and about 100 : 1 . In certain embodiments , 
the molar ratio of ( chex - MM + Cy - MM ) and Grubbs ( III ) is 
about 5 . 05 : 1 . In certain embodiments , the molar ratio of ( chex - MM + Cy - MM ) and Grubbs ( III ) is about 7 . 07 : 1 . In 
certain embodiments , the molar ratio of ( chex - MM + Cy 
MM ) and Grubbs ( III ) is about 9 . 99 : 1 . 
[ 0189 ] In certain embodiments , the molar equivalents of 
Acetal - XL with respect to Grubbs III is between about 1 
equivalent and about 100 equivalents . In certain embodi 
ments , the molar equivalents of Acetal - XL with respect to 
Grubbs III is about 15 equivalents . In certain embodiments , 
the molar equivalents of Acetal - XL with respect to Grubbs 
III is about 20 equivalents . In certain embodiments , the 
molar equivalents of Acetal - XL with respect to Grubbs III is 
about 30 equivalents . 
[ 0190 ] In certain embodiments , the macromonomer is of 
Formula ( III ) : 
alkyl , C . - C . heteroalkyl , or C , - C6 haloalkyl ; y is an integer 
between 1 and 100 , inclusive ; and m is 1 or 2 . [ 0191 ] In certain embodiments , Pis poly ( ethylene glycol ) 
with a molecular weight ranging from about 200 g / mol to 
about 6000 g / mol . 
[ 0192 ] In certain embodiments , B is C , - C alkylene , 
optionally substituted with 1 - 24 independently selected R ? ; 
R ! is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR4 , - N ( R4 ) 2 , - NR4C ( O ) R4 , - NR4C ( O ) ORA , 
- NR4C ( O ) N ( R4 ) 2 , C ( O ) N ( R4 ) 2 , C ( O ) R4 , C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR “ , - OC ( O ) N ( R4 ) , SR4 , 
or - S ( O ) R4 ; each R4 is independently hydrogen , C . - C . 
alkyl , C7 - C6 heteroalkyl , or C1 - C haloalkyl ; and m is 1 or 
[ 0193 ] In certain embodiments , A is C - C12 alkylene , 
optionally substituted with 1 - 24 independently selected R ' ; 
R ! is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR4 , - N ( R4 ) 2 , - NR4C ( O ) R4 , - NR4C ( O ) ORA , 
- NR4C ( O ) N ( R4 ) , C ( O ) N ( R4 ) , C ( O ) R4 , C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) - R “ ; each R4 is independently hydrogen , C . - C6 
alkyl , C . - C . heteroalkyl , or C , - C6 haloalkyl ; and m is 1 or 
Formula ( III ) 
[ 0194 ] In certain embodiments , Al is C - C12 alkylene , 
optionally substituted with 1 - 24 independently selected R ' ; 
R is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR4 , - N ( R4 ) 2 , NR4C ( O ) R4 , - NR4C ( O ) OR4 , 
- NR4C ( O ) N ( R4 ) , C ( O ) N ( R4 ) , C ( O ) R4 , C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) mR4 ; each R4 is independently hydrogen , C , - C . 
alkyl , C , - C6 heteroalkyl , or C . - C . haloalkyl ; and m is 1 or 
„ L - A - X 
N - B 
or a salt thereof , wherein : each of A , A ' , and B is indepen dently C , - C12 alkylene , Cz - C12 alkenylene , C2 - C12 alky 
nylene , or C , - C12 heteroalkylene , C2 - C12 heteroalkenylene , 
C2 - C12 heteroalkynylene , wherein each alkylene , alk 
enylene , alkynylene , heteroalkylene , heteroalkenylene , or 
heteroalkynylene is optionally substituted with 1 - 24 inde 
pendently selected R ' ; X is an imaging agent ; P is alkylene , 
heteroalkylene , or polymer ; L is a bond , O - , - S , 
- S S - , C - C12 alkylene , C2 - C12 alkenylene , C2 - C12 
alkynylene , C1 - C12 heteroalkylene , ( Co - C12 alkylene ) 
arylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - arylene ( Co - C12 alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 het 
eroalkylene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 
heteroalkylene ) , ( Co - C12 alkylene ) heteroarylene - ( Co - C12 
alkylene ) , ( Co - C12 heteroalkylene ) - heteroarylene - ( Co - C12 
alkylene ) , ( Co - C12 heteroalkylene ) heteroarylene - ( Co - C12 
heteroalkylene ) , ( Co - C12 alkylene ) - heterocyclylene - ( Co - C12 
alkylene ) , ( Co - C12 heteroalkylene ) heterocyclylene - ( Co - C12 
alkylene ) , ( Co - C12 heteroalkylene ) - aryl - ( Co - C12 heteroalky 
lene ) , or ( Co - C12 heteroalkylene ) - heterocyclylene - ( Co - C12 
heteroalkylene ) , wherein each alkylene , alkenylene , alky 
nylene , heteroalkylene , arylene , heteroarylene , or heterocy 
clylene is optionally substituted with 1 - 24 independently 
selected R1 , and combinations thereof , each R is indepen 
dently alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , oxo , 
nitro , OR “ , - N ( R4 ) 2 , - NR4C ( O ) R4 , - NR4C ( O ) OR4 , 
- NR4C ( O ) N ( R4 ) 2 , - C ( O ) N ( R4 ) 2 , - C ( O ) R4 , C ( O ) 
OR4 , OC ( O ) R4 , OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , 
or - S ( O ) mR4 ; each R4 is independently hydrogen , C . - C6 
[ 0195 ] In certain embodiments , the metathesis catalyst is 
a ring - opening metathesis polymerization ( ROMP ) catalyst . 
In certain embodiments , the metathesis catalyst is a transi 
tion metal complex . In certain embodiments , the metal is 
selected from the group consisting of scandium , titanium , 
vanadium , chromium , manganese , iron , cobalt , nickel , cop 
per , zinc , yttrium , zirconium , niobium , molybdenum , tech 
netium , ruthenium , rhodium , palladium , silver , cadmium , 
hafnium , tantalum , tungsten , rhenium , osmium , iridium , 
platinum , gold , mercury , rutherfordium , dubnium , seabor 
gium , bohrium , hassium , and meitnerium . In certain 
embodiments , the metathesis catalyst is a ruthenium com 
plex . In certain embodiments , the metathesis catalyst is a 
molybdenum complex . In certain embodiments , the metath 
esis catalyst is a zirconium complex . In certain embodi 
ments , the metathesis catalyst is selected from the group 
consisting of RuC1z / alcohol mixture , bis ( cyclopentadienyl ) dimethylzirconium ( IV ) , dichloro [ 1 , 3 - bis ( 2 , 6 - isopropylphe 
nyl ) - 2 - imidazolidinylidene ] ( benzylidene ) ( tricyclohexyl 
phosphine ruthenium ( II ) , dichloro [ 1 , 3 - Bis ( 2 
methylphenyl ) - 2 - imidazolidinylidene ] ( benzylidene ) 
( tricyclohexylphosphine ) ruthenium ( II ) , dichloro [ 1 , 3 - bis ( 2 , 
4 , 6 - trimethylphenyl ) - 2 - imidazolidinylidene ] [ 3 - ( 2 
pyridinyl ) propylidene ] ruthenium ( II ) , dichloro ( 3 - methyl - 2 
butenylidene ) bis ( tricyclopentylphosphine ) ruthenium ( II ) , 
dichloro [ 1 , 3 - bis ( 2 - methylphenyl ) - 2 - imidazolidinylidene ] ( 2 - isopropoxyphenylmethylene ruthenium ( II ) ( Grubbs 
C571 ) , dichloro ( benzylidene ) bis ( tricyclohexylphosphine ) 
ruthenium ( II ) ( Grubbs I ) , dichloro [ 1 , 3 - bis ( 2 , 4 , 6 - trimethyl 
phenyl ) - 2 - imidazolidinylidene ] ( benzylidene ) ( tricyclohexyl 
phosphine ) ruthenium ( II ) ( Grubbs II ) , and dichloro [ 1 , 3 - bis ( 2 , 4 , 6 - trimethylphenyl ) - 2 - imidazolidinylidene ] 
N
N
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( benzylidene ) bis ( 3 - bromopyridine ) ruthenium ( II ) ( Grubbs 
III ) . In certain embodiment , the metathesis catalyst is of the 
formula : 
Mes — N N — Mes . 
1 Luc H 
N - Rüz 
LN , Ph 
Compositions and Kits 
[ 0196 ] In one aspect of the present disclosure , composi 
tions and kits are described herein . In certain embodiments , 
a composition is comprised of a polymer described herein 
and a pharmaceutically acceptable excipient . In certain 
embodiments , a composition is comprised of an effective 
amount of a polymer described herein . [ 0197 ] Compositions described herein can be prepared by 
any method known in the art . In general , such preparatory 
methods include bringing the polymer described herein into 
association with a carrier or excipient , and / or one or more 
other accessory ingredients , and then , if necessary and / or 
desirable , shaping , and / or packaging the product into a 
desired single - or multi - dose unit . [ 0198 ] Compositions can be prepared , packaged , and / or 
sold in bulk , as a single unit dose , and / or as a plurality of 
single unit doses . A “ unit dose ” is a discrete amount of the 
pharmaceutical composition comprising a predetermined 
amount of the active ingredient . The amount of the active 
ingredient is generally equal to the dosage of the active 
ingredient which would be administered to a subject and / or 
a convenient fraction of such a dosage , such as one - half or 
one - third of such a dosage . 
[ 0199 ] Relative amounts of the active ingredient , the phar 
maceutically acceptable excipient , and / or any additional 
ingredients in a pharmaceutical composition described 
herein will vary , depending upon the identity , size , and / or 
condition of the subject treated and further depending upon 
the route by which the composition is to be administered . 
The composition may comprise between 0 . 1 % and 100 % 
( w / w ) active ingredient . 
[ 0200 ) Pharmaceutically acceptable excipients used in the 
manufacture of provided pharmaceutical compositions 
include inert diluents , dispersing and / or granulating agents , 
surface active agents and / or emulsifiers , disintegrating 
agents , binding agents , preservatives , buffering agents , 
lubricating agents , and / or oils . Excipients such as cocoa 
butter and suppository waxes , coloring agents , coating 
agents , sweetening , flavoring , and perfuming agents may 
also be present in the composition . [ 0201 ] Although the descriptions of compositions pro 
vided herein are principally directed to pharmaceutical com 
positions which are suitable for administration to humans , it 
will be understood by the skilled artisan that such compo - 
sitions are generally suitable for administration to animals of 
all sorts . Modification of pharmaceutical compositions suit - 
able for administration to humans in order to render the 
compositions suitable for administration to various animals 
is well understood , and the ordinarily skilled veterinary 
pharmacologist can design and / or perform such modifica 
tion with ordinary experimentation . 
[ 0202 ] The compounds and compositions provided herein 
can be administered by any route , including enteral ( e . g . , 
oral ) , parenteral , intravenous , intramuscular , intra - arterial , 
intramedullary , intrathecal , subcutaneous , intraventricular , 
transdermal , interdermal , rectal , intravaginal , intraperito 
neal , topical ( as by powders , ointments , creams , and / or 
drops ) , mucosal , nasal , bucal , sublingual ; by intratracheal 
instillation , bronchial instillation , and / or inhalation ; and / or 
as an oral spray , nasal spray , and / or aerosol . Specifically 
contemplated routes are oral administration , intravenous 
administration ( e . g . , systemic intravenous injection ) , 
regional administration via blood and / or lymph supply , 
and / or direct administration to an affected site . In general , 
the most appropriate route of administration will depend 
upon a variety of factors including the nature of the agent 
( e . g . , its stability in the environment of the gastrointestinal 
tract ) , and / or the condition of the subject ( e . g . , whether the 
subject is able to tolerate oral administration ) . In certain 
embodiments , the compound or pharmaceutical composition 
described herein is suitable for topical administration to the 
eye of a subject . 
[ 0203 ] The exact amount of a compound required to 
achieve an effective amount will vary from subject to 
subject , depending , for example , on species , age , and gen 
eral condition of a subject , severity of the side effects or 
disorder , identity of the particular compound , mode of 
administration , and the like . An effective amount may be 
included in a single dose ( e . g . , single oral dose ) or multiple 
doses ( e . g . , multiple oral doses ) . In certain embodiments , 
when multiple doses are administered to a subject or applied 
to a tissue or cell , any two doses of the multiple doses 
include different or substantially the same amounts of a 
compound or polymer described herein . In certain embodi 
ments , when multiple doses are administered to a subject or 
applied to a tissue or cell , the frequency of administering the 
multiple doses to the subject or applying the multiple doses 
to the tissue or cell is three doses a day , two doses a day , one 
dose a day , one dose every other day , one dose every third 
day , one dose every week , one dose every two weeks , one 
dose every three weeks , or one dose every four weeks . In 
certain embodiments , the frequency of administering the 
multiple doses to the subject or applying the multiple doses 
to the tissue or cell is one dose per day . In certain embodi 
ments , the frequency of administering the multiple doses to 
the subject or applying the multiple doses to the tissue or cell 
is two doses per day . In certain embodiments , the frequency 
of administering the multiple doses to the subject or apply 
ing the multiple doses to the tissue or cell is three doses per 
day . In certain embodiments , when multiple doses are 
administered to a subject or applied to a tissue or cell , the 
duration between the first dose and last dose of the multiple 
doses is one day , two days , four days , one week , two weeks , 
three weeks , one month , two months , three months , four 
months , six months , nine months , one year , two years , three 
years , four years , five years , seven years , ten years , fifteen 
years , twenty years , or the lifetime of the subject , tissue , or 
cell . In certain embodiments , the duration between the first 
dose and last dose of the multiple doses is three months , six 
months , or one year . In certain embodiments , the duration 
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between the first dose and last dose of the multiple doses is 
the lifetime of the subject , tissue , or cell . [ 0204 ] Dose ranges as described herein provide guidance 
for the administration of provided pharmaceutical compo 
sitions to an adult . The amount to be administered to , for 
example , a child or an adolescent can be determined by a 
medical practitioner or person skilled in the art and can be 
lower or the same as that administered to an adult . 
[ 0205 ] The compound or composition can be administered 
concurrently with , prior to , or subsequent to one or more 
additional pharmaceutical agents , which may be useful as , 
e . g . , combination therapies . Pharmaceutical agents include 
therapeutically active agents . Pharmaceutical agents also 
include prophylactically active agents . Pharmaceutical 
agents include small organic molecules such as drug com 
pounds ( e . g . , compounds approved for human or veterinary 
use by the U . S . Food and Drug Administration as provided 
in the Code of Federal Regulations ( CFR ) ) , peptides , pro 
teins , carbohydrates , monosaccharides , oligosaccharides , 
polysaccharides , nucleoproteins , mucoproteins , lipopro 
teins , synthetic polypeptides or proteins , small molecules 
linked to proteins , glycoproteins , steroids , nucleic acids , 
DNAs , RNAs , nucleotides , nucleosides , oligonucleotides , 
antisense oligonucleotides , lipids , hormones , vitamins , and 
cells . Each additional pharmaceutical agent may be admin 
istered at a dose and / or on a time schedule determined for 
that pharmaceutical agent . The additional pharmaceutical 
agents may also be administered together with each other 
and / or with the compound or composition described herein 
in a single dose or administered separately in different doses . 
The particular combination to employ in a regimen will take 
into account compatibility of the compound described herein 
with the additional pharmaceutical agent ( s ) and / or the 
desired therapeutic and / or prophylactic effect to be 
achieved . In general , it is expected that the additional 
pharmaceutical agent ( s ) in combination be utilized at levels 
that do not exceed the levels at which they are utilized 
individually . In some embodiments , the levels utilized in 
combination will be lower than those utilized individually . 
[ 0206 ] Also encompassed by the disclosure are kits . The kits provided may comprise a pharmaceutical composition 
or compound described herein and a container ( e . g . , a vial , 
ampule , bottle , syringe , and / or dispenser package , or other 
suitable container ) . In some embodiments , provided kits 
may optionally further include a second container compris 
ing a pharmaceutical excipient for dilution or suspension of 
a pharmaceutical composition or compound described 
herein . In some embodiments , the pharmaceutical compo 
sition or compound described herein provided in the first 
container and the second container are combined to form 
one unit dosage form . 
[ 0207 ] In certain embodiments , the kits are comprised are 
comprised of a polymer described herein and instructions for 
use . In certain embodiments , the kits are comprised of a 
composition described herein and instructions for use . 
[ 0208 ] In certain embodiments , a kit described herein 
further includes instructions for using the kit . A kit described 
herein may also include information as required by a regu 
latory agency such as the U . S . Food and Drug Administra 
tion ( FDA ) . In certain embodiments , the information included in the kits is prescribing information . A kit 
described herein may include one or more additional phar 
maceutical agents described herein as a separate composi 
Methods of Treatment 
[ 0209 ] In one aspect of the present disclosure , methods of imaging a subject or a portion of a subject are described 
herein , the method comprising steps of : administering to a 
subject a polymer described herein , or a composition 
described herein ; and acquiring an image . In certain embodi 
ments , the imaging modality is selected from the group 
consisting of radiography , magnetic resonance imaging 
( MRI ) , nuclear medicine , ultrasound , elastography , tactile imaging , photoacoustic imaging , tomography , echocardiog 
raphy , near - infrared fluorescence ( NIRF ) imaging , and mag 
netic particle imaging . In certain embodiments , the imaging 
modality is magnetic resonance imaging ( MRI ) . In certain 
embodiments , the imaging modality is near - infrared fluo 
rescence ( NIRF ) imaging . 
[ 0210 ] In certain embodiments , the subject is an animal . 
The animal may be of either sex and may be at any stage of 
development . In certain embodiments , the subject described 
herein is a human . In certain embodiments , the subject is a 
non - human animal . In certain embodiments , the subject is a 
mammal . In certain embodiments , the subject is a non 
human mammal . In certain embodiments , the subject is a 
domesticated animal , such as a dog , cat , cow , pig , horse , 
sheep , or goat . In certain embodiments , the subject is a 
companion animal , such as a dog or cat . In certain embodi 
ments , the subject is a livestock animal , such as a cow , pig , 
horse , sheep , or goat . In certain embodiments , the subject is 
a zoo animal . In some embodiments , the subject is a research 
animal , such as a rodent ( e . g . , mouse , rat ) , dog , pig , or 
non - human primate . In certain embodiments , the animal is a 
genetically engineered animal . In certain embodiments , the 
animal is a transgenic animal ( e . g . , transgenic mice and 
transgenic pigs ) . 
[ 0211 ] In certain embodiments , the time period between 
administering to a subject a polymer described herein , or a 
composition described herein ; and acquiring an image is 
between about 1 minute and about 100 hours . In certain 
embodiments , the time period between administering to a 
subject a polymer described herein , or a composition 
described herein ; and acquiring an image is between about 
1 hour and about 100 hours . In certain embodiments , the 
time period between administering to a subject a polymer 
described herein , or a composition described herein ; and 
acquiring an image is between about 1 hour and about 50 
hours . In certain embodiments , the time period between 
administering to a subject a polymer described herein , or a 
composition described herein ; and acquiring an image is 
between about 1 hour and about 20 hours . In certain embodi 
ments , the time period between administering to a subject a 
polymer described herein , or a composition described 
herein ; and acquiring an image is between about 1 hour and 
about 10 hours . In certain embodiments , the time period 
between administering to a subject a polymer described 
herein , or a composition described herein ; and acquiring an 
image is between about 1 hour and about 5 hours . 
EXAMPLES 
[ 0212 ] In order that the invention described herein may be 
more fully understood , the following examples are set forth . 
The examples described in this application are offered to 
illustrate the methods , compositions , and systems provided 
herein and are not to be construed in any way as limiting 
their scope . tion . 
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BASP - ORCA Design and Synthesis 
[ 0213 ] One of the most common ways to increase the 
relaxivity of MRI contrast agents ( including nitroxides ) 
involves attaching them to a rigid macromolecular scaffold . 
For example , Rajca et al . , appended a spirocyclohexyl 
nitroxide derivative ( " chex " ) 69 to the surface of dendrimers 
to produce chex - dendrimer ORCAs where the per - chex r? 
was 0 . 42 mM - ' s - 1 compared to ry = 0 . 14 mM - ' s - 1 for the 
model nitroxide 3 - carboxy - 2 , 2 , 5 , 5 - tetramethyl - 1 - pyrrolidi 
nyloxy ( 3 - CP ) . In anotherstudy , chex was appended to the 
core of PEGylated branched - bottlebrush polymers . 70 The 
resulting polymers had a per - chex r? of 0 . 32 mm - ' s - ? , 
which was approximately 50 % greater than the chex - mac 
romonomer used to synthesize these polymers ( chex - MM , 
FIG . 1A ) . In this system , r2 also increased from 0 . 30 
mM - s - t for chex - MM to 0 . 82 mM - s - for the chex 
bottlebrush polymer , thus demonstrating that increasing the 
macromolecular size and chex density leads to increases in 
both r , and rz , with a greater increase in rz . In an effort to 
further increase these relaxivity values , the aim was to 
incorporate chex into the BASP macromolecules . Moreover , 
it was hypothesized that BASPs could provide enhanced 
nitroxide stability potentially making tumor imaging in vivo 
possible . The control and robustness of BASP synthesis 
would enable the scalable production of BASP - ORCAs with 
optimal sizes for tumor accumulation . [ 0214 ] BASP - ORCAs were synthesized following the 
brush - first ring - opening metathesis polymerization ( ROMP ) 
strategy ( FIGS . 1A - 1B ) . 71 , 72 Norbornene - based branched 
macromonomers ( MMs , FIG . 1A ) featuring 3 kDa ( PEG ) 
and either chex ( chex - MM ) or Cy5 . 5 dye ( Cy - MM , FIG . 
1A ) were copolymerized by exposure to Grubbs 3rd genera 
tion bis - pyridine initiator73 ( Grubbs III , FIG . 1A ; reaction 
stoichiometry : j equivalents chex - MM : 0 . 01j Cy - MM : 1 . 0 
Grubbs III ) for 30 minutes ( FIG . 1B ) . The resulting living 
bottlebrush polymers with an average degree of polymer 
ization ( DP ) of wj + 0 . 0lj = m were crosslinked via slow 
addition of N equivalents of bis - norbornene acetal cross 
linker ( Acetal - XL , FIG . 1A ) directly to the reaction mixture 
to generate the desired BASP - ORCA ( FIG . 1B ) . With this 
method , the BASP - ORCA size is determined by the 
MM : Grubbs III : Acetal - XL ratios ( i . e . , m and N values ) . 
Much less Cy - MM ( 0 . 01j ) relative to chex - MM ( j ) was used 
to bridge the difference in concentration requirements 
between MRI ( mM to uM ) and NIRF ( nM to PM ) . 
[ 0215 ] To identify optimal conditions for the synthesis of 
BASP - ORCAs with narrow size distributions within the 
range of ~ 25 - 40 nm , as well as high water solubility and 
relaxivity , m and N values from 5 - 10 and 15 - 30 , respectively 
were screened ( see Table 1 ) . Gel permeation chromatogra 
phy ( GPC ) revealed nearly quantitative MM - to - bottlebrush 
conversion as well as > 85 % bottlebrush - to - BASP conver 
sion for all m and N values ( FIGS . 7A - 7B ) . The NP 
diameters as determined by dynamic light scattering ( DLS ) 
and transmission electron microscopy ( TEM ) ranged from 
~ 28 to - 49 nm ( see Table 1 ) . A representative TEM image 
for the m = 7 . 07 and N = 20 BASP - ORCA ( referred to as 
BASP - ORCAI ) is provided in FIG . 2A . The hydrodynamic 
diameter ( D ) of this particle was 31 + 4 nm , which is suitable 
for extended in vivo circulation and tumor accumulation . 
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Table 1 . Characterization data for BASP - ORCAs and control compounds . 
composition diameter relaxivity 
ridrz / 
M ' s - 1 M ' s - 1 name Dn / nm DIEM / nm notes 
3 - CP 0 . 15 0 . 17 
0 . 21 0 . 30 chex - MM 
chex - dendrimer 
chex - bottlebrush 
0 . 44 0 . 86 
55 . 55 n . d . 0 . 32 0 . 82 
BASP - ORCA 5 . 05 31 + 2 n . d . 0 . 27 6 . 92 
BASP - ORCA | 5 . 05 I 30 49 + 6 n . d . | 0 . 53 7 . 11 
poor solubility 
( < 10 mg / mL ) 
poor solubility 
( < 10 mg / mL ) 
good solubility 
( > 50 mg / mL ) BASP - ORCA1 7 . 07 31 + 4 37 + 7 0 . 41 4 . 67 
BASP - ORCA 7 . 07 36 + 3 n . d . 0 . 35 7 . 40 
poor solubility 
( < 10 mg / mL ) 
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| BASP - ORCA 
BASP - ORCA 
9 . 99 | 
9 . 99 
15 
3 0 
| 28 + 3 
33 4 
38 = 10 
39 = 10 
| 0 . 33 
0 . 37 
2 . 90 | 
4 . 52 
low relaxivity 
low relaxivity 
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tions by mass as BASP - ORCA1 ) are provided in ( FIG . 2C ) , 
along with images for “ blank ” PBS buffer . The T - weighted 
images for BASP - ORCA1 , chex - MM , and chex - bottlebrush 
polymer are not obviously different while the Tz - weighted 
images clearly show a large decrease in signal for BASP 
ORCA1 as concentration increases . The PEG - BASP with no 
chex shows no change in contrast as a function of concen 
tration , which confirms that chex is required to observe any 
changes in image contrast . 
[ 0219 ] The data presented above demonstrate that the high 
nitroxide density of BASP - ORCA1 , which is a consequence 
of its unique crosslinked multi - layer nanostructure , affords 
an increased magnetization capability for r , enhancement . 
This finding is consistent with reports where nitroxides are 
utilized as magnetic catalysts for outer - sphere relaxation 
processes . 79 , 80 , 81 Most importantly , the exceptionally high rz 
of BASP - ORCA1 overcomes one of the maj or limitations 
of nitroxide - based contrast agents : inherently low contrast . 
Ascorbate Quenching Kinetics of BASP - ORCAS 
Characterization of BASP - ORCA Magnetic Properties 
[ 0216 ) Electron paramagnetic resonance spectroscopy 
( EPR ) was used to confirm the presence of chex in BASP 
ORCAs , as well as to study the chex environment in 
BASP - ORCA1 . The spin concentrations were 85 % for all 
BASP - ORCAs . The height - normalized EPR spectra for 
BASP - ORCA1 and chex - MM are shown in FIG . 2B . The 
spectrum for BASP - ORCA1 is significantly broader than 
chex - MM , which is consistent with the larger and more rigid 
BASP nanostructure where the chex molecules are bound at 
the dense interface between the acetal crosslinker core and 
the PEG shell ( FIGS . 1B and 2B ) . The BASP - ORCA1 
spectrum was simulated using the procedure developed by 
Budil and Freed74 , which allows for characterization of the 
chex mobility in terms of the correlation time for rotational 
diffusion ( T ) . The spectrum was best fitted by superimposing 
two computed components ( FIGS . 9A - 9D ) : 22 % corre 
sponded to a relatively fast - moving nitroxide with r = 0 . 2 ns 
while 78 % corresponded to a very slow - moving nitroxide 
with r = 10 . 0 ns . The faster - moving component likely corre 
sponds to nitroxides that are furthest from the BASP 
ORCA1 acetal core ( FIG . 1B ) , while the slow - moving 
component corresponds to nitroxides that are close to and / or 
entangled within the rigid acetal core . Notably , the r of 10 . 0 
ns measured for the slow component in BASP - ORCA1 is 
very large , which suggests that the majority of chex mol 
ecules are in a rigid environment . For comparison , in the 
previously reported chex - dendrimer ORCAS , TEMPO - la 
beled bottlebrush polymers , and BASPs , the largest r mea 
sured was ~ 1 ns . 
[ 0217 ] Next , the longitudinal ( r? ) and transverse ( r2 ) relax 
ivities of these BASP - ORCAs were evaluated using a 
Bruker 7 T MRI scanner . The per - chex r? values as a 
function of m and N ( Table 1 ) ranged from 0 . 27 - 0 . 53 
mM - ' s - 1 ; they were not significantly increased compared to 
Rajca ' s chex - dendrimer and the chex - bottlebrush polymers . 
However , the per - chex r , values ranged from 2 . 90 - 7 . 40 
mM - ' s - ? , which is ~ 3 . 5 - ~ 9 . 0 - fold greater than the per - chex 
r , in the chex - bottlebrush polymers and - 17 - - 44 - fold 
greater than 3 - CP ( Table 1 ) . BASP - ORCA1 displayed a 
per - chex r2 value of 4 . 67 mM - ' s - 1 . Though this value was 
not the highest that was measured , BASP - ORCA1 was 
selected because it offered the best balance of high relaxiv 
ity , solubility ( approximately 50 mg / mL , Table 1 ) , and size 
for translation to biological studies . Given the number 
average molar mass of BASP - ORCA1 as determined by gel 
permeation chromatography and static light scattering 
( M , = 4 . 75x10 g / mol , ? = 1 . 32 ) , it can be estimated that each 
BASP - ORCA1 particle contains an average of 92 chex 
groups . Based on this number , the estimated average 
molecular r? and r? values for BASP - ORCA1 are 37 . 6 
mm - ' s - 1 and 428 . 8 mm - ' s - 1 , respectively , which are 
greater than those for the commonly used FDA - approved 
Gd - based contrast agent Magnevist ( r1 = 3 . 1 mM - ' s - 1 and 
rz = 5 . 4 mM - ' s - 1 at 7 T ) and iron - based NPs such as Fera 
heme ( r , = 3 . 1 mM - ' s - 1 and r , = 68 mM - ' s - 1 at 7 T ) . 75 , 76 , 77 , 78 
The rz / r , ratio for BASP - ORCA1 is approximately one - half 
that of Feraheme . Thus , BASP - ORCA1 should provide 
effective T2 - weighted MRI contrast enhancement . 
[ 0218 ] MR phantom images of phosphate - buffered saline 
( PBS ) solutions of BASP - ORCA1 , chex - MM , and the pre - 
viously reported chex - bottlebrush polymer at various chex 
concentrations ( from 1 mM - 4 mM chex ) as well as a 
PEG - based BASP that lacks chex ( at equivalent concentra - 
[ 0220 ] As discussed above , nitroxide - based ORCAs typi 
cally suffer from rapid reduction to diamagnetic hydroxy 
lamines under biologically relevant conditions . Amongst the 
many potential biological reducing agents , ascorbate ( Asc ) 
is known to play a major role in in vivo nitroxide reduction , 
82 , 83 and Asc - induced reduction can be amplified by gluta 
thione ( GSH ) . It was hypothesized that the rigid chex 
environment in the BASP - ORCAS could help to lower the 
rate of chex reduction . To test this hypothesis , EPR spectra 
for BASP - ORCA1 at various times were collected following 
exposure to 20 equivalents of Asc and 20 equivalents of 
GSH per nitroxide ( both reagents were present in 10 mM 
concentrations ) . EPR spectra collected 1 minute , 40 min 
utes , and 180 minutes after exposure to these conditions are 
provided in FIG . 3A ; the reduction in peak height as a 
function of time is indicative of nitroxide reduction . The 
normalized peak height of the EPR spectra are plotted versus 
time in FIG . 3B . Reduction kinetics data for the previous 
chex - bottlebrush polymers and chex - MM are provided for 
comparison . In contrast to the chex - bottlebrush and chex 
MM samples , which both display an initial rapid chex 
reduction phase in the first hour , the reduction of chex in 
BASP - ORCA1 was significantly retarded with nearly 85 % 
remaining after 1 hour , and 70 % remaining after 3 hours 
( compared to 65 % and 57 % , respectively , for the chex 
bottlebrush ) . Based on the integrated peak heights as a 
function of time , the second - order rate constants for BASP 
ORCA1 reduction in the initial ( first 10 minutes ) and late 
( > 1 hour ) stages of the reduction process were calculated : 
keartv = 0 . 0376 M - ' s - 1 and kjate = 0 . 00672 M - ' s - 1 ) ( Table 2 ) . 
Simulation revealed that the EPR spectra collected during 
the reduction process still consisted of a “ fast ” and a " slow " 
component ( FIGS . 9A - 9D ) . Interestingly , t for the “ fast ” 
component remained constant at 0 . 2 ns , while t for the 
" slow ” component became increasingly larger with time 
( 11 . 0 ns at 40 minutes and 13 . 2 ns at 180 minutes ) . There 
fore , even after 3 hours there persists an extremely reduction 
resistant and slow moving nitroxide population , which sug 
gests that BASP - ORCAs could be used for tumor MRI over 
longer timescales than have been possible with previous 
nitroxide contrast agents ( vide infra ) . 
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Nitroxide Reduction Kinetics 
[ 0221 ] 
TABLE 2 
Kinetics of the reduction of nitroxides with 20 - fold molar excess of ascorbate ( Asc ) and 
0 - 25 - fold molar excess of glutathione ( GSH ) . Numerical fits to pseudo - first order rate equation 
( k ' ) peak height ( PH ) or integrated peak height ( IPH ) of the low - field EPR line . 
Avg 
kx Ni kx kx 
Initial 
Ki 
netics 
< 1 h ) 
Range 
of fits 
k ' x 104 trox Asc . GSH 
Data Conc . Conc . Conc . 
used ( MM ) ( MM ) ( MM ) 
Late 
Ki 
netics 
( > 1 h ) 
Range k ' x 
of 104 
fit ( h ) 5 - 1 ) R2 
1 . 2 - 2 . 8 0 . 672 0 . 9923 
104 
( M - 1 104 Run 
No . 
104 
( M - 1 Run 
Label 
( M - 1 
Compd ( s - 1 ) P RE 5 - 1 ) s - 1 ) 
366 + 25 
S - 1 ) 
67 . 2 BASP 
ORCA1 " 
1 JP1191 IPH 0 . 5 10 10 < 1000 3 . 294 0 . 8795 329 . 4 
334 + 55 0 . 586 0 . 9994 
0 . 297 0 . 9943 
58 . 6 
29 . 7 
2 0 . 5 10 10 115 - 595 
IPH * ? 
PH 
JP1190 IPH 
IPHa 
PH 
JP1189 IPH 0 . 5 10 10 113 - 613 
IPH * a 
3 . 40 
0 . 836 
3 . 712 
3 . 408 
3 . 377 
3 . 828 
3 . 238 
5 . 07 
3 . 818 
3 . 311 
5 . 072 
3 . 27 
3 . 42 
0 . 9948 
0 . 8721 
0 . 7664 
0 . 9910 
0 . 2923 
0 . 7646 
0 . 9863 
0 . 3068 
0 . 5387 
0 . 9938 
0 . 3366 
0 . 9633 
0 . 9702 
339 . 7 
83 . 6 
371 . 2 
340 . 8 
33 . 77 
382 . 8 
323 . 7 
50 . 7 
381 . 8 
331 . 1 
50 . 72 
327 , 0 
342 . 0 
4 
PH 
JP1188 IPH 0 . 5 10 10 126 - 603 
IPH * a 
1 
PH 
YW982 IPH 
PH 
0 . 5 10 5 . 0 177 - 897 3065 
3086 chex 
bottle 
brush 
2 0 . 5 10 5 . 0 396 - 1019 1 . 1 - 2 . 8 YW983 IPH 
PH 
YW981 IPH 
PH 
0 . 416 
0 . 386 
0 . 9216 
0 . 9938 
41 . 6 
38 . 6 
1 0 . 5 100 . 0 251 - 851 
2 . 85 
2 . 73 
3 . 05 
2 . 41 
0 . 9520 
0 . 9895 
0 . 9439 
0 . 9808 
285 . 0 
273 . 0 
305 . 0 
241 . 0 
2965 
254 chex 
bottle 
brush 
2 0 . 5 100 . 0 278 - 878 2 . 86 1 . 3 - 2 . 8 YW985 IPH 
PH 
JP609 IPH 
2 . 68 
0 . 9145 
0 . 9775 
0 . 6609 
286 . 0 
268 . 0 
620 . 0 
0 . 243 0 . 8838 
0 . 196 0 . 9735 
0 . 301 0 . 6847 
24 . 3 
19 . 6 
30 . 1 1 0 . 5 10 0 . 0 90 - 390 6 . 20 603 + 123 0 . 8 - 2 . 8 chex - 
den 
drimer 
579 59 . 6 0 . 354 0 . 9663 35 . 4 
0 . 5 10 0 115 - 415 
0 . 5 10 126 - 426 
PH 
JP610 IPH 
PH 
JP611 IPH 
PH 
JP899 IPH 
PH 
JP8100 IPH 
PH 
JP1101 IPH 
3 - CP < 600 608 . 0 + 4 . 2 
602 . 6 + 25 
0 . 2 4 . 0 5 . 0 < 600 
6 . 17 
7 . 18 
6 . 09 
4 . 72 
5 . 10 
2 . 435 
2 . 361 
2 . 438 
2 . 410 
2 . 423 
2 . 461 
2 . 547 
2 . 504 
2 . 498 
2 . 396 
2 . 459 
2 . 389 
0 . 9718 
0 . 6743 
0 . 9336 
0 . 7984 
0 . 9915 
0 . 9997 
0 . 9990 
0 . 9997 
0 . 9996 
0 . 9998 
0 . 9996 
0 . 9996 
0 . 9949 
0 . 9975 
0 . 9949 
0 . 9999 
0 . 9961 
617 . 0 
718 . 0 
609 . 0 
472 . 0 
510 . 0 
608 . 8 
590 . 3 
609 . 6 
602 . 4 
605 . 6 
615 . 2 
636 . 8 
636 . 0 
624 . 5 
599 . 0 
614 . 8 
597 . 3 
2 5 . 0 < 600 
PH 0 . 2 
0 . 2 
4 . 0 
4 . 0 3 - CP 1 JP460 0 . 0 < 3600 625 + 22 
611 + 44 
JP461 0 . 2 0 0 . 0 < 3600 
IPH 
PH 
IPH 
PH 
IPH 
PH 
3 JP462 0 . 2 4 . 0 0 . 0 < 3600 
> 1 1 . 18 0 . 9952 295 
" For BASP - ORCA1 , double integration of entire EPR spectra gave initial rate constant k = 449 = 23 M - 3 - 1 , which is somewhat larger than the integrated peak height ( IPH ) value , 
k = 366 + 25 M - 15 - 1 , 
PH * is the integrated peak height for the center line of the EPR spectrum . 
" For ORCA - Fluor , initial second order rate constants from 4 kinetic runs using 0 - 10 equivalents of GSH , k = 301 + 20 and 281 + 43 M ' s for baseline corrected PH and PH data , 
Data for chex - bottlebrush , data for chex - dendrimer ( baseline corrected ) and late kinetics for 3 - CP with Asc only , data for 3 - CP with 20 equivalents of Asc and 25 equivalents of GSH , 
and data for 3 - CP with Asc only ” were reported elsewhere . 
Fluorescence Properties of BASP - ORCAS 
[ 0222 ] As noted above , Cy5 . 5 was also incorporated into 
these BASP - ORCAS ( see FIG . 10 for BASP - ORCA1 
absorption and emission spectra confirming the presence of 
Cy5 . 5 ) in order to simultaneously use NIRF as an imaging 
modality for comparison to MRI . Nitroxides are well - known 
to quench fluorescence via catalysis of non - emissive pho - 
tophysical processes such as intersystem crossing . This 
quenching requires close interaction between the nitroxide 
and the fluorophore ; the systems with the greatest quenching 
typically feature the nitroxide directly linked to the fluoro 
phore via ur bonds ( i . e . , electronic conjugation ) . 84 , 85 , 86 
Given the fact that chex and Cy5 . 5 are incorporated into 
BASP - ORCAs via two different macromonomers , and not 
ing the limited mobility of chex in these nanoparticles , it was 
reasoned that Cy5 . 5 quenching would be minimal ; therefore , 
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Cy5 . 5 emission could be used as a fairly constant descriptor 
of particle concentration regardless of the extent of chex 
reduction . 
[ 0223 ] To test this hypothesis , BASP - ORCA1 was 
exposed to a large excess of Asc ( 40 to 120 equivalents to 
chex ) in water , and monitored the resulting Cy5 . 5 emission . 
In agreement with the expectation , only a 25 + 2 % to 30 + 2 % 
increase in fluorescence emission was observed ( FIG . 3C ) . 
Moreover , addition of GSH ( 60 equivalents ) as a co - reduc 
tant along with 60 equiv . of Asc gave only a 35 + 7 % increase 
in fluorescence . Taken together , these data suggest that 
Cy5 . 5 fluorescence is only minimally quenched by chex in 
BASP - ORCA1 . For comparison , exposure of the previously 
reported chex - bottlebrush polymer containing Cy5 . 5 to 
excess Asc or Asc + GSH led to 119 + 5 % and 250 + 5 % 
increases in fluorescence , respectively . Notably , the time 
required to achieve a fluorescence plateau varied signifi 
cantly between BASP - ORCA1 ( approximately 40 minutes ) 
and the chex - bottlebrush polymer ( a few minutes ) . Collec 
tively , these data suggest that the BASP nanostructure pro 
vides greater steric shielding and isolation of chex and Cy5 . 5 
compared to the analogous bottlebrush polymer . 
phase clearance behavior , with an early distribution phase of 
– 6 hours , followed by a steady elimination phase . Fitting the 
data presented in FIG . 13A with a standard two - compart 
ment model yielded a blood compartment half - life for 
BASP - ORCA1 of 10 hours . 89 This long half - life is attrib 
uted to the nanoscale size of BASP - ORCA1 , which limits 
renal clearance , and its PEGylated corona , which minimizes 
protein absorption and macrophage uptake . Consistent with 
these results and a plethora of studies on PEGylated nano 
particles , BD analysis revealed that a majority of BASP 
ORCA1 accumulated in the liver , with increasing accumu 
lation over 72 hours ( FIG . 13B ) . Less , but significant , 
accumulation in the kidney and negligible accumulation in 
other tissues was observed ( Note : fluorescence in extracted 
lung tissue is attributed to a high concentration of BASP 
ORCA1 in the blood ) . Notably , fluorescence images of fecal 
samples ( FIG . 13C ) suggest that BASP - ORCA1 is ulti 
mately cleared from the body via excretion . 
In Vitro Cytotoxicity and In Vivo Gross Toxicity , 
Pharmacokinetics ( PK ) , and Biodistribution ( BD ) of 
BASP - ORCA1 in Non - Tumor Bearing Mice 
[ 0224 ] Motivated by BASP - ORCAl ' s unprecedented 
combination of properties , which include nanoscopic size 
( D , = 31 + 4 nm ) and narrow size distribution , good water 
solubility , slow reduction kinetics , and exceptionally high rz 
relaxivity for an organic contrast agent , next the perfor 
mance of this nanomaterial in biological assays was inves 
tigated . As discussed above , one potential advantage of 
ORCAs is their low toxicity . To investigate the toxicity of 
BASP - ORCA1 , first in vitro human umbilical vein endothe 
lial cell ( HUVEC ) and HeLa cell viability assays were 
conducted . In these assays , the cells were incubated with 
varied concentrations of BASP - ORCA1 for 72 h . Cell 
viability was determined by the CellTiter Glo assay ( FIG . 
11 ) . The half - maximal inhibitory concentration ( IC ) of 
BASP - ORCA1 , i . e . , the concentration that led to 50 % cell 
death , was 1 . 5 mg / mL ( 280 UM chex ) and 4 . 5 mg / mL ( 830 
UM chex ) in HUVEC and HeLa cells , respectively . These 
results confirm that BASP - ORCA1 induces negligible in 
vitro cytotoxicity at practical concentrations . Next , the in 
vivo gross toxicity of BASP - ORCA1 was assessed . Healthy 
BALB / c mice were administered increasing doses ( from 5 to 
30 mg or 0 . 2 to 1 . 5 g / kg , respectively ) of BASP - ORCA1 via 
tail vein injection . The animal body masses and behaviors 
were monitored over the course of 30 days . Loss of 10 % 
body mass is generally considered to be a sign of unaccept 
able toxicity . 87 , 88 As shown in FIG . 12 , even the highest 
dose of BASP - ORCA1 ( administered to n = 4 animals ) 
induced no significant decrease in body mass , which sug 
gests that these particles are well - tolerated up to their 
solubility - limiting dose . 
10225 ] The pharmacokinetics ( PK ) and biodistribution 
( BD ) of BASP - ORCA1 were monitored in healthy , non 
tumor bearing BALB / c mice ( n = 3 ) using NIRF imaging 
( IVIS , Cy5 . 5 Nexhem = 640 / 700 nm ) . For PK analysis , blood 
samples were collected via cardiac puncture at various time 
points from 1 hour to 48 hours . Percent injected dose was 
plotted as a function of time ( FIG . 13A ) . As is common for 
spherical nanoparticles , BASP - ORCA1 exhibited a two 
BASP - ORCA1 BD in Tumor - Bearing Mice 
[ 0226 ] Given the long circulation of BASP - ORCA1 , it 
was hypothesized that this particle would passively accu 
mulate in subcutaneous tumors following systemic injection . 
To test this hypothesis , a tumor model was established via 
subcutaneous injection of a mixture of 2 . 0x10° lung carci 
noma cells ( A549 , ATCC ) , Matrigel , and PBS buffer into a 
hind flank of NCR - NU mice ( n = 4 ) . When the average tumor 
volume was ~ 1 cm , BASP - ORCA1 was administered at a 
dose of 0 . 23 mmol chex / kg via tail vein injection . The mice 
were imaged 20 hours after administration . This choice of 
imaging time strikes a balance between allowing for suffi 
cient tumor accumulation while limiting the extent of chex 
reduction in vivo . NIRF images indicated substantial tumor 
accumulation of BASP - ORCA1 , which is consistent with 
other reports for PEGylated nanoparticles of similar size 
including the related drug - conjugated BASPs ( FIG . 4A ) . Ex 
vivo BD data were consistent with the studies on non - tumor 
bearing BALB / c mice ( i . e . , liver accumulation and persis 
tence in blood , FIGS . 13A and 13B ) with the addition of 
significant tumor accumulation ( FIG . 4C and FIG . 14 ) . 
In Vivo MRI and NIRF Imaging with BASP - ORCA1 
[ 0227 ] The low toxicity , long circulation half - life , and 
tumor accumulation of BASP - ORCA1 , along with its excep 
tional chex stability and relaxivity , suggested that this par 
ticle could be suitable for MRI of tumors following systemic 
injection and accumulation ; a feat that has not yet been 
reported with ORCAs . Two groups of A459 tumor - bearing 
NCR - NU mice were administered different doses of BASP 
ORCA1 via tail - vein injection : the “ low dose ” group ( n = 3 ) 
received 0 . 165 mmol chex / kg ( 0 . 8 g BASP - ORCA1 / kg ) 
while the “ high dose ” group ( n = 4 ) received 0 . 23 mmol 
chex / kg ( 1 . 2 g BASP - ORCA1 / kg ) . The mice were anaes 
thetized and MR images were collected at various time 
points : 12 hours , 16 hours , and 20 hours post - injection for 
the low dose group and 20 hours post - injection for the high 
dose group . The images from each time point were com 
pared to images collected before BASP - ORCA1 injection . 
FIG . 5A shows T2 - weighted images for a selected mouse 
from the low dose group imaged before BASP - ORCA1 
injection ( top row of images ) and 20 hours ( bottom row of 
images ) after BASP - ORCA1 injection ; from left - to - right the 
images correspond to progressive slices of the same animal 
in the z - axis with the tumor observed on the bottom right of 
each image . FIG . 5B shows an analogous set of images for 
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injection , which is a testament to its unique structural 
features that combine optimal size for tumor accumulation 
with a high nitroxide density and stability . To set these 
results in context , the data outlined herein was compared to 
recent literature examples of MRI - contrast agents the rely on 
metals to achieve tumor imaging following systemic admin 
istration . For example , Kataoka and coworkers recently 
reported on a new class of Gd - based nanoparticles ( T1 
contrast agents ) for MRI of tumors . In their study , a - 40 % 
contrast enhancement ( at 0 . 05 mmol Gd / kg iv dose ) was 
observed plateauing 4 hours following injection into mice 
bearing subcutaneous C26 tumors . Notably , commercially 
available Gd - DTPA , which is a small molecule , exhibited 
negligible contrast enhancement ( at 0 . 23 mmol Gd / kg iv 
dose ) after 4 hours . This example highlights the importance 
of a nanoparticle system for extended circulation and tumor 
imaging , though the impact of Gd nanoparticle accumula 
tion in tissues would need to be addressed prior to clinical 
translation . In another example , the same group reported 
novel Fe - based nanoparticles ( T2 contrast agents ) for tumor 
imaging in a similar murine model ( subcutaneous C26 
tumors ) . Here , an approximately 25 % contrast difference 
was observed 24 hours following intravenous administration 
of 0 . 45 mg Fe / kg . Notably , less than 10 % contrast enhance 
ment was observed using commercially available Resovist 
( at 0 . 45 mg Fe / kg intravenous dose ) . Error ! Bookmark not defined 
It should be noted that the instrument parameters used to 
obtain T2 - weighted images in this work were similar to those 
used in the studies described herein ; thus , these results for 
BASP - ORCA1 are on par with recently reported nanopar 
ticle MRI contrast agents that rely on metals to achieve 
contrast . 
a selected mouse from the high dose group . Contrast dif - 
ferences between the pre - injection and post - injection images 
can be observed at both dose levels , with greater contrast 
observed in the high dose animal . Whole animal images 
similarly revealed a clear difference in tumor contrast ( FIG . 
5C , arrows ) . 
( 0228 ] The percent negative contrast enhancement ( i . e . , 
signal reduction ) before and after BASP - ORCA1 adminis 
tration was quantified by image analysis ( FIG . 5D ) . Signal 
reductions ranging from 14 : 2 % to 16 + 2 % ( P < 0 . 05 ) were 
observed for the 12 hour to 20 hour time points in the low 
dose group ( FIG . 5D , low dose bars ) . In the high dose group , 
a 24 + 2 % ( P < 0 . 001 ) signal reduction was observed 20 hours 
after BASP - ORCA1 administration ( FIG . 5D , high dose 
right bar ) . The clear BASP - ORCA1 dose - response effect 
suggests that the observed contrast differences between pre 
and post - injection are due to accumulation of BASP 
ORCA1 in the tumors . Keeping in mind that MRI phantoms 
revealed no observable contrast enhancement for PEG 
BASPs that lack chex ( FIG . 2C ) , these MRI data imply that 
20 hours following injection there is a sufficient concentra 
tion of non - reduced chex ( i . e . , chex radicals ) present on the 
BASP - ORCA1 to impart contrast . To confirm the presence 
of chex radicals in the tumors , the same mice that were 
imaged by MRI were sacrificed 21 hours after BASP 
ORCA1 administration and their tissue homogenates and 
blood were analyzed by EPR spectroscopy ( FIG . 6A ) . From 
these spectra , the radical concentration per g protein in each 
tissue sample , the latter obtained via a bicinchoninic acid 
assay ( BCA ) , of the tissue homogenate , was evaluated and 
normalized by the radical concentration per g protein in 
muscle tissue ( FIG . 6B ) . In agreement with the MRI data , 
the concentration of free radicals in the tumor was quite high 
22 hours after BASP - ORCA1 injection ; the measured value 
of 0 . 25 umol = 0 . 04 chex / g of protein corresponds to 4 . 5 % of 
the injected dose of chex radicals ( Note : this value does not 
include any chex radicals that were reduced , and thus the 
percent injected dose of BASP - ORCA1 in the tumor is 
likely larger than 4 . 5 % ) . Moreover , consistent with the in 
vivo NIRF imaging results ( vide supra ) , relatively high 
radical concentrations were observed in the liver and kidney , 
which suggests that the clearance of BASP - ORCA1 pro 
ceeded mostly through these organs . Notably , the murine 
liver contains a high concentration of Asc ( millimolar 
range ) ; the observation of radicals in the liver 22 hours after 
injection is further evidence of the extremely stable nature of 
the chex units in BASP - ORCA1 ( Note : in the previous 
chex - bottlebrush polymers , there was very little chex radical 
in the liver following 30 minutes and none after 24 hours ) . 
A high chex concentration was also observed in the heart , 
which is in accord with a long blood compartment half - life 
and is consistent with the PK data obtained by NIRF imaging . Finally , NIRF imaging of these homogenates pro 
vided fluorescence radiant efficiencies that were in good 
agreement with the spin concentrations ( FIG . 6B ) , which 
suggests that the chex radicals and Cy5 . 5 dyes are still 
co - localized within the BASP - ORCA1 construct 22 hours 
after injection . Unlike the previous chex - bottlebrush poly 
mers , which displayed dramatic increases in fluorescence as 
chex was reduced , the signal uniformity offered by BASP 
ORCA1 provides for straightforward multi - modal confirma 
tion of BD . 
[ 0229 ] BASP - ORCA1 is the first nitroxide MRI contrast 
agent capable of providing significant contrast 20 hours after 
Conclusion 
[ 0230 ] In conclusion , a nitroxide - nanoparticle MRI con 
trast agent - BASP - ORCA1 — that enables simultaneous 
MRI and NIRF imaging in vivo over timescales suitable for 
tumor imaging following systemic injection was developed 
herein . BASP - ORCA1 addresses the two major challenges 
that have historically limited nitroxide - based organic radical 
contrast agents for MRI : low relaxivity and poor stability . 
These functions were made possible by the brush - arm star 
polymer ( BASP ) nanostructure , which enables the place 
ment of chex nitroxides at the interface between a rigid 
poly ( acetal ) core and a hydrophilic PEG shell . Altogether , 
BASP - ORCA1 displayed unprecedented per - nitroxide and 
per - molecule transverse relaxivities for organic radical con 
trast agents , exceptional stability , high water solubility , low 
in vitro and in vivo toxicity , and a long blood compartment 
half - life . These features combined to facilitate the imaging 
of subcutaneous tumors in mice 20 hours after tail - vein 
injection , providing contrast enhancements on par with 
commercial and literature examples of metal - based contrast 
agents . This work suggests that organic radicals can be 
viable alternatives to metal - based MRI contrast agents , and 
sets the stage for the development of theranostic systems 
that combine organic radical contrast agents with therapeutic 
payloads to achieve simultaneous tumor imaging and drug 
delivery without concerns over long - term accumulation of 
metals . 
Materials , General Methods , and Instrumentation 
[ 0231 ] All reagents were purchased from commercial sup 
pliers and used without further purification unless stated 
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240 , 252 , 264 , 276 , 288 , 300 , 312 , 324 , 336 , 348 , 360 ms . 
Custom routines written in Matlab ( Mathworks , Natick , 
Mass . ) were used to reconstruct the images and compute 
relaxation time constants by fitting image intensity data to 
exponential decay curves . 
otherwise . Grubbs 3rd generation bispyridyl catalyst , 73 mac 
romonomers ( MMs ) chex - MM , Cy - MM , 90 PEG - MM and 
cross - linker Acetal - XL were prepared according to literature 
procedures . Size exclusion chromatography ( SEC ) analyses 
were performed on an Agilent 1260 Infinity setup with two 
Shodex KD - 806M columns in tandem and a 0 . 025 M LiBr 
DMF mobile phase run at 60° C . The differential refractive 
index ( DRI ) of each compound was monitored using a Wyatt 
Optilab T - rEX detector , and the light scattering ( LS ) signal 
was acquired with a Wyatt Dawn Heleos - II detector . Column 
chromatography was carried out on silica gel 60F ( EMD 
Millipore , 0 . 040 - 0 . 063 mm ) . 
[ 0232 ] Dynamic light scattering ( DLS ) measurements 
were performed using a Wyatt Technology Mobius DLS 
instrument . Samples were prepared at 1 . 0 mg / mL in either 
nanopure water ( MilliQ ) , PBS buffer , or 5 % glucose solution 
( in nanopure water ) . The resulting solutions were passed 
through a 0 . 4 um Nalgene filter ( PES membrane ) into 
disposable polystyrene cuvettes , which were pre - cleaned 
with compressed air . Measurements were made in sets of 10 
acquisitions , and the average hydrodynamic diameters were 
calculated using the DLS correlation function via a regular 
ization fitting method ( Dynamics 7 . 4 . 0 . 72 software package 
from Wyatt Technology ) . 
[ 0233 ] TEM images were acquired using a FEI Tecnai 
Multipurpose TEM ( G2 Spirit TWIN , 12 kV ) at the MIT 
Center for Materials Science and Engineering . Samples 
were prepared as follows : 5 uL of a 1 . 0 mg / mL aqueous 
solution of BASP - ORCA was pipetted onto a carbon film 
coated 200 - mesh copper grid ( Electron Microscopy Sci 
ences ) placed on a piece of parafilm . Next , the solution was 
carefully absorbed at the base of the droplet using the edge 
of a Kimwipe , leaving behind the nanoparticles on the TEM 
grid . The samples were then negatively stained by adding a 
drop of 2 wt % uranyl acetate ( Electronic Microscopy 
Sciences ) . After 3 min , the residual uranyl acetate solution 
was carefully absorbed onto a Kimwipe , and the samples 
were allowed to dry completely . 
[ 02341 Excitation / emission spectra and fluorescence mea 
surements were acquired using a Tecan Infinite® 200 Pro 
plate reader . Electron Paramagnetic Resonance ( EPR ) spec 
tra were acquired at the University of Nebraska using a 
Bruker CW X - band spectrometer equipped with a frequency 
counter . The spectra were obtained using a dual mode 
cavity ; all spectra were recorded using an oscillating mag 
netic field perpendicular ( TE102 ) to the swept magnetic field . 
DPPH powder ( g = 2 . 0037 ) was used as a g - value reference . 
Kinetics of Nitroxide Quenching by EPR Spectroscopy 
[ 0236 ] A solution was prepared with ascorbic acid ( Asc ) , 
sodium phosphates ( < 30 ppm transition metals ) , sodium hydroxide and diethylenetriaminepentaacetic acid ( DTPA , 
- 0 . 1 % ( mol / mol ) to sodium phosphates ) at pH 7 . 4 . Reduced 
L - GSH was then dissolved to provide the Asc / GSH solution . 
BASP - ORCA solution was prepared in phosphate buffer , 
which was made from sodium phosphates and DTPA ( - 0 . 1 % 
( mol / mol ) to sodium phosphates ) at pH 7 . 4 . Equal volumes 
of the freshly prepared 1 mM ( in nitroxide ) sample solution 
and 20 mM Asc / GSH solution were combined and vortexed 
for 6 seconds , and then added to a 2 mm OD EPR tube . 
Kinetic studies were performed on 0 . 5 mM nitroxide solu 
tion in the presence of 125 mM sodium phosphates , 10 mM 
Asc , and 10 mM GSH . The peak height of the low - field line 
of the triplet was measured as a function of time . Microwave 
power was kept under 6 . 5 mW and the temperature was 
controlled at 295 K with a nitrogen flow system . 
Computational Analysis of Nitroxide Quenching by EPR 
Spectroscopy 
[ 0237 ] The EPR spectra are constituted by a “ fast ” and a 
" slow ” component . From visual inspection , it was clear that 
the slow component was changing from one to another 
sample , while the fast one showed an almost equivalent line 
shape in the three spectra . Therefore , first a computation 
( program by Budil & Freed74 ) of the fast component to be 
subtracted from the three spectra to obtain a reliable line 
shape for the slow components was employed . This suc 
ceeded for the fast component shown in FIG . 9A ( the 
subtracted experimental line in black and the computed line 
is in red ) . The main parameters used for the computation are 
shown in the figure and described below . Subtraction of this 
fast component from the overall spectra produced the three 
slow components shown in FIGS . 9B , 9C and 9D for 1 min , 
40 min , and 180 min , respectively in FIGS . 9A - 9D the 
spectra are normalized in height ) . Their computations are 
shown as well , together with the main parameters used for 
computation and analysis . The following parameters were 
calculated . 
[ 0238 ] The gir components for the coupling between the 
electron spin and the magnetic field ( accuracy from com 
putation - 0 . 0002 ) . The starting values , which were used in 
previous studies using nitroxide radicals , are 2 . 009 , 2 . 006 , 
2 . 003 , for gxx Sy , and gzz , respectively . It was found that 
these values worked for the computations of the fast com 
ponent and for the t = 1 minute slow component ; however , for 
computing the slow components of t = 40 minutes and 180 
minutes it was necessary to decrease the g , values to 2 . 0025 
and 2 . 002 , respectively . This observation indicated an 
increased structural anisotropy of the nitroxide labels from 
1 minute to 40 minutes to 180 minutes . [ 0239 ] The Aii components for the coupling between the 
electron spin and the nitroxide - nitrogen nuclear spin ( accu 
racy from computation + 0 . 5 G ) . These parameters increase 
with an increase in the environmental polarity of the nitrox 
ide . Mainly , as done in previous studies , the A , and Aw 
Relaxivity Measurements by MRI 
[ 0235 ] Phantom MRI data were acquired in a 12 cm outer 
diameter birdcage transceiver for imaging in a 20 cm bore 
Bruker 7 T Avance III MRI scanner . Samples at varying 
concentrations ( 0 up to 5 mM ) in PBS buffer were loaded 
into the wells of a 384 - well clear polystyrene plate ( Thermo 
Scientific Nunc ) , which had been pre - cut in half to optimally 
fit the coil . Unused wells were filled with PBS buffer . 2 mm 
slices were imaged through the samples with the field of 
view of 5x5 cm and the data matrices were 256x256 points . 
Longitudinal ( r? ) and transverse ( r ) relaxivity measure 
ments were acquired using multi - spin multi - echo ( MSME ) 
sequences ( flip angle = 180° ) . r , ; TE = 12 ms , TR = 300 , 350 , 
400 , 450 , 500 , 600 , 800 , 1000 , 1200 , 1500 , 3000 , 5000 , 
10000 ms . r . ; TR = 5000 ms , TE = 12 , 24 , 36 , 48 , 60 , 72 , 84 , 
96 , 108 , 120 , 132 , 144 , 156 , 168 , 280 , 192 , 204 , 216 , 228 , 
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allowed to adhere overnight . The media was then replaced 
with fresh media containing BASP - ORCA1 at various con 
centrations . The plate was incubated for 72 hours , and cell 
viability was then determined using the CellTiter - Glo assay 
( Promega ) . HeLa cells were plated in 96 - well plates ( Corn 
ing ) and cytotoxicity was studied following the same experi 
mental procedure used for HUVEC cells . 
values were maintained constant ( 6 G ) and only A z was 
changed . The polarity was found to be slightly lower for the 
fast component ( A2 = 35 G ) than for the slow one ( A . - = 36 
G ) ; it was constant for the different slow components . 
[ 0240 ] The correlation time for rotational diffusion of the 
radical , z ( accuracy from computation + 0 . 05 ns ) . This param 
eter increases with an increase in the local viscosity around 
the nitroxide group and with a decrease in the rotational 
mobility of the nitroxide . The local viscosity largely 
increased ( the mobility decreased ) from the fast component 
to the slow ones and it also increased the mobility 
decreased ) from 1 minute ( 10 ns ) to 40 minutes ( 11 ns ) to 
180 minutes ( 13 . 2 ns ) . Notably , by performing a subtraction 
procedure using the double integrals of the components of 
the spectra , it was found that the fast component was 
contained in all the three spectra in almost the same relative 
percentage , that is , about 20 % ( the accuracy in this percent 
age is about 1 % ) . [ 0241 ] The line width ( accuracy from computation 0 . 1 
G ) , which measures spin - spin interactions due to a high local 
concentration of paramagnetic species ( like colliding nitrox 
ide groups in fast motion , or nitroxides bound in close 
proximity in slow motion ) . The line width was quite high for 
all samples , indicating a high local concentration of nitrox 
ides , but it was the highest ( 7 . 6 G ) for the slow component 
of the t = 1 minute sample , and it decreased at 40 minutes ( 5 . 5 
G ) and further decreased at 180 minutes ( 4 . 2 G ) . The latter 
value is even smaller than the line width of the fast com 
ponent ( 4 . 8 G ) . 
Animal Usage 
[ 0245 ] All experiments involving animals were reviewed 
and approved by the MIT Committee for Animal Care 
( CAC ) . BALB / c mice ( female , 8 - 12 weeks old , Taconic ) 
were used for in vivo toxicity , pharmacokinetic studies , and 
biodistribution ( n = 3 ) . NCR - NU nude mice ( female , 8 - 12 
weeks old , Taconic ) were used for in vivo MRI , NIRF 
imaging , and biodistribution ( n = 3 ) . All animals received an 
alfalfa - free diet ( TestDiet ) at least 2 weeks prior to the start 
of the studies to minimize auto - fluorescence . 
In Vivo Toxicity 
[ 0246 ] Solutions containing 5 . 0 - 30 mg of BASP - ORCA1 
in 5 % glucose were prepared , passed through sterile 0 . 2 um 
filter ( Nalgene , PES membrane ) , and administered into 
BALB / c mice via tail vein injection . The mice were moni 
tored over a period of 30 days . Initial injections were 
performed in one mouse for each dose , all of which appeared 
to be well - tolerated . The highest dose ( 30 mg ) was then 
administered to another set of mice ( n = 3 ) . No adverse 
physical effects and / or significant weight losses were 
observed . 
In Vivo MR and NIRF Imaging Instrumentation 
Fluorimetry 
[ 0242 ] Fluorescence analysis was performed using a 
Tecan Infinite® 200 Pro plate reader . Absorption / emission 
spectra of BASP - ORCA1 were acquired to determine Nexlem , 
which were 640 nm and 705 nm respectively ( as expected 
for the dye used in these studies : Cyanine5 . 5 ) . Absorption 
spectra were acquired using a 1 nm wavelength step size at 
9 nm bandwidth ; emission spectra were obtained using Nex 
of 640 nm , a 5 nm wavelength step size , and 10 nm 
bandwidth . To examine the effect of nitroxide - quenching on 
fluorescence emission intensity , samples were prepared in 
96 - well plates ( Corning , n = 3 ) by mixing 50 uL of 5 mg 
BASP - ORCA1 / mL solution with 50 uL of Asc / GSH solu 
tion with one of the following compositions : 120 equivalents 
( eq , with respect to chex ) Asc , 60 eq Asc , 40 eq Asc , and 60 
eq Asc + 60 eq GSH . Control samples ( n = 3 ) were prepared by 
mixing 50 uL of 5 mg BASP - ORCA1 / mL solution with 50 
uL of PBS . Fluorescence intensity was monitored continu 
ously for 2 hours ; a plateau was typically reached within 
40 - 50 min . 
[ 0247 ] All imaging experiments were performed at the 
Koch Institute for Integrative Cancer Research at MIT . In 
vivo MRI was acquired using a Varian 7T / 310 / ASR - whole 
mouse MRI system . Scans were collected with respiratory 
gating ( PC - SAM version 6 . 26 by SA Instruments Inc . ) to 
avoid confounding noise due to chest movement . The respi 
ratory rate and animal temperature were closely monitored 
during image collection . Coronal T2WIs were collected 
using the fast spin echo multiple slices pulse sequence with 
TR = 4000 ms ; TElep = 48 ms ; ETL = 8 ; FOV = 100x50 mm² ; 
512x256 matrix and 2 averages over 12 slices of 1 mm 
thickness and 0 mm gap . Axial T2WIs were collected using 
the fast spin echo multiple slices pulse sequence with 
TR = 4000 ms ; Telep = 48 ms ; ETL = 8 ; FOV = 45x45 mm² ; 
256x256 matrix and 2 averages over 10 - 16 ( to capture entire 
tumor ) slices of 1 mm thickness and 0 mm gap . [ 0248 ] In vivo NIRF imaging was performed on an IVIS 
Spectrum - bioluminescent and fluorescent imaging system ( Xenogen ) . Epi - fluorescence imaging was acquired through 
excitation of the Cy5 . 5 fluorophore Qedem = 640 / 700 nm , 
exposure time 2 - 10 seconds ) present in BASP - ORCA1 . 
Cell Culture 
[ 0243 ] A549 and HeLa cells ( ATCC ) were cultured in 
DMEM media ( Sigma - Aldrich ) supplemented with 10 % 
fetal bovine serum ( FBS , VWR ) and 1 % penicillin / strepto 
mycin ( Thermo Fisher Scientific ) . Human umbilical vein 
endothelial cells ( HUVEC , Lonza ) were cultured in EGM + 
media ( Lonza ) supplemented with 1 % penicillin / streptomy 
cin . All cells were housed in 5 % CO , humidified atmosphere 
at 37° C . 
Pharmacokinetics ( PK ) and Biodistribution ( BD ) Studies 
[ 0249 ] BASP - ORCA1 doses ( 5 . 0 mg in 5 % glucose ) were 
prepared , passed through sterile 0 . 2 um filters , and injected 
into BALB / c mice ( groups of n 3 ) . Blood samples were 
taken at 1 , 3 , 6 , 24 , and 48 hours via cardiac puncture after 
euthanization in a CO2 chamber . The blood samples were 
subjected to fluorescence imaging ( IVIS , Cy5 . 5 Nex / em = 640 / 
700 nm , Xenogen ) for analysis of blood - compartment PK . 
In Vitro Cell Viability 
[ 0244 ] HUVEC cells were plated at 5 , 000 cells per well ( in 100 uL ) in 96 - well collagen - coated plates ( Corning ) and 
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For BD , organs from these BALB / c mice were harvested 
and subjected to fluorescence imaging ( IVIS , Cy5 . 5 dex ) 
em = 640 / 700 nm , Xenogen ) . 
Fisher Scientific ) . These protein contents were then used as 
a normalizing parameter to compare nitroxide spin concen 
tration and NIRF signal ( FIG . 6B ) . 
Ex Vivo NIRF Imaging 
[ 0256 ] To acquire BD , the collected organs and organ 
homogenates were subjected to NIRF imaging following the 
same aforementioned experimental procedure as for in vivo 
NIRF imaging . Furthermore , tissue homogenate samples 
were transferred into a 96 - well plate and imaged for the 
correlation of NIRF signal and spin concentration . 
In Vivo MR and NIRF Imaging in Tumor - Bearing Mice 
[ 0250 ] A549 cells were cultured in DMEM media supple 
mented with 10 % fetal bovine serum and 1 % penicillin / 
streptomycin in 5 % CO , humidified atmosphere ( 37° C . ) to 
a final concentration of 20 % . Cells were then harvested , 
mixed with Matrigel and sterile pH 7 . 4 PBS buffer ( 1 : 1 ) , 
filtered through sterile 0 . 2 um filters , and injected subcuta 
neously ( 2 . 0x100 cells ) into the hind flank of NCR - NU mice . 
Tumor growth was monitored for 2 - 4 weeks until appropri 
ate cumulative diameters ( ~ 1 cm ) were achieved . ( 0251 ] MRI and NIRF images were acquired for each 
animal ( n = 3 - 4 ) before injections . BASP - ORCA1 doses 
( 0 . 16 mmol chex / kg or 0 . 23 mmol chex / kg in 5 % glucose ) 
were prepared , passed through a sterile 0 . 2 um filter , and 
administered to the tumor - bearing mice via tail vein injec 
tion . Tumor imaging was done at pre - determined time 
points ; at the last imaging time point , mice were immedi 
ately euthanized in a CO2 chamber , and organs were col 
lected , imaged by NIRF , and stored in dry ice for EPR 
analysis . 
In Vivo MRI Data Analysis 
[ 0257 ] Signal intensities pre - and post - injection were 
compared only using slices where tumors and muscle were 
clearly visible . Using ImageJ software , a region of interest 
( ROI ) around each component was manually drawn . The 
average signal intensity and area of the ROI were measured ; 
these data were then normalized against the signal intensity 
of the muscle tissue . Signal intensity was acquired by 
multiplying area and normalized signal intensity . This pro 
cess was repeated for all relevant slices for a given organ ; the 
sum of these signal intensities was then calculated and 
divided for the total area , affording the volume - averaged 
signal intensity . Signal enhancement by BASP - ORCA1 was 
quantified by comparing the volume - averaged signal inten 
sities pre - and post - injection . 
Procedure for BASP - ORCA Synthesis 
Ex Vivo EPR Spectroscopy 
[ 0252 ] Harvested organs were shipped on dry ice to the 
University of Nebraska , where they were stored on dry ice . 
For EPR sample preparation , each tissue sample , one at a 
time , was rapidly thawed and transferred to a weighed vial ; 
900 uL of PBS buffer ( 0 . 5 mM , PH 7 . 2 ) was then added . The 
mixture was put into an ice - water bath and homogenized 
with a rotor stator homogenizer , then pipetted into a 4 - mm 
outer diameter EPR sample tube . The samples were 
degassed by sonication as needed ( for instance , when gas 
bubbles were visible ) . The EPR tube was capped , sealed 
with parafilm , and stored briefly in acetone / dry ice bath 
before spin concentration measurements . [ 0253 ] Spin concentrations of nitroxide radicals in tissues ( mol chex per g protein ; Note : see below for details of 
protein content determination ) were measured at - 30° C . 
( 243 . 2 K ) to increase signal - to - noise of the aqueous 
samples . Measurements of tissue samples were alternated 
with that of the spin concentration reference ( see next 
paragraph ) and g - value reference ( 2 , 2 - diphenyl - 1 - picrylhy 
drazyl powder was used as the g - value reference ) . For tissue 
samples with low signal - to - noise , the cavity background 
was recorded with identical parameters , including number of 
scans and receiver gain . Typical parameters were as follows : 
microwave attenuation - 20 dB , modulation amplitude - 5 
Gauss , spectral width - 300 Gauss , resolution - 512 points , 
conversion - 40 . 96 , time constant - 10 . 24 , and sweep time - 20 . 
97 seconds . These parameters were kept identical for the 
tissues , references , and cavity backgrounds . The number of 
scans ( 8 - 256 ) and receiver gain were adjusted as needed for 
each sample . 
[ 0254 The reference for spin concentration was 0 . 50 mm 
Proxyl in PBS ( pH 7 . 2 ) . This reference was always stored in 
dry ice , except during measurements , and occasionally re 
checked for spin concentration decay . 
[ 0258 ] Representative Procedure for BASP - ORCA Syn 
thesis with Brush Length of 7 . 07 ( m ) and 20 Equivalents ( N ) 
of Cross - Linker ( BASP - ORCA1 , m = 7 . 07 , N = 20 ) 
[ 0259 ] All BASP - ORCA syntheses were performed in a 
glovebox under N2 atmosphere ; however , similar results are 
expected under ambient conditions . All ROMP reactions 
followed the same general procedure , which was modified 
from literature examples . 
[ 0260 ] To a 4 mL vial , a suspension of Acetal - XL ( 15 . 6 
mg , 26 . 8 umol , 20 . 0 eq ) in THF ( 268 . 0 ul , 0 . 1 M Acetal 
XL ) was prepared . To a second 4 mL vial containing a stir 
bar , chex - MM ( 35 . 0 mg , 9 . 4 umol , 7 . 0 eq ) was added ; 
Cy - MM was then added from a premade 12 . 5 mg / mL 
solution in THF ( 30 . 6 uL , 0 . 094 umol , 0 . 07 eq ) . To a third 
vial , a solution of Grubbs 3rd generation bispyridyl catalyst ( Grubbs III , 0 . 02 M in THF ) was freshly prepared . THF ( 91 . 8 uL ) was then added to the MM vial , followed by the 
addition of Grubbs III solution ( 67 . 0 UL , 1 . 3 mol , 1 . 0 eq ) to 
give the desired MM : Grubbs III ratio of 7 . 07 : 1 ( 1 mol % of 
the Cy - MM ) , while achieving a total MM concentration of 
0 . 05 M , affording a dark blue solution . The reaction mixture 
was allowed to stir for 30 minutes at room temperature 
before an aliquot ( ~ 5 uL ) was taken out and quenched with 
1 drop of ethyl vinyl ether for GPC analysis . The Acetal - XL 
suspension was then added dropwise ( in aliquots of 5 eq , or 
~ 70 uL , every 5 minutes ) over the course of 20 minutes into 
the MM vial , and the polymerizing mixture was allowed to 
stir for 6 hours at room temperature , affording a dark blue 
solution . To quench the polymerization , a drop of ethyl vinyl 
ether was added . The reaction mixture was transferred to an 
8 kD molecular weight cutoff dialysis tubing ( Spectrum 
Laboratories ) in 10 mL nanopure water , and the solution was 
Protein Content Determination 
10255 ) . The protein content of tissue homogenate samples 
was determined using the BCA Protein Assay Kit ( Thermo 
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dialyzed against water ( 500 mLx3 , solvent exchange every 
6 h ) . The solution of BASP - ORCA was then lyophilized to 
afford a blue solid . 
10261 ] Other BASP compositions were prepared as fol - 
lows : MM : Grubbs III ratios of 9 . 99 : 1 , 7 . 07 : 1 , or 5 . 05 : 1 ( m 
values ) . Acetal - XL were used in 15 , 20 , or 30 equivalences 
( N values ) . PEG - BASP , which contained no chex - MM , was 
prepared in an analogous manner to BASP - ORCAs using a 
PEG - MM lacking chex . Chex - bottlebrush was prepared as 
previously described . 90 
embodiment of the invention can be excluded from any 
claim , for any reason , whether or not related to the existence 
of prior art . 
f0265 ] Those skilled in the art will recognize or be able to 
ascertain using no more than routine experimentation many 
equivalents to the specific embodiments described herein . 
The scope of the present embodiments described herein is 
not intended to be limited to the above Description , but 
rather is as set forth in the appended claims . Those of 
ordinary skill in the art will appreciate that various changes 
and modifications to this description may be made without 
departing from the spirit or scope of the present invention , 
as defined in the following claims . 
EQUIVALENTS AND SCOPE 
[ 0262 ] In the claims articles such as “ a , ” “ an , ” and “ the ” 
may mean one or more than one unless indicated to the 
contrary or otherwise evident from the context . Claims or 
descriptions that include “ or ” between one or more members 
of a group are considered satisfied if one , more than one , or 
all of the group members are present in , employed in , or 
otherwise relevant to a given product or process unless 
indicated to the contrary or otherwise evident from the 
context . The invention includes embodiments in which 
exactly one member of the group is present in , employed in , 
or otherwise relevant to a given product or process . The 
invention includes embodiments in which more than one , or 
all of the group members are present in , employed in , or 
otherwise relevant to a given product or process . 
[ 0263 ] Furthermore , the invention encompasses all varia 
tions , combinations , and permutations in which one or more 
limitations , elements , clauses , and descriptive terms from 
one or more of the listed claims is introduced into another 
claim . For example , any claim that is dependent on another 
claim can be modified to include one or more limitations 
found in any other claim that is dependent on the same base 
claim . Where elements are presented as lists , e . g . , in 
Markush group format , each subgroup of the elements is 
also disclosed , and any element ( s ) can be removed from the 
group . It should it be understood that , in general , where the 
invention , or aspects of the invention , is / are referred to as 
comprising particular elements and / or features , certain 
embodiments of the invention or aspects of the invention 
consist , or consist essentially of , such elements and / or 
features . For purposes of simplicity , those embodiments 
have not been specifically set forth in haec verba herein . It 
is also noted that the terms “ comprising ” and “ containing " 
are intended to be open and permits the inclusion of addi 
tional elements or steps . Where ranges are given , endpoints 
are included . Furthermore , unless otherwise indicated or 
otherwise evident from the context and understanding of one 
of ordinary skill in the art , values that are expressed as 
ranges can assume any specific value or sub - range within the 
stated ranges in different embodiments of the invention , to 
the tenth of the unit of the lower limit of the range , unless 
the context clearly dictates otherwise . [ 0264 ] This application refers to various issued patents , 
published patent applications , journal articles , and other 
publications , all of which are incorporated herein by refer 
ence . If there is a conflict between any of the incorporated 
references and the instant specification , the specification 
shall control . In addition , any particular embodiment of the 
present invention that falls within the prior art may be 
explicitly excluded from any one or more of the claims . 
Because such embodiments are deemed to be known to one 
of ordinary skill in the art , they may be excluded even if the 
exclusion is not set forth explicitly herein . Any particular 
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1 . A brush - arm star polymer comprising at least 100 
repeating units selected from Formula ( I ) and Formula ( II ) : 
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Formula ( I ) 
and 
Formula ( II ) 
THY Z 
Z 
ma 
each of a and b are independently an integer between 1 
and 10000 , inclusive ; 
each of “ 1 ” , “ 2 ” , “ 3 ” , “ 4 ” , “ 5 ” , and “ 6 ” is independently 
a terminal group selected from the group consisting of 
hydrogen , halogen , optionally substituted alkyl , option 
ally substituted alkenyl , optionally substituted alkynyl , 
optionally substituted carbocyclyl , optionally substi 
tuted heterocyclyl , optionally substituted aryl , option 
ally substituted heteroaryl , optionally substituted acyl , 
optionally substituted hydroxyl , optionally substituted 
amino , and optionally substituted thio ; or represents a 
bond to a structure of Formula ( I ) or Formula ( II ) ; 
y is an integer between 1 and 100 , inclusive ; and 
m is 1 or 2 . 
2 . The brush - arm star polymer of claim 1 , wherein P is 
polymer selected from the group consisting of polyethers , 
polyesters , polyacrylamides , polycarbonates , polysiloxanes , 
polyfluorocarbons , polysulfones , polystyrene , and polyeth 
ylene glycol with a molecular weight ranging from about 
200 g / mol to about 6000 g / mol . 
3 . ( canceled ) 
4 . The brush - arm star polymer of claim 1 , wherein B is 
CZ - C12 alkylene , optionally substituted with 1 - 24 indepen 
dently selected R ' ; 
R ! is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , 
oxo , nitro , ORA , — N ( R4 ) 2 , NR4C ( O ) R4 , 
NR4C ( O ) OR4 , - NR4C ( O ) N ( R4 ) 2 , C ( O ) N ( R4 ) 2 , 
- C ( O ) R4 , - C ( O ) OR4 , - OC ( O ) R4 , OC ( O ) OR4 , 
OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) mR4 ; 
each R4 is independently hydrogen , C . - C . alkyl , C . - C . 
heteroalkyl , or C . - C , haloalkyl ; and 
m is 1 or 2 . 
5 . The brush - arm star polymer of claim 1 , wherein A is 
C - C12 alkylene , optionally substituted with 1 - 24 indepen 
dently selected R ' ; 
R ? is alkyl , alkenyl , alkynyl , heteroalkyl , halo , cyano , 
oxo , nitro , OR , - N ( R4 ) 2 , NR4C ( O ) R4 , 
- NR4C ( O ) OR4 , - NR4C ( O ) N ( R4 ) 2 , - C ( O ) N ( R4 ) 2 , 
C ( O ) R4 , - C ( O ) OR4 , OC ( O ) R4 , OC ( O ) OR4 , 
OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) mR4 ; 
each R4 is independently hydrogen , C . - C . alkyl , C7 - C6 
heteroalkyl , or C . - C haloalkyl ; and 
m is 1 or 2 . 
6 . ( canceled ) 
7 . The brush - arm star polymer of claim 1 , wherein L is 
independently selected from 
or a salt thereof , wherein : 
each of A , A ' , and B is independently C7 - C12 alkylene , 
C2 - C12 alkenylene , C2 - C12 alkynylene , or C1 - C12 het 
eroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , 
alkynylene , heteroalkylene , heteroalkenylene , or het 
eroalkynylene is optionally substituted with 1 - 24 inde 
pendently selected R ' ; 
X is an imaging agent ; 
P is alkylene , heteroalkylene , or polymer ; 
L is a bond , 0 % , - 5 % , - S — 5 — , alkylene , alk 
enylene , alkynylene , heteroalkylene , alkylene - arylene 
alkylene , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 
alkylene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 het 
eroalkylene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 
heteroalkylene ) , ( Co - C12 alkylene ) - heteroarylene - ( Co 
C12 alkylene ) , ( Co - C12 heteroalkylene ) - heteroarylene ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - het 
eroarylene - ( Co - C12 heteroalkylene ) , ( Co - C12 alkylene ) 
heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , 
or ( Co - C12 heteroalkylene ) - heterocyclylene - ( Co - C12 
heteroalkylene ) , wherein each alkylene , alkenylene , 
alkynylene , heteroalkylene , arylene , heteroarylene , or 
heterocyclylene is optionally substituted with 1 - 24 
independently selected R ' , and combinations thereof ; 
each R is independently alkyl , alkenyl , alkynyl , het 
eroalkyl , halo , cyano , oxo , nitro , OR4 , — N ( R4 ) , 
- NR4C ( O ) R4 , - NR4C ( O ) OR4 , - NR4C ( O ) N ( R4 ) , 
C ( O ) N ( R4 ) , , - C ( O ) R4 , - C ( O ) ORA , OC ( O ) R4 , 
- OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , or S ( O ) 
„ R4 : 
each R4 is independently hydrogen , C . - C . alkyl , C , - C6 
heteroalkyl , or C1 - C6 haloalkyl ; 
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- continued 15 . The brush - arm star polymer of claim 1 , wherein the 
repeating unit of Formula ( I ) is of formula : 
Formula ( I ) 
and 
HN 
N 
wherein : 
q , p , and o are independently an integer between 0 and 20 , 
inclusive . 
8 . ( canceled ) 
9 . The brush - arm star polymer of claim 1 , wherein the 
imaging agent X is a chelated metal , inorganic compound , 
organic compound , or salt thereof . 
10 - 11 . ( canceled ) 
12 . The brush - arm star polymer of claim 1 , wherein the 
imaging agent X is of the formula : 
or a salt thereof , wherein : 
each of A , A ' , and B is independently C7 - C12 alkylene , 
C2 - C12 alkenylene , C2 - C12 alkynylene , or C , - C12 het 
eroalkylene , C2 - C12 heteroalkenylene , C2 - C12 het 
eroalkynylene , wherein each alkylene , alkenylene , 
alkynylene , heteroalkylene , heteroalkenylene , or het 
eroalkynylene is optionally substituted with 1 - 24 inde 
pendently selected R ' ; 
X is an imaging agent ; 
P is alkylene , heteroalkylene , or polymer ; 
L is a bond , O , S , S _ S , C , - C12 alkylene , 
C2 - C12 alkenylene , C2 - C12 alkynylene , C1 - C12 het 
eroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 
heteroalkylene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co 
C12 heteroalkylene ) , ( Co - C12 alkylene ) - heteroarylene 
( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - het 
eroarylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) 
heteroarylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 
heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , 
or ( Co - C12 heteroalkylene ) - heterocyclylene - ( Co - C12 
heteroalkylene ) , wherein each alkylene , alkenylene , 
alkynylene , heteroalkylene , arylene , heteroarylene , or 
heterocyclylene is optionally substituted with 1 - 24 
independently selected R ' , and combinations thereof ; 
each R ' is independently alkyl , alkenyl , alkynyl , het 
eroalkyl , halo , cyano , oxo , nitro , OR4 , — N ( R4 ) 2 , 
NR4C ( O ) R4 , - NR4C ( O ) OR “ , - NR4C ( O ) N ( R4 ) 2 , 
- C ( O ) N ( R4 ) 2 , - C ( O ) R4 , - C ( O ) ORA , OC ( O ) R4 , 
OC ( O ) OR4 , OC ( O ) N ( R4 ) 2 , SR4 , ors ( 0 ) 
mR4 ; 
each R4 is independently hydrogen , C . - C . alkyl , CZ - C6 
heteroalkyl , or C1 - C , haloalkyl ; 
y is an integer between 1 and 100 , inclusive ; and 
m is 1 or 2 . 
Btima
13 - 14 . ( canceled ) 
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16 . The brush - arm star polymer of claim 1 , wherein the 
repeating unit is of formula : 
lene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co - C12 alky 
lene ) , ( Co - C12 alkylene ) - arylene - ( Co - C12 
- OH or mm 
NH 
- O 
N 
?? 
165 
NH 
PI 
mm 
17 . ( canceled ) 
18 . The brush - arm star polymer of claim 1 , wherein the 
repeating unit of Formula ( II ) is of formula : 
Formula ( II ) 
heteroalkylene ) , ( Co - C12 heteroalkylene ) - arylene - ( Co 
C12 heteroalkylene ) , ( Co - C12 alkylene ) - heteroarylene ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - het 
eroarylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) 
heteroarylene - ( Co - C12 heteroalkylene ) , ( Co - C12 
alkylene ) heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - heterocyclylene - ( Co - C12 alkylene ) , ( Co - C12 heteroalkylene ) - aryl - ( Co - C12 heteroalkylene ) , 
or ( Co - C12 heteroalkylene ) - heterocyclylene - ( Co - C12 
heteroalkylene ) , wherein each alkylene , alkenylene , 
alkynylene , heteroalkylene , arylene , heteroarylene , or 
heterocyclylene is optionally substituted with 1 - 24 
independently selected R ' , and combinations thereof ; 
each R ' is independently alkyl , alkenyl , alkynyl , het 
eroalkyl , halo , cyano , oxo , nitro , OR “ , – N ( R4 ) 2 , 
- NR4C ( O ) R4 , - NR4C ( O ) OR4 , - NR4C ( O ) N ( R4 ) , 
C ( O ) N ( R4 ) 2 , C ( O ) R4 , C ( O ) OR4 , OC ( O ) RA , 
OC ( O ) OR , OC ( O ) N ( R4 ) 2 , SR4 , or - S ( O ) 
N - L N . 
mR4 ;a salt thereof , wherein : L is a bond , 0 , S , S S - , C7 - C12 alkylene , 
C2 - C12 alkenylene , C2 - C12 alkynylene , C1 - C12 het 
eroalkylene , ( Co - C12 alkylene ) - arylene - ( Co - C12 alky 
each R4 is independently hydrogen , C . - C . alkyl , C . - C6 
heteroalkyl , or C , - C6 haloalkyl ; and 
m is 1 or 2 . 
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19 . The brush - arm star polymer of claim 1 , wherein the 
repeating unit is of formula : 
minn Foto mun 
20 . The brush - arm star polymer of claim 1 , wherein the 
ratio of repeating unit of Formula ( I ) and repeating unit of 
Formula ( II ) is between about 1 : 20 to about 20 : 1 , respec 
tively . 
21 . ( canceled ) 
22 . A method of producing a brush - arm star polymer 
comprising 
( a ) reacting one or more macromonomers including an 
imaging agent with a metathesis catalyst to form a 
living polymer ; and 
( b ) mixing a crosslinker with the living polymer . 
23 - 46 . ( canceled ) 
47 . A composition comprising the polymer of claim 1 and 
a pharmaceutically acceptable excipient . 
48 . ( canceled ) 
49 . A kit comprising a polymer of claim 1 , and instruc 
tions for use . 
50 . A method of imaging a subject , the method compris 
ing steps of : 
administering to a subject the polymer of claim 1 ; and 
acquiring an image . 
51 . A method of performing magnetic resonance imaging 
( MRI ) of a subject , the method comprising steps of : 
administering to a subject the polymer of claim 1 ; and 
acquiring a magnetic resonance image . 
52 . A method of performing near - infrared fluorescence 
( NIRF ) imaging of a subject , the method comprising steps 
of : 
administering to a subject the polymer of claim 1 ; and 
acquiring a near - infrared fluorescence image . 
53 . A particle comprising a polymer of claim 1 . 
54 . A nanoparticle comprising a polymer of claim 1 . 
55 . ( canceled ) 
